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SUMMARY: Studies on Atrial Natriuretic Peptide.
Atrial Natriuretic Peptide (ANP) is a hormone secreted by the 
heart with a unique spectrum of actions: natriuresis, diuresis,
vasorelaxation and suppression of the renin-angiotensin system. This 
thesis is divided into four sections each of which examines a 
different aspect of ANP. The common theme is the question of how the 
actions of ANP may be "harnessed11 therapeutically, either directly 
using novel inhibitors of the enzyme Neutral Endopeptidase (NEP; EC 
3.4.24.11) which degrades ANP, or indirectly, by investigating 
potential interactions with available therapeutic agents including 
Angiotensin Converting Enzyme (ACE) inhibitors, and calcium channel 
blockers.
1. The first section describes plasma levels of ANP in a variety of 
human conditions including hypertensive disorders, pregnancy, and in 
the human fetus. Data are presented to support the presence of a 
functional ANP hormonal system in the human fetus. Samples obtained by 
cordocentesis demonstrate that plasma levels are higher in rhesus 
disease, and are related to the severity of the anaemia in this 
condition. Furthermore - like the adult - the fetus can be shown to 
release ANP in response to volume esqpansion (blood transfusion).
In adults ANP levels are also elevated in volume expanded states 
such as mineralocorticoid hypertension and pregnancy; and are lower in 
volume depleted states such as adrenocortical insufficiency. Although 
the major influence on the release of ANP is thought to be 
intravascular volume, ANP levels are also very high in patients with 
pre-eclampsia (PET) and malignant phase hypertension (where
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intravascular volume is not expanded) indicating that cardiac 
afterload is also a determinant of ANP release.
2. The second section examines the renal actions of ANP and the 
interaction with the renin-angiotensin system in dogs. Infusion of 5 
pmol/kg/min ANP is shown to cause a four to five-fold increase in 
plasma ANP, with a two to three-fold increase in urine volume and 
sodium excretion, a minor fall in blood pressure and a 50% reduction 
in renin.
Inhibition of the renin-angiotensin system by acute 
administration of enalaprilat caused a three-fold increase, whilst 
infusion of low dose Ang II virtually abolished, the natriuretic and 
diuretic effects of ANP. Circulating (and intrarenal) Ang II levels 
are thus proposed to exert a major modulatory role on the renal 
actions of ANP, and that combination with ACE inhibitors may 
potentiate the possible therapeutic effects of ANP. The interaction 
between ANP and Ang II is proposed to occur largely at the level of 
the renal. In the simplest model the proximal tubular effects of Ang 
II on sodium reabsorption regulate the delivery of sodium to the 
distal tubule where ANP has its major effects. However, interactions 
at other sites within the nephron cannot be excluded. Plasma renin was 
suppressed by ANP to a similar extent regardless of changes in sodium 
excretion (when given alone or combined with Ang II or ACE inhibition) 
with the inference that ANP suppresses renin secretion by a direct 
effect on the juxtaglomerular apparatus, rather than indirectly via 
delivery of sodium to the macula densa. Finally, from the relationship 
between ANP, Ang II and sodium excretion it is possible to estimate 
that physiological levels of ANP achieve approximately 15% of their 
natriuretic effects by suppression of endogenous Ang II.
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3. The third experimental section examines the effects of NEP 
inhibition (NEPi) on ANP. In anaesthetised rats acute administration 
of the NEPi UK 69,578 caused a rise in plasma ANP, associated with a 
natriuresis, diuresis and kaliuresis which paralleled the response to 
5 pmol/kg/min ANP in the same preparation.
In a subsequent study in man, acute administration of UK 69,578 
caused a dose-related increase in plasma ANP, associated with a rise 
in urine volume and sodium excretion and suppression of renin 
consistent with the known actions of ANP, and the predicted effects of 
inhibition of ANP degradation. However, although 10 day administration 
of the oral NEP inhibitor UK 79,300 produced an upward trend in plasma 
ANP and down regulation of platelet ANP receptors consistent with 
sustained inhibition of ANP degradation, and was associated with a 
natriuresis on the first day of treatment, there were no sustained 
effects on sodium balance. Furthermore, although treatment with UK 
79,300 blunted the pressor response to phenylephrine (on the final day 
of treatment), the response - both pressor and on aldosterone release 
- to Ang II infusion was enhanced. This unexpected effect is likely to 
be due to the effects of NEPi of Ang II degradation and will restrict 
the therapeutic application of NEP inhibitors.
Finally, treatment with the NEPi SCH 34,826 inhibited the 
development of hypertension in DOCA salt hypertensive rats, but was 
without effect on renal function, sodium excretion or exchangeable 
body sodium. Although modest, this study demonstrates the therapeutic 
potential of NEPi - at least in the restricted setting of a renin- 
independent model of hypertension.
4. The final section investigates the possible role of Calcium on the 
release of ANP in the isolated superfused rat atrium. Reduction of
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extracellular Calcium - either by omission from the bathing medium, 
by the use of EGTA - or treatment with the calcium channel blocker 
Verapamil, resulted in the dissociation of developed tension and ANP 
release but had no direct effect on the release of ANP. It is 
concluded that ANP release is, at least partially, independent of 
Calcium and that the therapeutic use of calcium channel blockers is 
unlikely to impair the release of ANP.
This theme is extended in the subsequent chapter where it is 
shown that acute administration of Nifedipine has no effect on the 
release of ANP in response to a saline infusion in normal volunteers. 
Indeed, the saline load is cleared more rapidly in the presence of 
Nifedipine.
The general conclusions are that ANP has therapeutic potential 
and, although NEP inhibitors represent a useful first attempt to 
harness this potential they are limited by their modest effects on 
plasma ANP and their lack of specificity (particularly with respect to 
Ang II degradation). The studies with ACE inhibitors and, to a lesser 
extent, calcium channel blockers suggest potential therapeutic 
combinations with NEP which require further investigation. However, it 
is likely that the development of alternative, more potent and more 
specific agents will be needed to harness the therapeutic potential of 
ANP.
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SECTION 1.
INTRODUCTION AND LITERATURE REVIEW.
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Chapter 1.
Introduction.
The concept of a natriuretic hormone has been the subject of 
debate for many years (see deWardener & Clarkson (1985)). However, the 
clear identification of such a hormone eluded discovery until the 
seminal observation of deBold (deBold et al., (1981)) that extracts of 
atrial tissue cause a natriuresis and diuresis when infused into an 
anaesthetised rat. These findings permitted the re-interpretation of 
two much older observations: firstly that the cardiac atria contain 
granules on both light and electron microscopy which are similar to 
granules in which peptide hormones are stored in other tissues (Kirsch 
(1955)) and, secondly, that distension of the atria by balloon 
catheter resulted in a natriuresis in experimental animals (Henry et 
al., (1956)). From these observations deBold deduced that a peptide 
hormone (now known as Atrial Natriuretic Peptide or Factor, ANP) was 
synthesised by the heart and acted on the kidney to cause a
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natriuresis and diuresis. Since then thousands of reports1 have been 
published confirming and extending these observations. It is now known 
that ANP is indeed synthesised and secreted by the cardiac atria (and 
is also present in other tissues), that the principal stimulus to 
release is atrial distension and that the peptide acts not only to 
cause natriuresis and diuresis, but as a vasodilator, an antagonist of 
the renin-angiotensin-aldosterone system and as a neurohormone, 
together with a number of other actions. The major actions of ANP are 
summarised in Figure 1.1 and Chapter 2 reviews more fully the known 
physiological and pathophysiological actions of ANP.
The work in this thesis covers several different areas relating 
to ANP. It is divided into four experimental sections (2-5), each of 
which is self-contained. Following the introduction and review 
(Section 1), Section 2 (Chapter 3) describes a number of small studies 
of plasma ANP levels in humans of relevance to the development and 
regulation of the ANP hormonal system. Section 3 (Chapter 4) examines 
the renal actions of physiologically relevant infusions of ANP in the 
conscious dog and, by the use of inhibitors of Angiotensin Converting 
Enzyme (ACE) and angiotensin II infusion, examines the importance of 
the interaction between ANP and this major antinatriuretic hormonal 
system. In Section 4 (Chapters 5-10) the possibility of "harnessing" 
the actions of ANP to therapeutic advantage is examined using 
inhibitors of Neutral Endopeptidase (NEP, EC 3.4.24.11) to inhibit 
hormone degradation in both man and experimental animals. In the final
^The literature on ANP is beyond the scope of this review and is 
covered comprehensively in two recent monographs (Brenner and Stein 
(1989), Struthers (1990)).
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FIGURE 1.1. 
PHYSIOLOGY OF ANP.
Outline of the major actions and regulation of Atrial 
Natriuretic Peptide (ANP).
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experimental section (Section 5, Chapters 11&12) the influence of 
calcium in the regulation of ANP release is examined in vitro and in 
man. Section 6 (Chapter 13) is a short general discussion of the 
findings and draws together the main theme of the thesis which is the 
possible therapeutic actions of ANP and potential interactions with 
other pharmacological agents in the treatment of a variety of common 
conditions including hypertension and heart failure.2
2Tenninology. Many names have been proposed for the atrial 
hormone based on its chemical nature, site of production and actions. 
Atrial Natriuretic Factor (ANF) was the term first used by deBold 
(deBold et al., (1981)) at a time when the nature of the hormone was 
unknown. With the finding that the factor was a peptide most workers 
adopted the name Atrial Natriuretic Peptide (ANP). However, recently 
the working party of the World Health Organisation and International 
Society for Hypertension have suggested that the term ANF should be 
adopted but this advice has not been universally adopted and in this 
thesis in view of the peptide nature of the hormone I have used the 
term ANP. Most of the other names (including cardionatrin, auriculin, 
atriopeptin and many others) have fallen from use. Dzau (1987) also 
suggested that the amino acid (AA) numbering of ANP should be from the 
amino terminal of the precursor molecule (also termed pro-ANP) rather 
than the carboxyl terminus of the active peptide, such that the active 
circulating form previously termed ^.^sANP should now be termed 99_ 
X26ANP (see Chapter 2, Figure 2.2). This has been followed as far as 
possible, as has the use of prefixes (h, human; r, rat) to indicate 
the species of origin. Previously the prefixes a, B and y were used to 
indicate the circulating 28 amino acid form (a), a dimer of a (B) and 
the prohormone (y). These prefixes have been dropped, although still 
used for commercial ANP preparations (e.g. Bachem UK). Finally, many 
individualised terms were used for purified peptide fractions or 
synthetic derivations of ANP (e.g. the 15 AA analogue of ANP 
synthesised by Maack et al,.(1987)) was termed C-ANP). This 
terminology has also been abandonned in favour of the numerical system 
with AA labelled numerically from the amino end of the prohormone.
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Chapter 2.
Atrial Natriuretic Peptide: Review of the literature.
2.1 Historical Background.
The cardiac atria have been implicated in sodium and volume 
homeostasis for many years, the prevailing theory being that neural 
input from receptors in the atria produced alterations in the activity 
of the autonomic nervous system and vasopressin (ADH). This view was 
based on the results of a variety of different experiments. In 1956, 
Henry et al., observed that balloon distension of the atrium in 
anaesthetised dogs caused a diuresis, which was abolished by cardiac 
denervation. The renal effects of intravascular volume esqpansion were 
also shown to be absent if atrial volume was kept constant by 
selective atrial tamponade (Goetz et al,.(1970)). Natriuretic effects 
of atrial distension were later demonstrated by Reinhardt et al., 
(1977) who found that left atrial distension caused a natriuresis in 
conscious dogs. The ability of cardiac denervation to abolish these 
effects suggested that neural input from volume receptors in the heart 
in some way regulated renal function probably through ADH, the renin-
angiotensin system (RAAS) and sympathethic nervous activity. However, 
in a series of experiments deWardener provided evidence that a 
circulating factor was involved in the natriuresis of volume expansion 
and that this factor was separate from the RAAS and ADH. Infusion of 
plasma from a volume expanded dog caused natriuresis in a recipient 
animal (deWardener et al.,(1961)), implicating a circulating factor, 
and these renal effects occur in the presence of elevated levels of 
ADH and aldosterone. These results suggested the presence of another 
natriuretic substance which deWardener termed "third factor". At the 
same time, histological investigation of mammalian atria also revealed 
the presence of dense granules (Kisch (1956), Jamieson and Palade 
(1964), Figures 2.1a & 2.1b) with characteristics of secretory
granules. Although the density of granules was later found to change 
under certain conditions -notably alterations in sodium balance 
(deBold (1979)) - their contents remained uncertain until the
publication of deBold et al., (1981) showing that extracts of atria, 
but not ventricle (which do not contain granules (Jamieson and Palade 
(1964)) caused a 30 fold increase in sodium excretion in a bio-assay 
rat. From these observations deBold hypothesised that the atria 
produce a natriuretic hormone (termed "atrial natriuretic factor"), 
in response to changes in intravascular volume and sodium balance. 
This theory drew together the above observations by explaining the 
presence of secretory granules in the atria, the diuretic and 
natriuretic effects of atrial distension and the involvement of a 
circulating hormone in the response to atrial distension. An atrial 
hormone may, in fact, only explain part of the story. The cardiac 
nerves also influence renal function by other mechanisms and the 
hormone subsequently purified from the heart (atrial natriuretic
i .4
.2 ; •
FIGURE 2.1(A):
ATRIAL MYOCYTE AND STORAGE GRANULES.
(A) Electron micrograph of an atrial myocyte showing electron 
dense ANP storage granules in a typical perinuclear 
distribution (Magnification x 2,600).
1. Nucleus. 2. Myofibrils.
fL' r"
-X.' , v '•■.•'■;,•:■
FIGURE 2.1(B):
ATRIAL MYOCYTE AND STORAGE GRANULES.
(B) Localisation of ANP to the storage granules using 
immunogold labelling with an antibody to hANP99_126 
(Magnification x 36,000; after Lindop et al.,(1987)).
1. Myofibrils. 2. Mitochondria. 3. Smooth Endoplasmic. 
Reticulum. 4. ANP Storage Granules, dotted with immunogold 
label.
Photomicrographs courtesy of Ms. Jane Hair, Department of 
Pathology, Western Infirmary, Glasgow.
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peptide or factor, ANP or ANF) does not fulfil all the functions of 
deWardener*s third factor since it does not inhibit Na/K ATPase 
activity. It seems likely that a separate low molecular weight Na/K 
ATPase which exhibits digoxin-like immunoreactivity (DLIF) may also 
circulate (deWardener and Clarkson (1985), Kelly and Smith (1989)). 
The role of this digoxin-like substance and of the cardiac nerves is 
beyond the scope of this review and I will concentrate on the specific 
role of ANP.
2.2. Structure and synthesis of ANP.
Initial attempts to sequence ANP from plasma and atrial extracts 
resulted in the identification of many structurally related peptides 
(for review see Inagami et al.,(1989)) many of which were artefacts of 
the extraction process, differing only in the length of the peptide 
recovered. However, the synthesis of oligonucleotide probes from these 
peptides allowed several groups to virtually simultaneously identify 
the gene for ANP in 1984 in human and rat (Nakayama et al.,(1984), 
Oikawa et al.,(1984), Flynn et al.,(1985)) atrial tissue. From the 
gene sequence the structure of peptide itself was confirmed.
The gene for ANP in man is located on the short arm of 
chromosome 1 (Dracopoli et al.,(1988)). It contains 3 exons and two 
introns and encodes a peptide of 151 AA in man - and of similar length 
in other species (see Jarcho et al.,(1989), Gardner et al.,(1990) for 
reviews of the molecular biology of ANP). This 151 AA peptide 
(preproANP) has a 25 AA "signal peptide" at its amino terminal which 
contains a high percetage of hydrophobic amino acids and is thought to 
be involved in the processing of the hormone by the endoplasmic 
reticulum. Removal of this "signal peptide" leaves the 126 AA peptide
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(proANP, previously termed gamma ANP (Kangawa and Matsuo (1984), 
Figure 2.2.), which is the major intracellular form of ANP (Kangawa 
and Matsuo (1984)) and which can be shown immunohistochemically within 
the storage granules in the atria (Lindop et al.,(1987)). The further 
processing of ANP is less clear. Stimuli which cause ANP release cause 
centrifugal movement of the storage granules which are largely found 
in the perinuclear distribution (Jamieson and Palade (1964), Agnoletti 
et al.,(1989), Figures 2.1a and 2.1b) and these granules subsequently 
release their contents by exocytosis (Severs (1989)). The peptide 
which is present in the peripheral circulation is the 28 AA peptide 
(99-126 ANP, aANP) cleaved from the carboxy terminal of the prohormone 
(Yamaji et al.,(1985), Figure 2.2.). This low molecular weight peptide 
is similarly found in coronary sinus plasma in man (Espiner et 
al.,(1986), Yandle et al.,(1987)) and in the isolated perfused heart 
or atrium (Lang et al.,(1985), Dietz (1987), Schiebinger et 
al.,(1987)) suggesting that cleavage of proANP to ANP does not occur 
in plasma. However, cultured atrial cells have been reported either to 
secrete low or high molecular weight ANP (Shields and Glembotski 
(1988), Ito et al.,(1988), Greenwald et al.,(1989)) and there is 
therefore still debate as to whether the final processing of ^ occurs 
within the atrial granule or is mediated by an enzyme within the 
atrial interstitium as has been proposed by Needleman (Ito et 
al.,(1988)). Wherever the site of cleavage, the N-terminal fragment 
also circulates with a much longer plasma half life than the smaller 
peptide, plasma levels are 10 times higher than 99_x 2 6 ANI) (Buckley 
et al.,(1989) and may have some renal effects (Martin et al.,(1990)) 
although the biological role is not known. An outline of the synthesis 
and forms of ANP is shown in Figure 2.2. There is a high degree of
FIGURE 2.2:
STRUCTURE OF ANP.
Structure of Atrial Natriuretic Peptide and related peptide 
hormones using standard amino acid nomenclature. NEP indicates 
the major site of enzymatic cleavage by Neutral Endopeptidase; 
S=S indicates the position of the disulphide bond forming the 
loop of ANP (see text for details).
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homology between the structure of ANP in different species. The 
biologically active, circulating peptide is virtually identical 
between species and, for example, rat and man differ only in the 
substitution of Methionine for Isoleucine at position 110 (Figures
2.2, 2.3.). Similarly, there is approximately 85% homology in the 
overall sequences of proANP between rat and man.
Regulation of atrial gene egression: Synthesis of ANP appears to be 
a major role of the atria and, quantitatively, messenger RNA (mRNA) 
for ANP has been reported to account for as much as 3% of the total 
mRNA. Changes in mRNA have been studied in a variety of conditions and 
experimental situations and a general pattern has emerged. ANP mRNA 
levels tend to follow long term changes in plasma ANP levels, with 
reciprocal changes in atrial immunoreactive ANP content i.e. if 
synthesis is increased, plasma levels are increased but stores are 
reduced indicating more rapid turnover within the atria. For example 
in two studies of the effect of prolonged water deprivation (Nakayama 
et al.,(1984), Takayanagi et al.,(1985)), ANP mRNA levels were reduced 
by more than 70%, with a rise in intracellular immunoreactive ANP 
(two-fold). Changes in salt intake have beeen found to have more 
variable effects, although Takayanagi et al.,(1985) found that a low 
salt diet reduces ANP mRNA. Chronic volume and sodium expansion in the 
DOCA salt rat (Ballerman et al.,(1986)) also increases mRNA and plasma 
ANP. In another hypertensive model, the SHR, Arai et al.,(1987) found 
an increase in plasma ANP and in ANP mRNA, with reduced atrial ANP 
content. However, these changes were more marked in the left atrium 
and provide evidence for a differential role of the atria in response 
to changes in pre- and after-load. This is explored in more detail in 
chapter 3, but it appears that the right atrium is perhaps more
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important in the regulation of ANP release in response to changes in 
preload (volume expansion) while the left atrium is more importnant in 
the response to changes in afterload (hypertension). Other factors 
also regulate ANP gene expression. In rats (Gardner et 
al.,(1986,1987), Matsubara et al.,(1987)) glucocorticoids and thyroid 
hormone increase in vitro atrial mRNA expression; with similar effects 
on atrial cells in culture (Matsubara et al.,(1987)). Thyroid hormones 
have a non-specific effect on gene expression but the effect of 
glucocorticoids may be due to the association of a glucocorticoid-like 
receptor close to the ANP gene.(Jarcho and Seidman (1989)). Finally, 
the expression of ANP mRNA is also dependent on the concentration of 
calcium in the bathing medium (Lapointe et al.,(1990)) and can be 
increased by calcium, calcium agonists or phorbol ester. The potential 
role of calcium is considered further below (2.4).
Ventricular ANP gene expression: Immunoreactive ANP and mRNA are
present in cardiac tissue in humans, and in other species, from the 
earliest stages of development. There is now abundant evidence 
(Chapter 3, Kikuchi et al.,(1988), Wu et al.,(1988)) that a functional 
ANP hormonal system exists in fetal life (Robillard and Weiner (1987); 
Chapter 3). What appears to differ between the fetus and the adult is 
that the ventricular and atrial expression of the ANP gene are very 
similar in the fetus, atrial levels prodominate in the neonate and 
normal adult. However, in the adult with heart failure (Yasue et 
al.,(1989), Saito et al.,(1989)) or in experimental models of heart 
failure (Thibault et al.,(1989)) there is renewed ventricular 
expression of ANP. The stimulus to this "return" to the fetal state 
appears to be ventricular dilatation and it may well contribute to the 
raised plasma levels of ANP which are seen in heart failure.
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The gene for ANP is also expressed in other tissues including the 
aortic arch (Gardner et al.,(1987)) and the nervous system (see below, 
2.10). Plasma levels appear to be almost entirely of atrial origin 
except in heart failure when the ventricles (Saito et al.,(1989), 
Yasue et al.,(1989)) and possibly the lung (Gutkowska et al.,(1989)) 
may contribute.
2.3. Secretion of ANP:
Th release of ANP and plasma hormone levels are inextricably 
linked; plasma levels being dependent on secretion rate, in the 
absence of changes in clearance. However, for clarity, it is simplest 
to deal with them individually; this section includes the experimental 
control of ANP release and the section deals principally with normal 
and pathophysiological levels.
Manipulation of ANP release in vivo: The earliest study of plasma ANP 
in man (Lang et al.,(1985)) found that plasma hormone levels were 
elevated in response to acute volume expansion, as one might predict 
for a natriuretic and diuretic hormone. Subsequent studies have gone 
on to assess the dynamic regulation of plasma ANP, predominantly in 
man. Short-term intravenous infusions of 1-2 litres of saline increase 
circulating plasma ANP 2-3 fold (Anderson et al.,(1986), Richards et 
al.,(1988)). Head out water immersion, which causes a redistribution 
of intra - vascular fluid to the thorax, also increases ANP (Epstein 
et al.,(1987)) as does head down tilt (Hodsman et al.,(1987)) and 
plasma volume expansion following treatment with adrenocortical 
steroids (Connell et al.,(1987), Weidmann et al.,(1988)). Conversely, 
decreases in atrial volume due to haemorrhage, water deprivation, 
frusemide or head up tilt tend to lower plasma ANP (Gauquelin et
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al.,(1988), Kimura et al.,(1986), Hodsman et al.,(1987), Haller et 
al.,(1987), Cameron et al.,(1988), Hollister et al.,(1986)). Similar 
volume-dependent changes in plasma hormone levels are seen in 
pathological conditions and these are discussed below (2.4). These 
observations suggest that the atria "sense" intravascular volume and 
release hormone appropriately. Although these studies involve 
manipulation of intravascular, and hence atrial, volume there was for 
some time debate as to whether atrial volume, or pressure, was the 
final common stimulus to the release of ANP. Studies such as those of 
Richards et al.,(1986) and Anderson et al.,(1986) showed a close 
correlation between atrial pressure and plasma ANP in patients 
undergoing cardiac catheterisation and normal subjects infused with 
saline. However, if pressure and volume are dissociated, for example 
in cardiac tamponade (where the collection of pericardial fluid 
results in increased atrial pressure but reduced volume) plasma ANP is 
not elevated and studies in man (Northridge et al.,(1989)) and in 
experimental animals (Roller et al.,(1987), Mancini et al.,(1987), 
Edwards et al.,(1988), Stone et al.,(1990)) have shown that hormone 
levels rise if the tamponade is released (despite the fall in atrial 
pressure). Thus, atrial distension is the final common stimulus to ANP 
release - although under most circumstances pressure and volume will 
tend to change in parallel.
Chronic regulation of plasma ANP follows a similar pattern to the 
acute regulation and to the regulation of the ANP gene (2.2), in both 
experimental and pathophysiological conditions. For example, higher 
levels are found in normal subjects with experimental steroid induced 
hypertension (Connell et al.,(1987), Weidmann et al.,(1988)) and a 
similar pattern in animals treated with deoxycorticosterone (DOCA;
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Ballerman et al.,(1985), Grekin et al./(1986)). However, debate 
surrounds the role of dietary salt intake in regulation of plasma 
hormone levels. Some (Sagnella et al.,(1987), Richards et al.,(1986a)) 
have found a positive correlation between plasma ANP and sodium 
intake, however others disagree (Weidmann et al.,(1986)), and, in view 
of the small changes in ANP produced by large differences in sodium 
intake, it is quite likely that ANP responses are secondary to 
vascular volume changes. Other factors have been shown to elevate 
plasma ANP. Levels are higher in paroxysmal tachyarrhythmias (Espiner 
et al.,(1986)), and in experimental pacing-induced increases in heart 
rate suggesting that ANP release may be heart rate dependent and 
increases in cardiac afterload by infusion of pressor substances 
(Uelinger et al.,(1987), Christensen et al.,(1989)) increases plasma 
ANP indicating that increased blood pressure can independently 
stimulate ANP release (as it can in the isolated heart (Dietz 
(1987))); probably due to a relative increase in left atrial secretion 
(Arai et al.,(1987)).
In vitro release: From the in vivo studies above it is clear that ANP 
is released in response to changes in atrial volume. The classical 
explanation for this would involve stimulation of atrial "stretch" 
receptors and, presumably, reflexly mediated release. However, the 
stimulus secretion coupling mechanism appears to lie within the 
individual atrial myocyte, since the isolated working heart (Dietz
(1987)), isolated atria (Bilder et al.,(1986), Agnoletti et 
al.,(1987), Cho et al.,(1988)) and even isolated myocytes (Gibbs 
(1987b)) release ANP when stretched. Isolated atrial preparations also 
release ANP in response to increases in heart rate (Schiebinger and 
Linden (1986)) and in response to a variety of hormonal stimuli
including a- and 6-adrenoceptor agonists, acetylcholine, angiotensin 
II and endothelin (Rankin (1987), Wong et al.,(1988b), Gibbs (1987a), 
Schiebinger et al.,(1987,1988,1990), Schiebinger (1989)). Furthermore 
direct activation of the second messenger systems using the calcium 
ionophore A23187, forskolin, dibutyryl cAMP or activators of Protein 
Kinase C (Iida and Page (1989), Matsubara et al.,(1988), Hirata et 
al.,(1988), Saito et al.,(1986)) have also been reported to increase 
ANP release. These divergent in vitro stimuli all potentially involve 
intracellular calcium by different mechanisms and, taken together with 
the suggestion (Allen et al.,(1989)) that stretch-sensitive calcium 
channels may exist within the heart, this has led to the theory that 
an increase in intracellular calcium is the final common stimulus to 
ANP release. This is discussed more fully in chapters 11 and 12. 
Briefly, in support of this theory, Schiebinger has shown (Schiebinger 
(1989), Schiebinger and Gomez-Sanchez (1990)) that the effects of 
endothelin and adrenoceptor agonists on ANP release are blocked by 
calcium channel blockers and others have shown that treatment of 
isolated cell or the whole animal with ouabain (to increase 
intracellular calcium) increases the release of ANP (Bloch et 
al.,(1988), Yamamoto et al.,(1988)). Similarly, infusion of sub­
pressor doses of calcium (Finn et al.,(1988), Fujimura et al.,(1989)) 
increases plasma hormone levels. However, the release mechanism does 
not appear to be this simple. Reduction of extracellular calcium using 
EGTA has been shown to increase ANP release (deBold and deBold (1989), 
Ito et al.,(1989)) and at present the role of calcium remains 
uncertain. It seems likely that intracellular calcium should play a 
role, but perhaps different intracellular calcium pools are involved 
in control of tension-development and hormone release (Chapter 11).
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Extra-atrial ANP: The contribution of non-atrial tissues to
circulating levels of ANP is also uncertain. In the fetal heart both 
atria and ventricular cells synthesise ANP (Kikuchi et al.,(1987), Wu 
et al.,(1987)) but by the time of birth the ventricular component 
becomes insignificant and remains dormant in normal adults. Recent 
studies in animals and man have demonstrated that ventricular ANP 
production may be "switched on" in cardiac failure (Saito et al.,
(1989), Franch et al., (1988)'). During cardiac catheterisation in 
patients with heart failure, Yasue et al.,(1989) found a rise in 
plasma ANP between the atria and aorta suggesting active secretion by 
the ventricle. The relationships between mRNA, stored ANP, secretion 
and the stimuli to secretion in the ventricle are still to be fully 
elucidated, but peptide appears to be synthesised on demand, with no 
intermediate.storage step.
2.4. Plasma levels of ANP.
Normal levels: With the advent of radio-immunoassays for ANP there 
have been many reports on plasma hormone levels. Richards et 
al., (1987a) were amongst the first to report on the effects of pre­
extraction of plasma which, in addition to removing high molecular 
weight species, removes interfering substances in plasma resulting in 
lower, more consistent plasma ANP values. Results from direct RIA 
therefore must be viewed with caution. The levels of ANP now reported 
by most groups are in the range 5-50 pg/ml (2-15 pmol/1), in normal 
man. Similar or slightly higher plasma levels have been reported in 
other species (e.g rat (Soejima et al.,(1988), and dog (Cernacek et 
al.,(1987), O ’Hanian et al.,(1987), Bie et al.,(1988)).
Circulating ANP is detectable during fetal life (Chapter 3,
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Robillard and Weiner (1987), Kingdom et al.,(1989)), but its role and 
normal range unknown. Levels are high at birth and in the early 
neonatal period (Yamaji et al.,(1987), Ito et al.,(1988)) but fall 
rapidly in the puerperium. Thereafter, there is a slow age-related 
increase in plasma ANP (Chapter 3, Ohashi et al.,(1987), Haller et 
al.,(1987)). Careful diurnal measurement of plasma ANP has revealed no 
significant rhythm in normal subjects (Richards et al.,(1987c)), 
although one may emerge under certain pathological circumstances (eg 
Pre-eclampsia; Miyamoto et al.,(1988a,b)). Plasma levels are also 
determined by changes in posture (Hodsman et al.,(1987)), levels 
falling in the upright position, and by exercise (Richards et 
al.,(1986), Hodsman et al.,(1987)).
Pathophysiological levels: Following on from the list of factors which 
stimulate the experimental release of ANP (2.3) there is general 
agreement that circulating levels are elevated in pathological 
conditions where plasma volume is expanded such as chronic renal 
failure, congestive heart failure, and Conn’s syndrome (Tonolo et 
al.,(1988, 1989a), Walker et al.,(1987), Cody et al.,(1987), Raine et 
al.,(1986), Richards et al.,(1986), Yamaji et al.,(1986, 1988), Ogawa 
et al.,(1987), Raine et al.,(1986), Chapter 3) and that in these 
syndromes plasma levels fall in response to appropriate therapy: 
dialysis, diuretic therapy and amiloride respectively. In cardiac 
failure the levels are related to right atrial pressure and hence the 
degree of plasma volume expansion (Richards et al.,(1986)) and may be 
increased as much as 10-20 times the upper limit of normal. A similar 
pattern is seen in animal models of heart failure (Riegger et 
al.,(1987), Franch et al.,(1988)). In essential hypertension the 
general consensus appears to be that levels are only modestly elevated
(< 50%, Sagnella et al.,(1988), Montorsi et al.,(1988)) on average and 
are often still within the "normal11 plasma range. In the absence of 
increased intravascular volume in this condition elevated levels are 
probably due to increased cardiac afterload and in experimental models 
ANP mRNA is higher in the left rather than the right atrium (Arai et 
al.,(1987)). However, Ferrier et al.,(1989) have reported that ANP 
levels may be low in the offspring of hypertensive parents, and thus 
proposed ANP deficiency as the cause of hypertension. However, this 
has not been confirmed. In animal models of essential hypertension 
reported levels are variable although the consensus is for an increase 
in the SHR (Arai et al.,(1987), Gutkowska et al.,(1986)). Normal 
pregnancy is accompanied by an expansion of plasma volume of up to 
50%. There is an appropriate increase in circulating levels of ANP 
which correlates with the gestational age (Jackson et al.,(1988)) in 
some series, but not in others (Steegers et al.,(1990), Chapter 3). In 
pre-eclampsia ANP is further increased despite the relative volume 
contraction in this condition (Otsuki et al.,(1988), Miyamoto et 
al.,(1989a,b), Chapter 3). The reason for this is not known but again 
presumably relates to increased cardiac afterload and, in keeping with 
this, plasma hormone levels closely follow the abnormal diurnal rhythm 
in arterial pressure in pre-eclampsia (Miyamoto et al.,(1989a,b)). 
Whether elevated ANP contributes to the reduction in plasma volume, 
proteinuria, oedema and suppression of the renin-aldosterone system 
which characterise pre-eclampsia is not yet clear. Even in the fetus 
there is evidence of a pathophysiological role for ANP. The peptide is 
synthesised by the fetal heart (Kikuchi et al.,(1987)) from the 
earliest periods of development and circulates in human fetal blood. 
Plasma ANP concentrations rise in response to intravascular
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transfusion and are relatively increased in Rhesus iso-immunisation 
(Robillard and Weiner (1987), Weiner and Robillard (1988), Kingdom et 
al.,(1989)), where they are related to the severity of the anaemia 
(Chapter 3).
Other factors which are reported to increase plasma ANP include 
spontaneous tachyarrhythmias (Espiner et al.,(1986)) and exercise, 
where levels may rise up to three-fold at peak exercise (Richards et 
al.,(1987), Hodsman et al.,(1987)). The changes in both these 
conditions may be related to heart rate and have been proposed to 
contribute to the diuresis which follows paroxysmal tacharrhythmias, 
in particular. Elevated levels have also been reported in Bartter's 
syndrome (Gordon et al.,(1986), where they are inappropriate for the 
blood pressure and plasma volume; and poorly controlled diabetes (Bell 
et al., (1988)) where they have been proposed to contribute to the 
development of albuminuria. Neither the mechanism, nor the the 
significance of these observations is currently understood.
2.5. Degradation and clearance of ANP.
In man ANP has a very short plasma half life, as was initially 
suggested by the short duration of the biological effects of bolus 
administration (Richards et al.,(1985)). The disappearance of the 
peptide from the circulation is best fitted by a biexponential decay 
with half-life values of between 1 and 2 minutes for the fast 
component and around 15 minutes for the slow component of the decay 
curve in man (Ohashi et al.,(1987), Nakao et al.,(1986)). Other 
workers have fitted a single exponential curve and the values obtained 
relect the fast component only with values of 1.3 minutes in the rat 
(Almeida et al.,(1988)) and 3.1 minutes in man (Yandle et al.,
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(1986)). The volume of distribution in man is around 200 ml/kg, and 
the calculated metabolic clearance rate 20-25 ml/min/kg (Nakao et al., 
(1986), Ohashi et al.,(1987)). These data suggest rapid clearance of 
the peptide by tissues.
The sites of ANP clearance have been determined by a variety of 
methods. When radiolabelled ANP is injected into rats and the peptide 
distribution determined radiographically (Condra et al.,(1987)), most 
activity develops in the kidney and liver over the first few minutes. 
Radioactivity persists at these sites before appearing in the urine 
and thyroid (free iodine). Although this suggests that the kidney is 
a major site of degradation radioactivity was diffusely located in 
other vascular beds. Further assessment of the role of other tissues 
and vascular beds has been made by the measurement of arterio-venous 
gradients in hormone levels and by the measurement of degradtion in 
isolated perfused organs. Approximatley 80 % of ANP is removed by a 
single passage through the kidneys in dogs (Weselcouch et al.,(1987)), 
with similar falls in man (Richards et al.,(1986b), Schutten et 
al.,(1987)). Nephrectomy has been reported to prolong the half life of 
plasma ANP approximately two-fold (Luft et al.,(1987). In the isolated 
kidney (Brier et al.,(1988)) radiolabelled ANP is rapidly removed, 
even in the non-filtering kidney by a process that is saturable and 
with a reported clearance rate (Brier et al.,(1988)) six times the 
GFR. Thus, the balance of evidence suggests the kidney to be a major 
site of ANP clearance. Plasma hormone levels also fall across other 
vascular beds (Richards et al.,(1986b)), including the liver, lung 
(Northridge et al.,(1990b)) and limbs (Yandle et al.,(1986), Schutten 
et al.,(1987)), and in the mesenteric circulation in vitro (Murthy et 
al.,(1986)).
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Two processes appear to be involved in the clearance of ANP of 
ANP at these sites; both are dealt with elsewhere. First, in 1977, 
Kenny demonstrated that neutral endopeptidase (NEP, EC 3.4.24.11), an 
enzyme found principally in the kidney, specifically degrades ANP 
(Stephenson and Kenny (1987)). This has subsequently been confirmed 
and the role of NEP is discussed in Section 4 (and specifically 
reviewed in Chapter 5). Secondly, also in 1977, Maack prpoposed the 
existance of a clearance receptor (Maack et al.,(1987)) which binds 
circulating peptide, followed by internalisation and degradation (see 
below). Both these mechanisms appear to operate and inhibition of both 
produces greater effects than either alone (Koepke et al.,(1988)), but 
nothing is known about their relative importance. Based on studies 
with NEP inhibitors (Section 4) Sybertz has proposed that enzymatic 
degradation of the peptide corresponds to the fast component of the 
plasma decay curve, and receptor mediated uptake the slow component 
(EJ Sybertz, personal communication).
2.6. ANP receptors and mechanism of hormone action.
Cyclic GMP and mechanism of action:
Shortly after the discovery of ANP it was noted that the actions 
of ANP in vascular smooth muscle were associated with the generation 
of cyclic GMP (cGMP, Winquist et al.,(1984)). This relationship has 
subsequently been confirmed in all the major target tissues for ANP, 
including kidney, adrenal, lung, liver, brain (see Lewicki (1989) for 
review) and in isolated cell lines (Lyall et al.,(1987), Lewicki
(1989)). Cyclic GMP has thus been proposed to act as the intracellular 
"nd messenger for ANP and recently it has been shown that the ANP-B
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receptor is a single transmembrane protein containing an ANP binding 
site and guanylate cyclase (below).
In many tissues our knowledge of the mechanism of action of ANP 
goes no further than generation of cGMP. In some early studies there 
were reports that cAMP was also reduced, but this is not a consistent 
finding and may be secondary to changes in cGMP (Lewicki (1989)). In 
vascular smooth muscle, the mechanism of ANP-dependent vasodilatation 
is better understood. In addition to the generation of cGMP, there is 
a fall in intracellular calcium concentration or inhibition of 
agonist-stimulated increases in intracellular calcium (Meyer-Lehnert 
et al.,(1986), Appel et al.,(1987), Hassid (1986), Lewicki (1989)). 
The contraction of the smooth muscle cell is dependent on 
intracellular calcium and the state of phosphorylation of myosin light 
chain which is in turn dependent on the calcium and a cGMP-dependent 
enzyme - myosin light chain kinase. In keeping with the suggestion 
that ANP may cause vasorelaxation by this mechanism, Paglin et 
al.,(1988) have shown that ANP reduces the phosphorylation of myosin 
light chain in aortic rings. In other tissues the subcellular 
mechanism of action is not known. In the kidney, at least in the 
distal tubule and in the suppression of renin, cGMP is involved; but 
in the adrenal cGMP does not appear to be involved (see below).
In vivo, cGMP in plasma and urine correlates well with the 
biological actions of infused ANP (Wong et al.., (1988)), even in the 
lowest dose studies (Richards et al.,(1988b) and to follow, for 
example, diurnal changes in plasma ANP (Miyamoto et al.,(1989)).
ANP Receptors:
Membrane receptors for ANP were identified shortly after the
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discovery of the peptide and, following the experimental work of Maack 
(Maack et al.,(1987)), it is now known that these can be classified 
into two sub-groups: a guanylate cyclase (GC) linked receptor (or ANP- 
B receptor), which mediates the biological actions of ANP through the 
second messenger cGMP; and a smaller, non-GC linked receptor (the ANP- 
C or "clearance" receptor) which is involved in removing ANP from the 
circulation.
The presence of a guanylate cyclase linked receptor was suggested 
initially by the observations that cGMP levels follow plasma ANP
(above). The existence of a second receptor subtype was initially
suggested by Maack et al.,(1987)) who found that a 15 AA ring
contracted analogue of ANP (4-23 ANP, C-ANP, dANP or 102-121 ANP; see 
Figure 2.3) bound with high affinity in the isolated rat kidney but 
was devoid of demonstrable effects. However, it did cause natriuresis 
and diuresis in the intact animal and, if co-infused with full-length 
ANP in the isolated kidney, the renal effects of the latter were 
augmented. From these observations Maack proposed that the truncated 
ANP bound to a receptor involved in the clearance of ANP. Similar 
effects have since been reported for related truncated ANP analogues 
(Koepke et al.,(1989)) and Almeida et al.,(1989) have shown that co­
infusion of 4 _23ANP and radiolabelled 28 AA ANP results in
prolongation of the half-life of the intact peptide, reduced volume 
of distribution and delayed appearance of degradation products.
ANP-B Receptor: Initial attempts to characterise the ANP receptor 
using standard cross-linking and purification techniques demonstrated 
a 130 kDa protein which co-purified with guanylate cyclase activity 
(Paul et al.,(1987)). The reason for this difficulty in separating 
the ANP receptor and guanylate cyclase was subsequently demonstrated
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FIGURE 2.3:
STRUCTURE OF ANP AND C-ANP:
Structure of the circulating form of ANP in man, showing the 
disulphide-linked ring, and of the truncated C-ANP receptor 
analogue 4_23ANP (Maack et al.,(1987)).
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by Lowe (Lowe et al.,(1989), Schulz et al., (1989a)). Using the gene 
sequence from a known (sea urchin) membrane form of guanylate cyclase 
(GC) to probe a human cDNA library. They identified partial cDNA 
clones for membrane GC and these were then used to prepare full length 
DNA sequences of rat and human DNA (Chinkers et al. ,(1989), Lowe et 
al.,(1989)). Expression of these genes in cell culture conferred 
specific high affinity ANP binding sites and ANP stimulated GC 
activity (Lowe et al.,(1989), Chinkers et al.,(1989)). The gene 
encodes a protein of 130 kDa identical to that found with standard 
biochemical methods. Analysis of the protein found that it contained 
a short extracellular domain with a high degree of homology with the 
ANP binding site of the C-ANP receptor (below, Fuller et al.,(1988), 
Porter et al.,(1989)), a short single transmembrane domain and an 
intracellular component with two domains showing homology to the 
catalytic sites of protein kinases and soluble guanylate cyclase. Thus 
a single molecule contains both an extracellular ANP "receptor" and 
the enzyme GC. The GC activity is found at the COOH terminal and 
deletion of the sequence coding for the protein kinase domain 
(Chinkers and Garbers (1989)) produces a receptor with high 
constitutive GC activity which was unresponnsive to ANP; implying that 
the GC activity is normally suppressed by a protein kinase element and 
this suppression is released by ANP binding.
Recently the terminology of GC-linked receptors has become 
slightly confused by their subdivision into A-ANP and B-ANP subtypes 
following the isolation of a gene coding for a similar, but non­
identical, GC-linked receptor from rat brain (Schultz et al.,(1989)). 
This receptor was labelled B-ANP and the original GC-ANP receptor re­
labelled A-ANP. The major difference between the coded proteins lies
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in the extracellular "binding" site and the "new" receptor appears to 
have a higher affinity for BNP (2.10), although its functional role 
remains to be established.
ANP-C Receptor: This receptor is smaller and the basic subunit is a 
65-70 kDa protein which may exist as a homodimer of 120-130 kDa 
(Fuller et al.,(1988), Porter et al.,(1989)). Analysis of the gene 
for this receptor (Fuller et al.,(1988), Porter et al.,(1989)) has 
shown that the gene encodes a protien which, by hydrophobic analysis, 
is predicted to to have a 436 amino acid extracellular domain, a short 
single transmembrane domain of 23 AA and a short intracellular tail of 
37 AA. The protein binds ANP equally well in the mono or dimeric forms 
and does not contain guanylate cyclase by either structural analysis 
or functional studies.
Localisation: Receptors have been localised by in vitro
autoradiography and analysis of isolated tissues. For the most part 
their distribution coincides with the 'known functions of ANP (Chai et 
al.,(1986), see Martin and Ballerman (1989) for review). For example, 
using autoradiography (Chai et al.,(1986), Mendelsohn et al.,(1987)) 
ANP specific binding is found in the kidney (principally the 
glomerulus, intra-renal vasculature and inner medulla), in the 
vasculature (of the kidney, aorta, adrenal cortex, lung, liver and 
isolated smooth muscle cells) and in the adrenal gland and brain 
(particularly in the areas involved in volume homeostasis). 
Interestingly, the pattern of distribution closely parallels that of 
Angiotensin II (Mendelsohn et al.,(1987)). The affinity and density of 
these sites are reviewed by Martin and Ballerman (1989). Using 
standard ligand binding techniques (which do not discriminate between 
ANP-B and ANP-C receptors) the Kd values obtained (i.e. concentrations
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at which 50% binding is achieved) are in the range of 10-9-10-:li'M 
which are obviously consistent with biological activity. The reported 
density of receptors varies from 10 sites per cell (platelet) to 
values in the range of 100,000 sites per cell in cultured smooth 
muscle cells with similar values in membrane preparations of 10 to 
greater than 1000 fmol/mg membrane protein in vascular tissue (see 
Martin and Ballerman (1989) for review). The density of receptors and 
their Kd values (which are close to the observed plasma levels of ANP 
- in the pM range) are consistent with a physiological role for ANP.
Little is known of the relative density of B-ANP and C-ANP 
receptors. Maack et al.,(1987) initially suggested that 99% of the 
receptors in the kidney were of the clearance type. However, this 
seems likely to be an over estimation based on the failure to allow for 
ligand degradation and more recent estimates (using in vitro 
autoradiography and the ability of excess 4_23ANP to displace :L25I- 
ANP as a measure of C-ANP receptor binding) suggest more equal numbers 
of receptor subtypes (Brown et al.,(1990)) in the kidney. Brown et 
al.,(1990) have also shown that the C-receptor is limited to the renal 
cortex (glomeruli) but the B-receptor is present throughout the 
kidney. However, the relative density of receptor subtype is likely to 
vary between tissues (Martin and Ballerman (1989)).
Function of the C-ANP receptor: In contrast to the B-ANP receptor, 
where ligand binding stimulates production of cGMP, the precise 
function of the C-ANP receptor is uncertain. The most likely function 
remains that initially proposed by Maack, based on his physiological 
studies in the isolated kidney, and subsequently confirmed by Koepke 
et al.,(1988) and Almeida et al.,(1989). Further evidence to support 
receptor-mediated clearance of ANP comes from studies in cultured
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cells (Morel et al.,(1987)), where there is rapid internalisation of 
ANP. This process appears to be specific to the low molecular weight 
receptor (Murthy et al.,(1989)). The suggestion (Morel et al.,(1987)) 
that internalised peptide may exert a physiological role has yet to be 
explored.
Receptor regulation: When ligand concentrations are increased receptor 
numbers are usually reduced (down-regulation). ANP receptors appear to 
behave in this way. For example, in man, platelet ANP binding is 
reduced in heart failure and hypertension, where plasma ANP is 
elevated (Schiffrin (1987), Schiffrin et al.,(1988)). Similarly, in 
experimental animal models with elevated plasma ANP, such as the DOCA- 
salt hypertensive rat (Schiffrin and St. Louis (1987)) ANP binding is 
reduced. There is also evidence of heterologous ANP receptor 
regulation by ligands other than ANP. In circumstances where 
Angiotensin II is elevated ANP binding is also reduced. However, in 
contrast to the effects of ANP where down-regulation is associated 
with loss of biological activity, the effects of exogenous ANP are 
enhanced. This is interpreted as suggesting that Ang II causes 
reduction of the C-ANP receptor, thus increasing the availability of 
the peptide at the guanylate cyclase linked receptor (Chabrier et 
al.,(1988)).
In summary, two types of ANP membrane receptors have been 
described: one linked to guanylate cyclase (and hence the biological 
actions of ANP, through the generation of cGMP) and the other not 
linked to any second messenger system, apparently involved in 
receptor-mediated removal of ANP from the circulation.
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2.7. Renal actions of ANP.
The first demonstrated effects of atrial extracts were on the 
kidney (deBold et al (1981)) and, since then, studies have 
consistently reported that infusion of synthetic ANP causes 
natriuresis, diuresis and suppression of renin release (considered 
below, 2.9.). The mechanisms underlying these effects are still 
unresolved despite attempts to dissect out the intrarenal mechanisms 
using either infusion of exogenous ANP in the whole animal (the 
clearance of markers, such as PAH and Inulin, being used to infer 
sites of action within the kidney) or in vitro investigation of 
isolated nephron segments.
Renal effects of ANP infusion:
Early studies of the renal effects of ANP used large 
supraphysiological doses of the peptide and, although these produced 
dramatic increases in urine volume and electrolyte excretion, their 
physiological role is difficult to interpret (eg Richards et 
al.,(1985), Weidman et al.,(1986) in man; Burnett et al.,(1984) in 
dogs). However, several recent studies have examined the effects of 
low dose (<2 pmol/kg/min; Anderson et al.,(1987), Richards et 
al.,(1988a,b), Cottier et al.,(1988), Morice et al.,(1988), Solomon et 
al.,(1988)) ANP infusion - which raise plasma ANP less than two-fold. 
The renal response to this physiologically relevant increase in plasma 
ANP comprises a 50-100% increase in sodium excretion, a lesser 
increase in urine volume, no change in potassium excretion and, where 
measured (Richards et al.,(1988a,b), Solomon et al.,(1988)), small 
increases in the excretion of magnesium and calcium. These studies 
have also addressed the question of how these effects arise. The
consensus is for no change in glomerular filtration rate (GFR); a 
downward trend in renal plasma flow, with an upward trend in 
filtration fraction and thus the rise in sodium excretion is either1 
demonstrated (or inferred) to result from reduced tubular reabsorption 
of sodium (FeNa, Cottier et al.,(1988), Anderson et al.,(1987)). Only 
Solomon et al.,(1988) have attempted, by the use of lithium clearance 
as a marker of proximal tubular function, to indentify the segment of 
the tubule involved; but found only an upward trend in lithium 
clearance. In dogs and rats similar overall patterns are observed in' 
urine volume and electrolyte excretion (eg Soejima et al.,(1988), 
Zimmerman et al.,(1989), Pichet et al.,(1988), Seymour et al.,(1986), 
Dunn et al.,(1986), Harris et al.,(1989), Chapter 4). Caution is 
required, however, in interpreting these data. As a marker of GFR, 
inulin claerance may only be accurate to within 10% (Maack (1986)) and 
may thus conceal changes of a few percent which may be enough to 
account for the overall changes in sodium excretion. With higher 
levels of ANP this becomes evident. In rats and dogs further increases 
in the infused dose of ANP result in increased sodium excretion and 
the emergence of increasing potassium excretion and GFR (Soejima et 
al.,(1988), Bie et al.,(1988), Burnett et al.,(1986), Dunn et 
al.,(1986), Seymour et al.,(1986), Harris et al., (1989)). In man, 
higher infusion rates (15 pmol/kg/min, Brown and Corr (1987); 30 
pmol/kg/min, Weidmann et al.,(1986)) result in greater increases in 
sodium excretion and urine volume (3-6 fold) and also to a 
demonstrable rise in GFR (about 15%), but with additional increases 
in total and proximal tubular (FeNa & FeLi; Brown and Corr (1987)) 
excretion of sodium. Thus, from these studies it appears that a 
tubular component is essential and it is not clear whether a change in
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GFR only appears at high doses, or is always present and only detected 
at high doses - which seems most likely. In support of this, ANP 
(McMurray et al.,(1988d)) causes an increase in excretion of albumin 
(filtered by the glomerulus) but not B2-microglobulin (a tubular 
protein), implying a glomerular action.
The other information which infusion studies have given us is the 
long term response to ANP. Low doses in man (Janssen et al.,(1989)) or 
dogs (Kivlign et al.,(1988), Mizelle et al.,(1990)) infused for 
several days cause an increase in sodium excretion only over the first 
day or so, but slightly higher doses (around 10 pmol/kg/min; Mizelle 
et al.,(1988)) cause a sustained rise in sodium excretion. The reasons 
for these differences are unclear but they are important when it comes 
to assessing the therapeutic potential of ANP (see below, Section 4) 
and where higher plasma levels may be required to produce sustained 
effects.
Intrarenal Mechanisms:
More detailed intrarenal investigations - both structural and 
physiological - have attempted to unravel the site of action of ANP. 
Receptor Localisation: Specific binding sites for ANP have been
localised by autoradiography and are found in the glomeruli and in the 
medulla, where binding sites are distributed along the vasa recta and 
collecting ducts (Chai et al.,(1986), Koseki et al.,(1986), Brown et 
al.,(1990)). Receptors have also been characterised in isolated rat 
glomeruli (eg Ballerman et al.,(1986); Kd 0.46 nM), rat mesangial 
cells (Ballerman et al.,(1986), Kd 0.22 nM), and inner medullary 
collecting duct (Gunning et al.,(1987), Kd 0.07 nM), but are 
apparently absent from proximal tubule. Thus, at all these sites ANP 
receptors are present with physiologically relevant binding
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coefficients, at which ANP might act- The evidence for and against 
activity at individual intrarenal sites is as follows:
Glomerulus: In addition to the data from infusion studies other
observations point to a role for the glomerulus. Mesangial ANP 
receptors are present (Ballerman et al.,(1986) and, in vitro, ANP 
antagonises angiotensin II-stimulated mesangial cell contraction 
(Appell et al.,(1986)). In vivo, this would increase glomerular 
surface area and glomerular filtration coefficient, and thus 
glomerular filtration rate. In the isolated perfused rat kidney ANP 
(although only pharmacological doses have been studied) causes an 
increase in GFR (eg Murray et al.,(1985), Firth et al.,(1986)), 
although a tubular component also contributes towards the diuresis 
especially with increasing dose.
Tubule: The proximal convoluted tubule is apparently devoid of ANP 
receptors and it is therefore surprising that some infusion studies 
have suggested a proximal tubular effect based on the results of 
studies using lithium clearance (FeLi; Brown and Corr (1987), Solomon 
et al.,(1988)). In vitro, in the isolated perfused proximal tubule 
segment ANP has no direct effect (Baum and Toto (1986)). It does, 
however, inhibit angiotensin II stimulated sodium reabsorption in the 
proximal tubule (Harris et al.,(1987)) at physiologically relevent 
levels. In the absence of ANP binding sites at this site this effect 
may be mediated by changes in local blood flow. A further mechanism by 
which ANP may indirectly alter function in the proximal tubule is by 
interfering with glomerulo-tubular feedback, through which proximal 
tubular reabsorption is altered in response to changes in GFR (Harris 
et al.,(1988, 1989), Zhuo et al.,(1989), Harris and Skinner (1989)). 
Such an effect has been proposed in the whole animal (Marguiles and
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Burnett (1990), Huang and Cogan (1987)).
Perfusion of the loop of Henle in vitro is similarly without 
effect (Kondo et al.,(1986)) and Vinay et al.,(1987)) found no effects 
on the metabolism of the thick ascending limb. However, the loop of 
Henle may be indirectly involved in the actions of ANP since some 
workers have suggested that ANP may increase medullary washout, 
thereby reducing the concentrating ability of the loop of Henle. This 
effect might also be mediated via changes in blood flow, specifically 
in the vasa recta (see below).
There is no evidence of a direct effect of ANP in the distal 
convoluted tubules. However, since ANP impairs the synthesis and 
secretion of aldosterone by the adrenal (see below) it will have an 
indirect effect on distal tubular Na/K exchange. The extent to which 
this is involved in the response to ANP is not known but, since 
aldosterone levels change relatively slowly (Hall (1986), Mitchell and 
Navar (1989)), it is unlikely to contribute to the acute effects of 
ANP.
Collecting Duct: Surprisingly, it is in the collecting duct that most
direct evidence points to a site of action for ANP. As noted above, 
membrane receptors are present at this site. Microperfusion and 
micropuncture of the collecting duct (Sonnenberg et al.,(1986), Briggs 
et al,(1982), van de Stolpe and Jamieson (1988)) have shown reduced 
reabsorption of sodium in the collecting duct due to ANP. Sonnenberg
(1990) has recently confirmed this by demonstrating in the intact 
nephron that retrograde perfusion of ANP into the collecting duct 
causes a natriuresis, presumably by interaction with luminal 
receptors. In the inner medullary collecting duct Ziedel has shown 
that ANP increases cyclic GMP production, inhibits oxygen consumption
46
and reduces sodium reabsorption (Ziedel et al.,(1987, 1988, 1989)), 
thereby confirming that ANP can exert direct effects at this site. In 
a mathematical modelling study of the effects of ANP in the rat 
kidney, Meija et al.,(1990) found that a 50% reduction in sodium 
transport in sodium transport in the collecting duct matched 
experimentally obtained values and could theoretically account for 
all the observed effects of ANP in the tubule.
Vasculature: The intra-renal vasculature has many binding sites for 
ANP and isolated preconstricted intra-renal vessels dilate in response 
to ANP (Aalkjaer et al.,(1985)). Using micropuncture (Dunn et 
al.,(1987)) in the rat 500 ng/kg/min ANP (a pharmacological dose) 
appears to selectively dilate the afferent arteriole while 
constricting the efferent arteriole, thus increasing intraglomerular 
capillary pressure. Marin-Grez et al.,(1987) have further studied this 
using video microscopy to show that ANP caused dilation of pre- 
glomerular and constriction of post-glomerular vessels. A similar 
study of in vitro perfused glomeruli (Veldkamp et al.,(1988)) reported 
a similar pattern and theoretically such changes might contribute to 
increases in GFR.
In the whole animal, however, although some high dose studies 
reported a transient (Burnett et al.,(1984) or sustained increase in 
ERPF (Dunn et al.,(1986), Hintze et al.,(1984)), the general consensus 
from pfysiological studies in man is for a fall (or downward trend) in 
ERPF (Biollaz et al.,(1986), Cottier et al.,(1988), Richards et 
al.,(1988a,b), Solomon et al.,(1988), Anderson et al.,(1987)), even 
when correction is made for extraction of PAH (Janssen et al.,(1987)).
However, as with inulin clearance (above), PAH clearance is a 
relatively insensitive method which may not detect small changes. Even
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in the absence of changes in overall renal plasma flow re-distribution 
of flow may take place within the kidney. Diverting blood from the 
cortex to the medulla would theoretically reduce the role of the 
glomeruli and also increase medullary washout, reducing concentrating 
capacity. Kiberd et al.,(1987) demonstrated that 67pmol/kg/min ANP 
caused an immediate increase in sodium excretion but found that 
increased vasa recta blood flow took approximately 45 minutes to 
develop, Davies and Briggs (1987) similarly reported that the 
medullary gradient was reduced. However, the question arises of 
whether changes in medullary concentration are primary or secondary to 
the natriuresis, since the natriuretic actions of ANP precede changes 
in solute gradient (Kiberd et al.,(1987)). Other factors, such as the 
renal interstitial pressure have been proposed to contribute to the 
effects of ANP but their role is unknown (Garcia-Estan and Roman
(1990)).
Overall, the balance of evidence fails to localise the effects 
of ANP to one single nephron segment and it seems more likely to 
involve the interaction of effects at several different nephron sites. 
The situation is further complicated by the existence of factors which 
modulate the effects of ANP on the kidney.
Factors modulating the renal effects of ANP: When the renal perfusion 
pressure is reduced in either the intact animal (Seymour et 
al.,(1987)) or in the isolated perfused rat kidney (Firth et 
al.,(1987)) then the natriuretic effects of ANP are blunted. The 
mechanisms underlying this are unclear. Redfield et al.,(1989) infused 
saralasin but failed to produce any improvement, infering from this 
observation that activation of the intra-renal renin angiotensin
system is not responsible. Furthermore when Ang II was used to restore 
perfusion pressure the natriuretic response was enhanced. However, 
saralasin is a partial agonist and the results are therefore difficult 
to interpret. Secondly, the renal sympathetic nerves are important 
Simmonetta et al.,(1990)). In experimental cirrhosis in the rat 
(Koepke et al.,(1987)) the natriuretic actions of ANP are similarly 
blunted. Denervation of the kidney restores the effect of ANP. Again, 
the underlying mechanism is unclear. A direct effect on renal blood 
flow may be important, but alternatively this may simply reflect a 
physiological antagonism since sympathetic activation causes sodium 
retention (Koepke and diBona (1987)). A further alternative involves 
activation of the renin-angiotensin system by sympathetic nerves. Once 
more further investigation is required to dissect out the relative 
importance of these actions. Finally, the renin-angiotensin system 
appears to have a central role in modulating the actions of ANP. When 
Ang II is infused (McMurray and Struthers (1988b), Seymour and Mazack
(1988)) or the renin-angiotensin system activated by diuretics, 
prostaglandins or other exogenous means (McMurray and Struthers 
(1988a,b), Lang and Struthers (1990) the natriuretic actions of ANP 
are blunted or abolished. Interuption of the renin-angiotensin system 
by ACE inhibition (Bie et al.,(1990), Chapter 4) can enhance the 
actions of ANP. This latter observation is the subject of debate (see 
Chapter 4) and ACE inhibitors have also been reported to have either 
no effect or to lessen the natriuretic action of ANP (Gaillard et 
al.,(1988,1989), Richards et al.,(1989a)), presumably reflecting the 
dual effects of suppression of Ang II and reduction in renal perfusion 
pressure (Polonia et al.,(1990)). The site of this interaction within 
the kidney is also uncertain and is discussed in more detail in
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chapter 4 but, briefly, may involve either a specific interaction 
between ANP and Ang II at a number of sites within the nephron, with 
the simplest model invisaging Ang II (by its proximal tubular effects 
on sodium reabsorption) regulating the delivery of sodium to the 
distal tubule where ANP then acts. Furthermore, suppression of renin, 
and thus intrarenal Ang II, may partly contribute to the observed 
natriuretic effects of ANP.
In summary the renal effects of ANP are exerted at three levels: 
(i) direct actions on the collecting tubule and possibly other nephron 
segments; (ii) inhibition of the synthesis of other renal hormones 
(aldosterone, renin, AVP); (iii) indirect effects by interference with 
the vascular (angiotensin) and tubular (AVP) actions of other 
hormones; and glomerulotubular feedback.
2.8. Cardiovascular actions of ANP.
The first studies with atrial extracts (deBold et al.,(1981)) 
and synthetic ANP (Burnett et al.,(1984), Maack et al.,(1984)) 
demonstrated hypotensive effects. However, these early studies 
employed pharmacological doses of ANP; more subtle vasodilator and 
hypotensive effects have been found with physiologically relevant 
doses, together with other effects including increased capillary 
permeability and impaired baroreceptor sensitivity. As with the renal 
actions of the peptide, investigators have studied the integrated 
action of ANP in the whole animal and the effects on its isolated 
components.
Actions of ANP on isolated vessels. In vitro, isolated segments of 
large capacitance vessels (such as the aorta), can be made to relax
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with ANP if preconstricted (Winquist et al./(1984)/ Garcia et al.,
(1984)). This effect is not endothelium dependant (Winquist et 
al.,(1984)) but nanomolar concentrations of ANP are generally required 
to produce effects. Similar effects have been confirmed in human 
capacitance vessels (Hughes et al.,(1988)). In resistance vessels, 
however, ANP appears to have little in vitro effect. Aalkjaer et al.,
(1985) studied the effects of ANP on cardiac, mesenteric, cerebral and 
peripheral resistance vessels, using the myograph technique, and found 
no effect at micromolar concentrations of ANP. These findings have 
been confirmed in the rat (deMay et al.,(1987)) and in human tissue 
(Hughes et al.,(1988), (1989)). One exception is the renal circulation 
(Aalkjaer et al.,(1985), deMay et al.,(1987)) where ANP does cause 
vasorelaxation in isolated resistance vessels, and in the isolated 
perfused kidney (Garcia et al.,(1984)), although whether this occurs 
in vivo is still debated (2.7). There are conflicting reports on the 
effects of ANP on veins. The rabbit facial vein dilates with ANP 
(Winquist et al.,(1984), although other preparations including the 
human saphenous vein (Hughes et al.,(1988)) do not. In fact the in 
vitro assessment of vasodilator substances - such as ANP - are 
difficult to interpret because of the need to preconstrict the 
vessels. Proctor and Bealer (1987) found that ANP was more effective 
at dilating skeletal muscle vessels preconstricted with Ang II rather 
than vasopressin or noradrenaline. The vasoconstrictor used is 
therefore important. Furthermore, the dose-relationships between the 
vasoconstrictor and vasodilator agents are seldom investigated and, 
the finding that ANP does not dilate a vessel maximally constricted 
with micromolar concentrations of Ang II means only that ANP is not an 
effective vasodilator in the presence of high concentrations of a
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potent constrictor. Clearer results come from isolated tissue 
preparations such as the "isolated" human forearm (Webb et 
al.,(1988)), Hughes et al.,(1988)). Infusion of doses as low as 10 
ng/min produced increases in forearm blood flow, although the plasma 
levels of ANP were increased above the physiological range. The only 
other site where human vessels are accessible in vivo is in the 
retinal circulation. Using fluorescein angiography Mann et al.,(1987) 
have shown that large doses (lpg/kg) dilate large retinal arteries. 
Although an elegant technique demonstrating vasodilator effects of ANP 
in vivo, pharmacological doses of ANP were employed and the resistance 
vasculature is probably beyond the resolution of this method.
Although ANP can dilate vessels from different tissues 
qualitative and quantitative differences in the vasodilator effects of 
physiologically relevant doses of ANP have not been fully assessed. 
Furthermore, attempts to examine overall changes in blood flow are 
limited by the fact that changes in blood pressure or flow in one 
organ may activate counter-regulatory influences which further alter 
regional blood flow. It is clear that muscle and skin blood flow is 
increased by low dose ANP infusion (Hughes et al.,(1988), Webb et 
al.,(1988)). Garcia et al.,(1985) investigated the regional effects of 
ANP (lpg/kg) using radiolabelled microspheres in the rat and found 
that high dose ANP increased skin and renal blood flow but had no 
effect on other organ flow. However, before we can draw conclusions on 
the differential effects of ANP on organ blood flow, these studies 
will need to be repeated with low dose infusions of the peptide.
Finally, ANP can reduce cardiac output (see below), one possible 
explanation for which would involve a direct negative inotropic effect 
on the heart. Although there is conflicting data, the balance of
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evidence favours no effect with studies such as that of Criscione et 
al.,(1987)) unable to demonstrate any direct effects on contractility 
in the isolated heart.
Infusion of ANP: In man, the history of the cardiovascular actions of 
ANP follows the same pattern as the renal effects, with large 
reductions in blood pressure being seen in the early studies (eg 
Richards et al.,(1985), Weidmann et al.,(1986)) but not in later 
studies using physiologically relevant doses of ANP (Richards et 
al.,(1988a,b), Solomon et al.,(1988), Cottier et al.,(1988), Anderson 
et al.,(1987)). Part of the reason for this apparent absence of effect 
is methodological. Richards et al.,(1988c) have recently shown that 
infusion of as little as 0.75 pmol/kg/min ANP can reduce blood 
pressure measured intra-arterially, but these changes cannot be 
detected by non-invasive measurement of blood pressure in the other 
low dose studies (above). If infusion is carried on beyond a few hours 
then reduction in blood pressure can be detected (1 pmol/kg/min; 
Janssen et al.,(1989)) non-invasively after approximately 24 hours. 
There are no other invasive studies in normal man, and we have instead 
to rely on data from patients with heart failure (e.g Cody et 
al.,(1987), Goy et al.,(1988)) and hypertension (Tonolo et 
al.,(1989)). The consensus from studies in heart failure (reviewed by 
Northridge et al.,(1991)) is for cardiac output to increase and right 
atrial, pulmonary capillary wedge, systemic vascular resistance and 
arterial pressure to fall, with infusions rates of greater than 10 
pmol/kg/min (eg Cody et al.,(1987)). With lower dose infusions (less 
than 10 pmol/kg/min; eg Goy et al.,(1988)) arterial pressure does not 
change, cardiac filling pressures fall and there is a trend towards an 
increase in cardiac output and reduced systemic resistance. In
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hypertensive patients (Tonolo et al.,(1989)) short tern administration 
of 1 or 2 pmol/kg/min ANP caused a 10 and 20 mmHg fall in blood 
pressure respectively, associated with a reduced haematocrit, a 
downward trend in cardiac output and in cardiac filling pressures. 
Interestingly, a significant rise in sodium excretion was only 
observed with the higher dose.
These studies indicate that ANP can lower blood pressure (most 
clearly at high doses) and cardiac filling pressures, possibly by a 
combined arteriovenous dilatation but also by contraction of the 
intravascular volume (see below). Cardiac output is generally 
maintained, and there is little change in heart rate, making ANP an 
attractive therapeutic agent in heart failure (see later; Section 4).
Studies in experimental animals permit more detailed 
characterisation of these effects by invasive measurement of 
cardiovascular function. The earliest studies of high dose ANP (Maack 
et al.,(1984), Burnett et al.,(1984) showed clear reductions in 
arterial pressure. Of later studies on the dose-response relationship 
of the haemodynamic effects of ANP that of Bie et al.,(1988) is 
possibly the most complete, involving infusion of 4, 8 and 16
pmol/kg/min ANP, each for 20 minutes. Sodium excretion only increased 
in the higher dosage groups, whilst 25-50% reductions in right and 
left atrial pressures were evident from the lowest dosage group. There 
were modest reductions in arterial pressure (approximately 5 mmHg) in 
the two higher dose groups and similar, modest reduction in cardiac 
output with high doses. Heart rate did not increase, nor was there any 
dramatic change in calculated total peripheral resistance. Zimmerman 
et al.,(1987b) observed a similar pattern with reduction of cardiac 
filling pressure with low doses of ANP. Such studies tell us that very
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low doses of ANP can cause acute reduction in cardiac filling 
pressures but the reasons are still not clear. In many studies changes 
in filling pressure were detected before changes in haematocrit and 
urinary changes, and are thus unlikely to be dependent on changes in 
intravascular volume. Furthermore veins (above) appear to be 
relatively insensitive to the effects of ANP in vitro and in vivo 
(Webb et al.,(1988)). An alternative suggestion is that venous 
resistance - rather than venous capacitance - is increased (Lee and 
Goldman (1988)), however, this has not been confirmed.
The precise mechanism of these vascular effects still awaits 
elucidation, as does the question of whether these (potentially 
therapeutic) effects are sustained during prolonged administration.
Although ANP dilates arteries in vitro this is not necessarily 
the mechanism by which it lowers blood pressure. Several studies have 
been designed to look specifically at the short and long-term 
mechanism of reduction of blood pressure. Acute falls in blood 
pressure appear to be dependent on reduced cardiac output. For 
example, in sheep, Parkes et al.,(1988) infused ANP for five days, 
producing a sustained reduction in blood pressure. On the first day a 
fall in blood pressure was accompanied by reduced cardiac output and 
intravascular volume. However, by the final day, the pattern had 
changed with cardiac output returning to normal, the reduced blood 
pressure at this stage being secondary to a reduction in calculated 
peripheral vascular resistance.
Whether reduced whole body sodium contribtes to the fall in blood 
pressure is still unclear; Janssen et al.,(1989) in their study of low 
dose ANP in essential hypertension found that the hypotensive effects 
of ANP were associated with a persistent negative sodium balance of
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approximately 50-100 mmoles. However, Garcia et al.,(1985) 
demonstrated in the SHR that low dose ANP (in the range 1-2 
pmol/kg/min) caused a fall in blood pressure without any effect on 
sodium excretion and, in a similar series of experiments, Garcia et 
al.,(1987) were unable to demonstrate any changes in plasma or 
extracellular volume accompanying the reduction in blood pressure with 
ANP.
In man, the only study to examine the blood pressure lowering 
effects of ANP with simultaneous invasive cardiac measurements is that 
of Tonolo et al.,(1989). Infusion of ANP (1, then 2 pmol/kg/min for 2 
hours) caused a 10 mmHg reduction in systolic pressure; associated 
with a natriuresis, increased haematocrit and reduced cardiac filling 
pressures but no change in total peripheral resistance. The inference 
from these studies is that when infusion of ANP causes a reduction in 
blood pressure, then the initial decrease is due to reduced cardiac 
output secondary to reduced filling pressures as a consequence of a 
combination of natriuresis-diuresis and increased capillary 
permeability. The longer term changes in blood pressure appear to be 
mediated by reduced vascular resistance. Whether this is a direct 
effect of ANP or indirectly mediated by suppression of pressor systems 
is still not known. Similarly, the contribution of natriuresis- 
diuresis to the intermediate and long-term hypotensive effects of ANP 
is also uncertain. In even the best documented study (Janssen et 
al.,(1989)) the hypotensive effects of low dose infusion and the 
return to baseline after cessation of ANP lagged 12-24 behind the 
changes in renal function.
Capillary permeability: During infusion of ANP many studies have shown
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a rise in haematocrit (eg Richards et al.,(1988a,b), Weidmann et 
al.,(1986), Solomon et al.,(1988), Trippodo et al.,(1986)). This 
effect is due to contraction of the intravascular volume and can occur 
in the absence of changes in urine volume, for example in 
nephrectomised animals and in man (Fluckinger et al.,(1986), Tonolo et 
al.,(1988)). The reason for this being that ANP can directly increase 
capillary permeability (Huxley et al., (1987)).
Baroreceptor function: As a general rule, although not without
exception, infusion of ANP is not associated with an increase in heart 
rate, even in the presence of a significant fall in blood pressure (eg 
Zimmerman et al.,(1987)). This has been interpreted as indicating that 
ANP inhibits the baroreceptor-mediated reflex tachycardia under these 
circumstances. ANP attenuates the heart rate response to externally 
applied neck pressure (Elbert and Cowley (1988)) in man; and has been 
shown to reduce the reflex increase in forearm vascular resistance in 
response to lower body negative pressure (Takeshita et al.,(1987), 
although others disagree (Volpe et al.,(1988)). The precise role of 
the effects of ANP are still unknown, as is the site of action. As 
noted above, ANP is present within the brainstem where it may 
interfere with cardiovascular reflexes. However, mRNA for ANP is also 
expressed in the aortic arch (Gardner et al.,(1988)) where it may have 
a local effect on the afferent limb of the reflex. Similarly, ANP has 
been shown to impair ganglionic transmission and to reduce sympathetic 
nerve activity measured directly in anaesthetised rats (despite 
reduced blood pressure; Thoren et al.,(1986). A final note of caution 
concerns the infrequent reports of vasovagal syncope with ANP infusion 
(eg Biollaz et al.,(1987)). This is only seen with high doses, rapidly 
recovers and is likely to be an idiosyncratic reaction.
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In summary ANP exerts a variety of vascular effects including 
increases in capillary permeability, direct vasodilator effects, 
inhibition of baroreceptor function and effects on the brain stem 
cardiovascular centres which together result in reduced arterial and 
cardiac filling pressures.
2.9. Endocrine actions of ANP.
In addition to its vascular and renal effects, ANP exerts a 
spectrum of endocrine effects the best documented of which are 
suppression of renin release and inhibition of the synthesis and 
secretion of aldosterone. Other interactions with neuroendocrine 
systems are covered later.
Renin: Suppression of circulating renin was one of the first effects 
of ANP to be demonstrated (Maack et al.,(1984), Burnett et 
al.,(1984)), setting it apart from other natriuretic agents where 
stimulation of renin is the rule. In experimental animals, subsequent 
studies employing low dose infusion of ANP have shown similar 
suppression of basal renin levels (e.g. Seymour et al.,(1986), 
Zimmerman et al.,(1987), Chapter 4, Figure 4.3.) or the renin response 
to, for example, reduced renal perfusion pressure (Scheuer et 
al.,(1987), or ACE inhibition (Chapter 4, Table 4.1.). In man, the 
earliest studies (e.g. Richards et al.,(1985)) found that renin did 
not rise during the hypotensive response to high dose ANP. The recent 
series of low dose infusion studies (Richards et al.,(1988a,b), 
Cottier et al.,(1988), Anderson et al.,(1987)) have confirmed the 
ability of very modest increments in plasma ANP to suppress renin 
release. Others have demonstrated the ability of ANP to inhibit the
58
release of renin in response to a variety of stimuli including B- 
agonists, diuretics and ACE inhibition (McMurray and Struthers 
(1988a,b; Lang and Struthers (1990). The mechanism through which ANP 
achieves these effects is still unresolved. Theoretically, it may 
involve a direct effect on the juxtaglomerular apparatus -which 
secretes renin - or be mediated indirectly by alterations in the 
delivery of sodium to the macula densa, or via baroreceptor-regulated 
renin release. The precise mechanism is difficult to resolve for the 
simple reason that under most circumstances infusion of ANP causes 
parallel increases in sodium excretion (and hence delivery of sodium 
to the macula densa) and suppression of renin. In support of a macula 
densa mechanism, in the non-filtering kidney (Opgenorth et al.,(1986) 
and in functionally anephric humans with chronic renal failure 
(Richards et al.,(1988d)) infusion of ANP has no effect on either 
basal or stimulated renin release. However, in the study in Chapter 4, 
ANP causes a similar fractional reduction in plasma renin regardless 
of changes in overall sodium excretion (manipulated by infusion of Ang 
II or an ACE inhibitor (Figure 4.8.,Table 4.1.)). Attempts to unravel 
this problem in vitro have similarly given conflicting results. In 
isolated juxtaglomerular preparations (Antonipallai et al.,(1986), 
Kurtz et al.,(1986)) ANP inhibits hormone release; an effect mediated 
by cGMP. However, in isolated segments of renal microvasculature, Itoh 
et al.,(1987) found that ANP stimulated renin release. A further 
potential mechanism is on baroreceptor mediated renin release, since 
it has been shown (Marin-Grez et al.,(1986), Veldkamp et al.,(1988)) 
that ANP can dilate the afferent arteriole.
Overall, although there are conflicing reports these mostly come 
from either in vitro studies or non-physiological preparations - like
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the non-filtering kidney. It seems likely, based on studies such as 
that in Chapter 4, where physiological increments of ANP are assessed 
in conscious animals, that in a physiological setting ANP has a direct 
effect on renin release. However, like the renal effects of ANP in 
general, suppression of renin may involve the balance of several 
different regulatory influences.
Adrenocorticosteroids: In contrast with renin there is no doubt that 
ANP directly inhibits aldosterone synthesis and secretion. However, 
the effects on cortisol secretion are uncertain.
In infusion studies, short term administration of ANP has a 
variable effect on plasma aldosterone with either no effect (eg 
Weidmann et al.,(1986), Richards et al.,(1985), Cottier et al.,(1988), 
Morice et al.,(1988), Anderson et al.,(1987)) or a reduction of about 
50% (Maack et al.,(1984), Zimmerman et al.,(1987); Solomon et
al.,(1988), Richards et al.,(1988a,b)). The absence of effects in some 
studies probably reflects the slow time course of changes in 
aldosterone (and the short duration of ANP infusion) and the
superimposed diurnal reduction in aldosterone during the period of 
study. When aldosterone is stimulated, then ANP blunts the rise in 
plasma levels in response to infusion of Ang II or ACTH (Cuneo et 
al.,(1987), McMurray et al.,(1988c)). In contrast ANP has no effect on
the cortisol response to ACTH (Cuneo et al.,(1987), McMurray et
al.,(1988c)). This ability of ANP to inhibit stimulated aldosterone 
production indicates a direct action on the adrenal (confirmed in 
vitro, below), although under normal circumstances the ANP-dependent 
reduction in renin (Maack et al.,(1984), Richards et al.,(1988a,b)) 
would be expected to cause a secondary reduction in aldosterone.
In addition long term exposure of the adrenal to ANP has been
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shown to result in down-regulation of zona glomerulosa receptors and 
to inhibition of the growth and steroidogenic capacity of the zona 
glomerulosa by a process which is independent of angiotensin II or 
ACTH (Rebuffat et al.,(1988), Mazzochi et al.,(1987)).
In vitro, ANP inhibits the synthesis and secretion of aldosterone 
by cultured adrenal glomerulosa cells from a variety of species (Kudo 
and Baird (1986), Goodfriend et al.,(1984), Lang and Struthers (1990) 
- for review) in response to many agonists including Ang II, 
potassium, ACTH, forskolin and dibutyryl cAMP. The mechanism by which 
ANP produces this reduction in aldosterone is unclear. Stimulation of 
adrenocortical cyclic GMP synthesis by ANP has been described but this 
appears not to be involved (Matsuoka et al,, (1987)) in the steroid 
response since cyclic GMP by itself will tend to stimulate rather than 
inhibit steroidogenesis (Nambi et al.,(1982), Ganguly et al.,(1989)). 
A common factor in the mechanism of all adrenal secretagogues is the 
change in cell calcium metabolism (Kojima et al, 1986)..However, ANP 
appears to reduce aldosterone secretion independently of changes in 
intracellular calcium (Capponi et al.,(1986)) or activation of the 
phosphotidylinositol pathway (Ganguly et al.,(1989)).
In summary, although ANP directly inhibits aldosterone secretion, 
the mechanisms are unknown (see Lang and Struthers (1990)) for more 
comprehensive review.
ANP also has effects on other hormonal systems. The suppression 
of ADH and of the pituitary hormones are the most completely described 
(see below, 2.10) but receptors for ANP are also present in the ovary 
(Kim et al.,(1987)), where ANP has been shown to stimulate luteal 
guanylate cyclase (Budnik et al.,(1987)) and in the placenta (Sen 
(1986), Hatjis and Grogan (1988)) where ANP may potentially exert
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other endocrine effects.
2.10. Actions of ANP in the nervous system.
Shortly after its identification in the heart ANP was 
demonstrated in the central nervous system (Morii et al.,(1985)). 
Immunoreactive ANP is present in high concentration in a number of 
areas of rat brain including the subfornical organ, area postrema and 
choroid plexus and to a lesser extent in other areas (Quirion et al., 
(1984)). ANP is also present in the adrenal medulla (Ong et al. , 
(1988)). There is now considerable evidence to show that ANP is 
locally produced in the brain not least because ANP does not readily 
cross the blood-brain barrier (Levin et al.,(1988)). Neurones with 
cell bodies which stain for ANP are present and project largely to 
regions in the lateral wall of the third ventricle known to be 
involved in osmoregulation (Standaert et al.,(1985)). Messenger RNA 
for ANP is present in neural tissue (Glembotski et al.,(1985), Gardner 
et al.,(1987)), but unlike the heart the major storage form of ANP 
appears to be the biologically active form (Shiono et al.,(1986)). Low 
doses of ANP administered into the cerebral ventricles inhibit the 
release of vasopressin in normally hydrated rats (Samson et 
al.,(1987)) and antagonise the stimulatory action of co-administered 
angiotensin II on AVP release in the rat (Yamada et al.,(1986)). 
Central ANP also inhibits dehydration- and angiotensin-stimulated 
water drinking in rats (Antunes-Rodriguez et al.,(1985)). Recent 
studies have shown that central administration of ANP can lower reduce 
sympathetic outflow (Schultz et al.,(1990)) and lower blood pressure 
via an a2 adrenergic mechanism (Levin et al.,(1988)). Within the 
central nervous system ANP also inhibits the pressor effects of
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centrally administered angiotensin (Itoh et al.,(1986), Casto et 
al.,(1987)). The role of ANP at other sites within the brain are not 
as clearly defined- Although ANP receptors are present in the 
pituitary and ACTH and LH are increased and decreased respectively by 
ANP (Horvath et al.,(1986), Samson et al.,(1988)) these effects are 
not apparent in isolated pituitary cells. They may be due to a 
hypothalamic action, inhibiting the release of LHRH and prolactin 
perhaps through an effect on dopaminergic pathways (Samson (1988)).
2.11. Related natriuretic peptides.
The search to identify the distribution of ANP led not only to 
the identification of ANP in other tissues but also in the 
identification of closely related peptide hormones. The most studied 
is Brain Natriuretic Peptide (BNP, Sudoh et al.,(1988), Figure 2.2), 
which in man is a 32 AA peptide (Kambayashi et al.,(1990)). 
Paradoxically, although it was discovered in the brain BNP is widely 
distributed and is also present in atrial tissue (Kambayashi et 
al.,(1990).
Brain Natriuretic Peptide.
Sudoh et al.,(1988) initially identified a 26 AA peptide from 
porcine brain with approximately 50% homology with ANP, and containing 
a 17 AA disulphide linked ring structure. In the same year a larger 32 
AA peptide (BNP-32, Sudoh et al.,(1988)) was discovered, which is the 
same size as human BNP, subsequntly identified in atrial tissue 
(Kambayashi et al.,(1990)).
The processing of BNP is similar to that of ANP, and has been 
best characterised in porcine heart where two large forms of the
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peptide are found: a 131 AA peptide (preproBNP, Maekawa et al.,(1988)) 
and a 106 AA peptide (y-BNP, Minainino et al.,(1988)). At the carboxyl 
end of both these peptides is the 32 AA BNP and it seems likely that 
removal of a 25 AA "signal peptide" from preproBNP produces yBNP, 
which is then cleaved to leave the active 32 AA peptide (Porter et 
al.,(1989)). As with ANP the predominant storage form in the heart is 
the propeptide (yBNP) but in the brain the 26 and 32 AA forms 
predominate. Although there is strong homology between BNP and ANP, 
this is less marked for the precursors which show little homology and, 
unlike ANP, there are apparently large species differences and in man, 
for example, preproBNP has been shown to contain 134 AA (Sudoh et 
al.,(1989)).
In the brain concentrations of immunoreactive BNP are at least 
ten times those of ANP, but show a similar distribution through the 
areas involved in cardiovascular homeostasis (2.10). BNP is also 
present in the atria where the concentration of immunoreactive hormone 
is about 1% of the level of ANP, although the absolute cardiac 
concentrations of BNP are much greater than those in the brain. 
Circulating hormone (Mukoyama et al.,(1990, 1991)) plasma levels of 
approximately 1 pmol/1, and appear to behave like ANP being increased 
increased in heart failure.
Finally, the functions of BNP closely parallel those of ANP. In 
most tissues ANP and BNP have been shown to bind to the same receptor 
sites with equal affinity, with a similar autoradiographic 
distribution, and to stimulate the production of cGMP (Iwata et 
al.,(1989), Brown and Czarnecki (1989), Gunning et al.,(1990)). In 
fact two subtypes of guanylate cyclase linked ANP receptor are now 
recognised based on their differential affinity for ANP and BNP (Chang
64
et al.,(1989); section 2.7). The GC-A subtype recognises both while 
the GC-B subtype shows preferential affinity for BNP. The spectrum of 
biological effects of BNP is identical to that of ANP; Sudoh et 
al.,(1988) demonstrated natriuretic, diuretic and hypotensive effects; 
in the adrenal gland BNP inhibits aldosterone secretion (Higuchi et 
al.,(1989)); and in the brain intraventricular administrtion of BNP 
has a similar spectrum of effects to ANP and, for example, inhibits 
the pressor response to Ang II (Shirakami et al.,(1988)).
Urodilatin.
Urodilatin is a 32 AA peptide identical to the 32 AA carboxy 
terminal of the ANP precursor (i.e. 95-126 hANP, Figure 2.2.)
identified in human urine (for review see Feller et al.,(1990)). This 
peptide does not appear to circulate in the blood and, unlike ANP, it 
is not cleaved by NEP (Gagelmann et al.,(1988)). Preliminary reports, 
using immunohistochemical techniques (Feller et al.,(1990)) suggest 
that urodilatin immunoreactivity can be localised in the tubular cells 
of the distal nephron, the suggestion being that it is produced at 
this site and acts as a local hormone within the kidney, with its 
proposed site of action being on luminal ANP receptors in the 
collecting duct. The biological effects of infused urodilatin are also 
similar to ANP and are mediated by cGMP (Riegger et al.,(1988)) 
although it may not cause suppression of renin and aldosterone (Feller 
et al.,(1990)).
Recently, more related natriuretic peptides have been discovered 
including Iso-ANP and CNP (Sudoh et al.,(1990)). The roles of these 
are yet to be established but it seems probable that more peptides 
related to ANP will be discovered which form part of the ANP "hormonal
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system".
2.12. Therapeutic effects of ANP.
Obviously the spectrum of actions of ANP (Figure 1.1) indicate 
that the hormone may be useful in the treatment of a variety of 
conditions including hypertension and heart failure, and in other 
oedematous states.
The effects of ANP in hypertension and heart failure are 
described in some detail in the section on the cardiovascular effects 
of ANP and are reviewed in detail by Richards (1990) and Northridge 
et al.,(1991). Studies in heart failure are limited to the acute 
effects of ANP but show the potentially beneficial combination of 
diuresis and natriuresis, renal effects, suppression of the renin- 
angiotensin system but more importantly a clear reduction in cardiac 
pre-load at low doses of ANP, without any significant impairment of 
cardiac output. The results of long term studies are therefore awaited 
with interest. In hypertension, acute administration of ANP has 
similarly been shown to reduce blood pressure. However, there are now 
several studies of prolonged low dose infusion of ANP in hypertensive 
animal models including DOCA salt, Goldblatt and Spontaneously (SHR) 
hypertensive rats. The models have been studied by Garcia and 
colleagues (eg Garcia et al.,(1985, 1987) who have found that infusion 
of 1-2 pmol/kg/day produces a fall in blood pressure within 24 hours, 
with maximal effects at the end of a six day infusion protocol. 
Reductions of up to 30 % were observed, and such reductions have been 
confirmed in the SHR over a 7 day infusion by deMay et al.,(1987)). 
Confirmation that these effects might by translated into an effective 
antihypertensive effect in man have recently been provided by Janssen
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et al.,(1989). Infusion of approximately 1 pmol/kg/min ANP for five 
days into six mild hypertensive patients resulted in a 10% fall in 
blood pressure. Blood pressure reduction was not evident until 12 
hours after the start of infusion and maximal, sustained effects were 
seen after 36 hours. Further assessment of the antihypertensive 
effects of ANP are limited by the need for intravenous administration 
of the peptide; possible ways to circumvent this problem are discussed 
in Section 4. The fact that such a low dose of ANP lowers blood 
pressure is reassuring since ANP might be predicted to be less 
effective in hypertensives than normal subjects for two reasons. 
Firstly, plasma levels of ANP are already elevated (2.3) and, 
secondly, ANP receptors are down-regulated (eg Schiffrin et 
al.,(1987)). However, to the contrary evidence in man (Weidmann et 
al.,(1986), Cusson et al.,(1987)) and in experimental animals 
(Onwochei et al.,(1987), Pollock and Arendshorst (1990)) suggests that 
there is an enhanced natriuresis in response to ANP, and enhanced 
release of ANP in response to atrial distension.
Other conditions: Other areas where ANP appears to have therapeutic 
potential include acute renal failure and asthma. In experimental 
ischaemic acute renal failure (Nakamoto et al.,(1987)) and Uranyl 
nitrate induced renal failure (Heidgreder et al.,(1988) in rats, 
pharmacological infusion of ANP improved glomerular filtration rate. 
In dogs infusion of 0.3 pg/kg/min ANP improved immediate and 24 hour 
function of autotransplanted kidneys, subjected to 24 hours cold 
ischaemia (Lewis et al.,(1989)). However, a controlled trial in human 
cadaveric transplants (Ratcliffe et al.,(1991)) failed to show any 
beneficial effects, reflecting the multitude of factors determining 
outcome in human transplantation.
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Recently, Hulks et al.,(1990a,b) have shown that ANP causes 
bronchodilation in the normal human airway at pharmacological 
concentrations and in asthmatic subjects at pathophysiological levels. 
The mechanism underlying this effect awaits further investigation and 
could conceivably be a direct action on bronchial smooth muscle or an 
indirect effect via vasodilation and the "washout" of 
bronchoconstrictor substances. Nevertheless, it does suggest that 
either ANP or stimulation of cGMP, may offer an alternative 
therapeutic approach to the treatment of asthma.
In summary, ANP has a unique and potentially beneficial spectrum 
of therapeutic effects, the use of which is limited by the need to 
administer the hormone parenterally.
2.13. Physiological Role of ANP.
Despite the considerable literature on the actions of ANP there 
is still debate as to whether ANP has any physiological role (Goetz 
(1990)). This suggestion has emerged for two main reasons. Firstly, as 
noted above, many of the early studies with ANP employed doses which 
we now know to be within the pharmacological range, and subsequent 
studies with physiological infusion have shown very modest increases 
in sodium excretion and urine volume (Richards et al.,(1988a,b), 
Cottier et al.,(1988), Anderson et al.,(1987), Morice et al.,(1988))'. 
Secondly, classical physiological and pharmacological techniques 
involve infusion of compounds and hormones in isolation without taking 
into account the physiological circumstances in which these chnages 
would normally occur. For example, with regard to ANP, volume 
expansion would normally cause not only an increase in plasma hormone 
levels but also suppression of a number of systems which oppose the
actions of ANP (2.7) notably the renin-angiotensin system, and (via 
centrally-mediated reflexes) vasopressin and the sympathetic nervous 
system. Hence, if exogenous ANP is infused to produce levels similar 
to those achieved by volume expansion then a similar natriuresis would 
not necessarily be expected. This is important when we consider the 
experimental evidence which has been used to support the claim that 
ANP has no physiological role. Goetz et al.,(1986a,b) found that 
balloon distension of the left atrium in dogs caused a four-fold 
increase in plasma ANP and a natriuresis. When the experiment was 
repeated in dogs with denervated hearts the same increase in plasma 
ANP was seen but the natriuresis abolished. The authors suggest that 
this implies the absence of a role for ANP in response to volume 
denervation but, since it is known that cardiac denervation by 
disrupting vagal inhibitory input to the central circulatory control 
centres results in activation of the renin-angiotensin system and 
sympathetic nervous system both of which can inhibit ANP action then 
it is clear that this conclusion is unfounded. In a similar type
of experiment Richards et al.,(1989b) examined the renal effects of a 
saline load and compared them with the effects of ANP infused to 
similar levels. ANP infusion was less effective than the rise of ANP 
produced by saline infusion. This is interpreted, correctly, as 
indicating that ANP is not the only factor involved in the clearance 
of a saline load, where there will be suppression of renin, ADH and 
the sympathetic nervous system. Goetz (Goetz et al.,(1988)) has also 
studied the clearance of a saline load in dogs. The saline was infused 
following a high dose ANP infusion - when plasma ANP was falling from 
1500 to 300 pg/ml - and caused an increase in urinary sodium 
excretion. Goetz has implied that increased sodium excretion in the
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presence of falling plasma ANP means that ANP has no role in sodium 
excretiom. However, once again this phenomenon can be explained by the 
potentiation of the renal effects of ANP by the other effects of 
atrial and intravascular volume expansion (Metzler and Ramsay (1988).
Two methods have been attempted to study the effects of "taking 
out" the ANP system. The simplest involves removal of the atrial 
appendages (Benjamin et al.,(1988)) as a result of which excretion of 
a saline load is impaired. However, this experiment may also remove
the influence of the cardiac nerves and so is non-specific. In the
absence of specific antagonists of ANP rats immunised against ANP have 
been studied (eg Greenwald et al.,(1988)). These models have problems 
in that the presence of ANP antibodies make measurement of circulating 
hormone levels impossible and the antisera used are often polyclonal 
and relatively non-specific. In the chronically immunised rat 
Greenwald et al.,(1988) found no difference in the adaptation to 
mineralocorticoid administration or changes in dietary sodium intake, 
although the ability to excrete a sodium load was impaired. These data 
have been interpreted as demonstrating that ANP has no effect on long 
term sodium balance. However, in the SHR (Itoh et al.,(1989))
immunisation against ANP increases the development of hypertension, 
suggesting long term effects are important. Using an alternative 
approach, transgenic mice with two copies of the ANP gene are 
hypotensive and show increased sodium excretion (Steinhelper et
al.,(1990), suggesting that ANP plays an essential role in 
cardiovascular homeostasis. Presumably the development of mice 
deficient in the ANP gene, and the development of specific ANP 
receptor antagonists will finally settle this argument.
The argument for a physiological role for ANP is, on the other
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hand, almost overwhelming. Gene expression, hormone release and plasma 
ANP levels are altered, appropriately for a natriuretic hormone, by 
changes in sodium balance and intravascular volume (see earlier in 
this chapter). Membrane receptors are present in all target tissues 
where effects are seen and have Kd values appropriate for an 
interaction to occur at "normal" plasma ANP levels. Finally, low dose 
infusion of ANP causes (albeit modest and slowly developing) increases 
in urine volume and sodium excretion, blood pressure, renin and 
aldosterone levels. Overall, the prevailing view of the role of ANP is 
moving away from that of a very powerful natriuretic hormone to that 
of a more modest hormone which does not simply have direct natriuretic 
effects on the kidney but has a spectrum of influences on the 
vasculature, the renin-angiotensin system and other hormonal systems 
giving it a more subtle modulatory role as a counterweight to the 
powerful antidiuretic, antinatriuretic and pressor systems.
The concept of ANP "balancing" the effects of the renin- 
angiotensin system is particularly attractive since ANP interacts with 
the RAAS at so many different sites. In addition to the physiological 
interaction between a natriuretic and antinatriuretic system, and the 
general overlap of ANP and Ang II receptors (Mendelsohn et al.,(1987)) 
there are several specific interactions in (a) the nervous system, (b) 
the vasculature and (c) the kidney. Furthermore, ANP inhibits the 
secretion of (d) renin and (e) aldosterone. Finally, as if to complete 
the interaction at virtually level of the renin-angiotensin system it 
has recently been shown that ANP may have ACE inhibitory potential 
(Kawaguchi et al.,(1990)). Thus, ANP is ideally placed to counter- 
regulate the major antinatriuretic hormonal system.
Finally, although the balance of evidence over the last few years
has moved away from the concept of ANP as a powerful hormone to one 
with a more subtle modulatory role, it should be borne in mind that 
this chapter has dealt with ANP alone. However, ANP now appears to be 
one of a family of related peptide hormones which includes BNP, CNP, 
urodilatin, the N-terminal fragments of pro-ANP, iso-ANP and possibly 
many more. Not until the complete family are identified, and their 
individual and additive effects studied, will we understand the 
complex role of this natriuretic peptide hormonal system.
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SECTION 2.
PLASMA LEVELS OF ATRIAL NATRIURETIC PEPTIDE.
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Chapter 3.
Circulating ANP in man: Pathophysiological regulation of plasma levels 
and development of the hormonal system.
Introduction:
In order to establish a physiological role for a putative hormone 
- such as ANP - it is essential to have a method for detecting 
circulating hormone. For ANP, such methodology lagged several years 
behind the discovery, sequencing and synthesis of the peptide (Chapter 
2). Early radio-immunoassays (RIA) became available in the mid-1980's 
but gave highly variable results (possibly due to an interfering 
substance in plasma (Richards et al., (1987a)) and subsequently, pre­
extraction of plasma using reverse phase (SEP-PAK) columns resulted in 
lower, but more consistent values. Since 1987 most groups have used 
these methods (Richards et al., (1987a), Appendix 1) resulting in 
hundreds of published reports on plasma ANP and a general consensus 
that plasma levels are principally regulated by changes in 
intravascular volume (Chapter 2).
It seems appropriate to begin this thesis by reviewing my own
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experience with measurement of plasma ANP using the RIA (with pre­
extraction) developed by Mark Richards and Brenda Leckie in the MRC 
Blood Pressure Unit (Richards et al., (1987), Appendix 1). Four groups 
of patients or studies are included in this chapter. The first 
includes levels in normal subjects and a mixture of patients, 
reflecting the spectrum of pathology admitted to the MRC Blood 
Pressure Unit, and included primarily for descriptive purposes. The 
remaining three sections cover specific studies: in (a) the human
fetus, (b) pregnancy and (c) malignant hypertension. The individual 
relevance of these studies is discussed but together they provide 
evidence of a physiological role for ANP in man from the stage of the 
developing fetus and demonstrate that plasma ANP in humans is 
regulated not only by cardiac pre-load, but also cardiac after-load.
Methods: 
Normal Subjects and Patients:
The "normal" subjects comprise people admitted to the MRC Blood 
Pressure Unit (between 1987 and 1989) for assessment of suitability/as 
kidney donors for relatives on renal replacement therapy. These 46 
"patients" (14 female, 32 male; mean age 32 [range 21-62] years) were 
assessed according to a standard protocol involving a three day 
admission to the Unit. None had any significant past medical history, 
all were normal on full . clinical examination (blood pressure 
123±2/76±1, mean±SEM) and none were on regular drug therapy. During 
the admission all subjects had serial blood pressure measurements 
performed by the nursing staff; two 24 hour urine collections for
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creatinine clearance; two blood samples for biochemical profile, 
renin, aldosterone and ANP; chest X-Ray, ECG and renal arteriography. 
The blood samples were taken between 8 and 9 a.m. with the subjects 
supine, through an in-dwelling catheter (Venflon, Viggo, Sweden), 
after a period of overnight rest. Assay methodology and collection 
procedure are described in Appendix 1.
The remaining samples from patients admitted electively for 
investigation (e.g. Conn’s syndrome, dexamethasone suppressible 
hyperaldosteronism [DSH], essential hypertension [EH], acromegally, 
hypothyroidism) were taken as above; whilst those for emergency 
admissions (e.g. malignant phase hypertension [MP], phaeochromocytoma, 
adrenal insufficiency) were taken after 30 minutes supine rest through 
an indwelling catheter according to established protocol in the MRC 
Blood Pressure Unit. No patients were on any drug treatment at the 
time of sampling unless stated and in some the response to treatment 
is documented (Conn’s syndrome, malignant hypertension, adrenal 
insufficiency).
Fetal Samples:
Samples were obtained from patients at the Queen Mother's 
Hospital, Glasgow undergoing cordocentesis (umbilical cord sampling 
under ultrasound guidance) for routine obstetric indications. The 
protocol was approved by the Hospital Ethical Committee and patients 
gave informed written consent. Samples were obtained from 13 patients 
with Rhesus iso-immunisation in whom 20 procedures were performed (3 
patients had three procedures, one had two); and in 12 patients where 
sampling was performed for karyotype determination. Mean gestational 
age was 27.5 weeks (range 23-32 weeks) in the Rhesus group and 25.8
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(17-34) in the karyotype group. Indications for karyotype determina­
tion were: abdominal wall, intestinal or diaphragmatic defect on
ultrasound scan (four), urinary tract obstruction (three), previous 
child with genetic abnormality (two), pre-eclampsia (PET, one), 
idiopathic growth retardation (IUGR, one) and unexplained 
polyhydramnios (one). One fetus with polyhydramnios and one fetus in 
the Rhesus group had abnormal karyotypes (trisomy 21).
Sampling: Cordocentesis was performed with the mother sedated using 
lorazepam, papaveretum and perphenazine. Maternal blood samples were 
taken with the mother recumbent, through an indwelling cannula, 
immediately before fetal sampling. Fetal samples were obtained through 
a 20G needle inserted into the umbilical vein under ultrasound 
guidance. In two of the karyotype group where this was not possible 
samples were taken from the heart. Fetal blood was confirmed by 
estimation of mean red cell volume and haematocrit. Fetal blood 
samples (1-2 mis) and maternal samples (10 mis) were collected and 
assayed for ANP by RIA as previously described (Richards et 
al.,(1987a), Appendix 1).
Transfusion: In 12 of the rhesus cases blood samples were obtained 
before and after intravascular transfusion of 32-105 (mean 63.5) mis 
of washed resuspended red cells (haematocrit 70-80%). ANP was 
undetectable in donor blood. The mean pretransfusion haematocrit was 
27.1% (range 9-39%), compared with 43.5% (35-57) in the karyotype 
group.
Statistical Analysis: Data is shown in figure 3.3. For the purpose of
statistical comparison the results of intracardiac samples were 
excluded and where cordocentesis was repeated in the sample patient 
only the first sampling is included (leaving a total of 10 in the
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karyotype group and 12 in the rhesus group, with 9 pre- and post­
transfusion samples). Comparison between groups is by Wilcoxon rank 
test or Students t-test as appropriate and relationships between 
variables by correlation coefficient.
Normal and Hypertensive Pregnancy:
A cross-sectional study was performed in women attending the 
ante-natal clinic at the Queen Mothers Hospital, Glasgow. Normal 
subjects of comparable age, with normal menstrual histories, were 
recruited from the staff of the Western Infirmary. The protocol was 
approved by the Queen Mothers Hospital Ethical Committee, and all 
subjects gave informed consent. The subjects were divided into five 
groups, each of 15 subjects: 1. Non-pregnant menstruating women, not 
on hormonal contraception. Normal pregnancies, gestation 2. 8-12
weeks; 3. 16-28 weeks; and 4. 36-40 weeks. 5. Patients (primigravida, 
36-40 weeks gestation) with pre-eclampsia, defined as a rise in blood 
pressure to >140/90, with a rise in diastolic of >15 mmHg during 
pregnancy. None of these patients had significant proteinuria at the 
time of sampling (i.e. > 0.3g/24 hours) although this subsequently 
developed in two. Blood was collected with the subjects in a semi- 
recumbent position after 15 minutes rest. Renin was determined by the 
method of Millar et al.,(1981) and samples for ANP collected and 
assayed as described above (Richards et al.,(1987), Appendix 1).
Statistical analysis is by non-paired T-test between non­
pregnant and pregnant groups and between third trimester groups.
Malignant Phase Hypertension:
The case records of 15 patients presenting with untreated
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malignant hypertension (defined by grade IV fundal changes) between 
1987 and 1989 were examined. All patients admitted during this period 
had blood pressure and blood samples taken according to a standard 
protocol. Blood samples were taken through an indwelling catheter 
after 30 minutes recumbency, and blood pressure was the mean of three 
recordings taken, using a standard mercury manometer, by the MRC Blood 
Pressure Unit nursing staff. Blood samples were analysed for urea and 
electrolytes, components of the renin-angiotensin system and ANP. The 
sampling techniques and assay methodology were as previously described 
(Appendix 1; Richards et al.,(1987)). Data are presented as meaniSEM 
or mean (range) where distribution was not normal. The relationship 
between variables was determined by coefficient of correlation; where 
appropriate data were log-transformed (e.g. ANP, Figure 3.1) before 
analysis.
Results: 
Normal subjects and patients:
The results are shown in Figures 3.1 and 3.2. In the normal group 
plasma ANP levels were normally distributed with levels similar to 
those reported by other groups using pre-extracted radio-immunoassays 
for ANP (meaniSEM 26.7±6.3 pg/ml, [8.1±2.0 pmol/ml]). In this group 
there was no relationship between ANP and blood pressure; there was a 
negative relationship with active renin concentration (23.8±1.9 
[meaniSEM] nU/ml) which failed to achieve significance (P=0.2) and a 
strong correlation with age (r=0.47, PCO.OOl, Figure 3.2). There were 
no differences between ANP levels between men and women. In the 
various pathological groups: ANP levels congregated towards the upper 
end of the "normal" group in patients with untreated essential
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FIGURE 3.1:
NORMAL AND PATHOLOGICAL HUMAN ANP LEVELS.
Plasma levels of Atrial Natriuretic Peptide in normal subjects 
and patients with a variety of clinical conditions - see text 
for details. EH=Essential Hypertension, MP=Malignant phase, 
Phaeo=Phaeochromocytoma, DSH=Dexamethasone Suppressible 
Hyperaldosteronism. Enclosed points represent treated subjects.
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FIGURE 3.2:
PLASMA ANP, AGE AND BLOOD PRESSURE:
Relationship between plasma ANP, age (years, A) and diastolic 
blood pressure (DBP, mmHg, B)..Data from the "normal" subjects 
in Figure 3.1 (• ) and patients with Essential Hypertension 
(A). r=correlation coefficient.
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hypertension, but were not statistically higher than levels in 
patients matched for age and sex in the normal potential renal donor 
group. Plasma levels were increased in untreated Conn’s syndrome 
(where intravascular volume and body sodium content are increased) but 
were normalised in patients with Conn's syndrome successfully treated 
with amiloride (Figure 3.1). Low ANP values were predictably found in 
two patients with acute adrenocortical insufficiency, where 
intravascular volume is depleted. The relationship between volume and 
sodium status in this condition is illustrated in Table 3.1 which 
shows the time course of the response to fluid and steroid replacement 
in a young man with acute adrenocortical insufficiency. ANP levels are 
low at the time of presentation, in contrast to the greatly elevated 
renin levels reflecting intravascular volume contraction; ANP rose, 
with appropriate reciprocal changes in renin levels during treatment.
All of the above findings are consistent with the view that ANP 
levels are determined principally by cardiac preload. However, some 
plasma ANP levels are not consistent with this view. In a single 
patient with untreated acromegally - where total body sodium and blood 
pressure (McLellan et al.,(1988)) are generally increased - one of the 
lowest recorded ANP levels was seen (4 pg/ml). Paradoxically, high 
values were seen in two other conditions - phaeochromocytoma and 
malignant phase hypertension - where hypertension is generally 
associated with reduced intravascular volume and sodium content 
(Genest et al.,(1983), Ball (1983)).
Fetal samples:
The full results are shown in Figures 3.3a and 3.3b. Mean plasma 
ANP (187.0±37.3 pg/ml) were significantly higher than maternal levels
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FIGURE 3.3:
HUMAN FETAL ANP.
(a) Plasma levels of Atrial Natriuretic Peptide (ANP, pg/ml) in 
human fetal samples and the response to intravascular 
transfusion.
(b) Relationship between ANP and haematocrit in Rhesus disease. 
See text for details (r=correlation coefficient).
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(37.3±4.9 pg/ml); meaniSEM; p<0.01, n=22). There was no significant 
correlation between maternal and fetal ANP (r=-0.25, p=0.25). Plasma 
ANP was significantly higher in the fetuses with rhesus iso­
immunisation compared with the karyotype group (262.3±61.7 [n=12] vs 
98.0±11.5 [n=10], p<0.05). The pre-transfusion fetal ANP showed a 
strong inverse relationship with haematocrit (r=-0.73, p<0.01, n=22) 
for the whole group and (r=-0.83, p<0.01, n=12) for the rhesus group 
(Figure 3.3b). Following transfusion, ANP rose from 264.2±64.4 pg/ml 
(p=0.02, n=12, Wilcoxon test; p=0.02, n=9 - excluding duplicate
transfusions). The rise with transfusion was evident despite the 
dilutional effects of transfusion of large volumes of blood containing 
negligible ANP.
There was no significant relationship between gestational age and 
ANP, or the rise in ANP and the volume of transfusion; nor were any 
trends evident in the four subjects who underwent repeated sampling. 
In the two intracardiac samples in the karyotype group excluded from 
statistical analysis, ANP was 311 and 388 pg/ml, higher than the 
values from the umbilical vein samples.
Normal and hypertensive pregnancy:
The results are shown in Figure 3.4. ANP and renin were 
significantly increased during pregnancy as compared with normal 
controls but showed no trend with gestation. In the pre-eclampsia 
group (5) there was a further significant (P=0.04) rise in ANP and a 
non-significant fall in renin compared with the normal third trimester 
group.
There was an inverse correlation between ANP and renin in the 
third trimester pregnancies (groups 4 and 5; r=-0.4, p=0.027, n=30).
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FIGURE 3.4:
ANP IN HUMAN PREGNANCY.
Plasma Atrial Natriuretic Peptide (ANP, pg/ml) and active renin 
concentration (Renin, jjiU/ml) in normal and hypertensive 
pregnancy (Pre-eclampsia). * indicate level of significance by 
T-test.
81
Although weak, this suggests that there is reciprocal relationship 
between ANP and renin, compatible with the suggestion that low renin 
levels may be a consequence of increased ANP. In addition in the 
hypertensive group (mean gestation at delivery 39 weeks) the ANP/renin 
ratio was inversely correlated with birthweight (r=-0.67, p<0.01, 
n=15). Since birthweight is a crude indicator of the severity of pre­
eclampsia in this group with similar gestational age, it may be that 
the ANP/renin ratio is related to the severity of pre-eclampsia.
Malignant phase hypertension:
The results are shown in Table 3.2. In keeping with a diagnosis 
of malignant phase hypertension blood pressure was elevated and there 
was biochemical evidence of activation of the renin-angiotensin 
system. Renal function was moderately impaired and plasma levels of 
ANP elevated.-
There was an inverse relationship between ANP and plasma Na (r=- 
0.56, P<0.05) and a positive relationship between ANP and active renin 
concentration (r=0.85, PC0.01).
In four patients where sampling was repeated within 48 hours of 
starting treatment, ANP levels fell in all cases by a mean of 66 
(range 10-128 pg/ml) without alteration in plasma creatinine 
concentration.
Discussion:
Normal Subjects and Patients:
The plasma levels of ANP reported here are similar to those 
reported by most other groups (e.g. Lang et al.,(1985), Richards et
TIME: 0 6 12 24 (HOURS) 
(DAYS)- 2 3 4 5 7 14 28
Na 119 123 125 127 129 132 130 138 136 138 139
K 7.3 7.2 5.3 5.2 4.9 4.9 4.5 5.4 4.3 4.8 4.7
U 16.2 15.5 12.2 9.1 6.5 5.4 4.1 4.3 4.7 5.6 7.9
Renin 1209 ... 757 ... ... ... ... 195 ... 5 ...
All ... ... 65 ... ... ... ... 38 ... ... ...
Aldo 6 ... 6 ... ... ... ... 1 ... ... ...
ANP
BP
11 ... 14 — — — — — — 85 ...
(Supine) 120 110 114 122 122 124 120 112 126 — —
72 70 64 68 92 64 68 74 68 ... ...
BP
(Standing)
90 ... 128 110 142 116 128 112 116 ...
T L fit;
70 94 88 74 78 82 60
nn 1 c\t,
TSH 26.7   10.7 8.6 6.3
TABLE 3.1:
ANP IN ADDISONIAN CRISIS.
Sequence of changes in plasma electrolytes, ANP, the renin- 
angiotensin system, blood pressure and thyroid function in a 43 
year old man presenting with an Addisonian crisis. Treatment 
was commenced with intravenous fluids and hydrocortisone at 
time 0, and replaced with oral hydrocortisone and 
fludrocortisone at 48 hours. Normal ranges: Na (135-145
mmol/1), K (3.5-5.1 mmol/1), U (Urea, 4-11 mmol/1), Renin (5- 
50 pU/ml), All (Ang II, 3-12 pg/ml), Aldo (<18 ng/dl), ANP (5- 
55 pg/ml), T4 (Thyroxine, 55-156 nmol/1), TSH (Thyroid 
Stimulating Hormone, <5.0 U/ml).
A typical pattern of electrolytes, blood presure, thyroid 
hormones and markers of the renin-angiotensin system are shown 
on admission; with appropriate responses to treatment.
Variable Units(NR) Number Value Correlation with ANP
SBP inmHg 15 232±7 0.21
DBP mmHg 15 138±5 0.18
Na mmol/1 . 15 139.3±0.1 -0.56
K mmol/1 15 3.6±0.1 -0.40
|imol/l 15
Renin nU/ml(5-50) 13
Angll pg/ml(3-12) 15
Aldo ng/dl( <18) 14
ANP pg/ml(5-35) 15
199.5±28.8
(80-525)
298±116
(18-1420)
93.7±23.4
(6-240)
13.1±2.4 
(1-38) 
220.5±55.2. 
(34-896)
0.35
0.85
0.45
-0.15
TABLE 3.2:
ANP IN MALIGNANT PHASE HYPERTENSION.
Data form 15 subjects with Malignant Phase Hypertension. Data 
are shown as meaniSEM if normally distributed and mean (range) 
if non-normal. Non-normal data were log-transformed before 
correlation.
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al.,(1987), Espiner et al.,(1986)) in normal subjects. Previous 
studies have demonstrated the relationship between ANP and age (Haller 
et al.,(1987), Ohashi et al.,(1987), Montorsi et al.,(1987)) shown in 
Figure 3.2. However, the mechanism of this increase with age is not 
known and may theoretically be due to either increased secretion or 
impaired clearance of the peptide. The ' finding that ANP was not 
related to blood pressure in this small group confirms the findings of 
Montorsi et al.,(1987) who found no relationship in normal subjects
but a strong positive correlation in subjects with essential
/
hypertension; the relationship with age, however, was absent in the 
hypertensive group. In normal subjects plasma renin activity has 
usually been inversely correlated with ANP (Richards et al.,(1988d), 
Montorsi et al.,(1987)) as one would predict for a hormone with an 
opposing physiological role and in view of the known inhibition of 
renin release by ANP (Chapter 2).
There has been debate over reported plasma levels of ANP in 
essential hypertension. Although several groups have reported no 
change in essential hypertension the larger studies using careful age- 
sex matching have revealled small increases in ANP in hypertension 
(Montorsi et al.,(1987), Sagnella et al., (1988)). The present study 
is probably representative in that levels were slightly high but many 
remained within the "normal" range and the finndings failed to achieve 
statistical significance. The mechanisms responsible for the observed 
increases in plasma ANP in essential hypertension are unknown but seem 
likely to be related to increased cardiac afterload, mediated by left 
atrial distension (below).
The first physiological stimulus to release ANP was intravascular 
volume expansion (Lang et al.,(1985), Chapter 2) leading to the view
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that the major regulatory influence on ANP release is intravascular 
volume (via atrial distension). The finding that levels are elevated 
in volume expanded states such as hyperaldosteronism or hypothyroidism 
and are reduced in volume deplete states such as adrenal insufficiency 
(and respond appropriately to treatment; Figure 3.1, Table 3.1) 
support this view. There is universal agreement that ANP is elevated 
in Conn’s syndrome (Yamaji et al.,(1986), Espiner et al.,(1987)), and 
in the present series the levels were three to four times the upper 
limit of normal. In the milder condition - DSH - where hypertension, 
electrolyte and hormonal disturbances are often less marked than in 
Conn’s syndrome, the changes in ANP were also less marked and within 
the ’’normal” range. Reports differ, however, on whether levels are 
normal (Ladenson et al.,(1987)) or even reduced in hypothyroidism 
(Zimmerman et al.,(1987)), and it is known that levels are also 
elevated in thyrotoxicosis (Woolf and Moult (1987)). This may reflect 
the fact the pathological changes in thyroid hormone status are 
dependent not only on intravascular volume but also heart rate (Bilder 
et al.,(1986), Schiebinger and Linden (1986)); tachycardia in 
thyrotoxicosis, bradycardia in hypothyroidism) which will tend to 
oppose the blood volume changes in thyroid disease. Furthermore, 
expression of the gene for ANP is dependent on thyroid hormone 
(Gardner et al.,(1987), Matsubara et al.,(1987)).
The levels in the other groups do not fit with volume dependant 
regulation. In both malignant phase hypertension and pre-eclampsia 
hypertension is associated with reduced intravascular volume; both are 
considered below. In acromegally, hypertension is associated with 
expanded intravascular volume (McKnight et al.,(1988)); paradoxically 
the levels of ANP are low and fail to rise following saline infusion
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(McKnight et al.,(1988)). The level in a single patient in the present 
series confirms this finding, and although the reason for the low ANP 
is not known it may be mechanical reflecting the inability of the 
hypertrophied heart to distend in this condition. Finally, there were 
four measurements from patients with a phaeochromocytoma, one of whom 
presented in a hypertensive crisis. In this condition intravascular 
volume is reduced, and the stimulus to release must come from either 
increased heart rate or afterload.
Fetal Samples:
Messenger RNA for ANP and iramunoreactive peptide are known to be 
present in the fetal heart of many species including man (Wu et 
al.,(1988), Mercadier et al.,(1989)). The present observations confirm 
that ANP is actively secreted by the human fetal heart, at least in 
the third trimester, and that the regulation of plasma levels is 
dependent on intravascular volume.
The evidence for physiological secretion of ANP by the fetus 
comes from three pieces of evidence. First, that the fetal hormone 
levels are higher than simultaneous maternal values. It is likely that 
this is the low molecular weight form of ANP (99-126 ANP), since the 
samples were pre-extracted and 28 AA ANP is the form present in cord 
blood (Ito et al.,(1988), Yamaji et al.,(1986)). Secondly, fetal 
plasma ANP levels rose in response to blood transfusion (i.e. 
intravascular volume esqpansion), confirming findings in the sheep 
(Ross et al.,(1987)) and earlier studies in the human fetus (Robillard 
& Weiner^ (1987), Kingdom et al.,(1989)). This occurs despite the 
dilutional effects of transfusion (with blood containing no ANP), 
although this may explain the fall observed in two cases (Figure 3.3).
85
Finally, the observation that the highest levels were found in 
intracardiac samples suggests that the source of circulating ANP in 
the fetus - like the adult - is the heart.
Further evidence that the regulation of fetal ANP release is 
similar to the adult comes from the pathophysiological changes that 
are seen in rhesus iso-immunisation. Levels of ANP were higher in 
fetuses with this condition compared with karyotype "control11 group. 
This confirms the findings of Weiner and Robillard (1988), and 
presumably reflects intravascular volume expansion due to anaemia. In 
keeping with this plasma ANP levels were, for the first time, noted to 
be related to the severity of rhesus disease, with a strong inverse 
correlation between fetal haematocrit and ANP. This contrasts with the 
findings of Robillard and Weiner (1988) but may reflect the small 
numbers in their study since the fetus with the lowest haematocrit had 
the highest ANP. Thus the long term regulation of ANP in the fetus - 
like the adult - is likely to be dependent on intravascular volume.
The precise role of ANP in the fetus is not known but there are 
several potential physiological and pathophysiological roles. Firstly, 
membrane receptors are present for ANP in the placenta (Sen (1986), 
McQueen et al.,(1990a,b)) and changes in receptor affinity and 
concentration have been noted in pre-eclampsia and IUGR respectively 
(Hatjis and Grogan (1989), McQueen et al.,(1990b)) suggesting some 
involvement in these pathophysiological processes. The localisation of 
receptors on vascular tissue suggests that ANP might act as a 
placental vasodilator and it can certainly attenuate the 
vasoconstrictor response to infused Ang II in the isolated perfused 
human placenta (McQueen et al.,(1990a)). The elevated levels of ANP in 
Rhesus disease may therefore have a role in improving placental
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perfusion in this condition. Elevated levels of ANP may also increase 
vascular permeability (Chapter 2, Huxley et al./(1987)) and contribute 
to oedema formation in rhesus disease. There is also some evidence for 
a potential renal effect in the fetus. When ANP is infused into the 
ovine fetus, albeit at pharmacological concentrations, there is an 
increase in urine volume and sodium excretion (Brace and Cheung 
(1987)). Since fetal urine output is the major source of amniotic 
fluid in the latter part of pregnancy, ANP may regulate amniotic fluid 
volume.
In summary, these results confirm the presence of an active ANP 
hormonal system in the human fetus, which appears to be regulated in 
the same way as the adult but the precise role of which will require 
further study.
Pregnancy:
Intravascular volume increases by about 1.5 litres in normal 
pregnancy, the largest increase occuring within the first trimester. 
In pre-eclampsia, however, there is a relative contraction of the 
plasma volume (for review, Lindheimer and Katz (1986), Brown (1988)). 
Pregnancy is therefore a reproducible model in which to study the 
effects of long term changes in volume status on plasma ANP. The 
findings in normal pregnancy, with a sustained rise in ANP from the 
first trimester onwards, suggest volume dependent regulation and are 
a consistent finding (Otsuki et al.,(1987), Jackson et al.,(1988), 
Bond et al., (1989)). In pre-eclampsia, however, despite the relative 
contraction of intravascular volume (Brown (1988)), plasma ANP is 
further increased - again a consistent finding. Unlike 
phaeochromocytoma (above) or malignant phase (below) PET is not
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generally associated with significant tachycardia or renal impairment, 
and increased afterload seems the most likely stimulus to ANP release. 
Miyamoto et al., (1989a,b) have confirmed this observation and 
extended it to show that there is a marked diurnal rhythm of ANP in 
PET - virtually absent in normals (Richards et al.,(1987)) - but which 
follows the diurnal rhythm of blood pressure (BP) and cGMP in PET. The 
superimposable rhythms of ANP, cGMP and blood pressure suggest that 
ANP is dependent upon BP rather than influencing it - where BP would 
be expected to be low in the presence of elevated ANP. Thus, PET 
appears to be another condition where ANP levels are regulated by 
cardiac afterload.
The other side to this study is the measurement of renin, which 
also rises in normal pregnancy but is then - paradoxically - 
suppressed in PET, despite volume contraction (Brown (1988), 
Lindheimer and Katz (1987)). These observations are well established, 
although they remain unexplained. The finding that ANP is elevated in 
PET offers one potential explanation for the reduced renin levels, 
since ANP is known to suppress renin release (Chapter 2). The inverse 
relationship between renin and ANP observed in the present series of 
measurements would support this suggestion. Furthermore, the severity 
of PET is difficult to quantify clinically but there was a 
relationship between the ratio of ANP/renin (the ratio multiplying the 
individual changes in these variables) and birthweight (a crude 
indicator of severity - since the gestational ages were similar). 
Thus, identification of these abnormal humoral patterns may be useful 
in identifying patients with PET, and a longitudinal study is required 
to see if such changes precede the clinical presentation.
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Malignant Hypertension:
Malignant phase hypertension is not a discrete diagnosis but 
rather a condition which may develop in patients with hypertension 
(Genest et al.,(1983)). In contrast to hypertension in general, the 
presence of an underlying cause for hypertension (secondary 
hypertension) is high - perhaps as high as 50%. The patients also have 
a mixture of end-organ damage, and particularly a variable degree of 
renal impairment. I have not given the underlying diagnosis, often 
because it was not clearly established, but none of the patients 
required dialysis. Renal impairment might be predicted to raise plasma 
ANP - as the kidneys are involved in clearance (Chapters 2, 5 - but 
the plasma levels were still higher than those reported in renal 
failure (Tonolo et al.,(1988,1989a)) where intravascular volume would 
also be increased. In support of this plasma levels fell after 
treatment in four subjects despite the absence of significant 
improvement in renal function. Intravscular volume is reduced in 
malignant phase and although there is likely to be an increased heart 
rate (sympathetic activation) it seems likely that the major stimulus 
to hormone release is increased afterload.
ANP levels were significantly correlated with plasma active renin 
concentration in contrast to the findings in normal subjects (e.g. 
Montorsi et al.,(1987)) but similar to the pattern seen in heart 
failure (Richards et al.,(1986b), Espiner et al.,(1986)) where 
overactivation of the renin-angiotensin system is similarly associated 
with loss of the normal inter-relationships between renin and ANP. In 
addition there was a negative correlation between ANP and plasma 
sodium. Whether this merely reflects the severity of malignant phase 
or whether ANP may contribute to the reduced body sodium content which
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is a feature of this condition is not clear. Elevated levels of ANP 
may also contribute, with reduced plasma potassium, to the absence of 
a significant increase in aldosterone despite high circulating Ang II 
levels, since ANP can directly inhibit aldosterone synthesis and 
secretion (Chapter 2).
Conclusions:
The studies in this chapter were largely performed through 
accidents of circumstance. However, they each describe measurements 
of plasma ANP in man and many of the observations are unique.
Taken together they show that a functional ANP hormonal system 
is present even in the developing human fetus. In the adult they 
reveal that plasma hormone levels are dependent on intravascular 
volume and blood pressure (pre-load and after-load) and that the 
relative contributions from these stimuli may change (for example in 
pregnancy/ PET). These observations confirm experimental observations 
that short term changes in intravascular volume (e.g. saline infusion; 
Hodsman et al.,(1986), Chapter 12, Figure 12.1) or blood pressure 
(infusion of pressor agents; Uelinger et al.,(1987), Chapter 8, 
Figures 8.3 and 8.4) increase plasma ANP. The mechanism underlying 
the differential release is not known but it appears from animal 
studies that afterload dependent release is primarily from the left 
atrium (Arai et al.,(1987)). This effect is likely to be mediated by 
atrial distension and, in this respect, Syndhorst and Gutkowska (1988) 
have shown that the left atrium is more sensitive to stretch than the 
right.
Overall, the findings that plasma ANP follow changes in blood 
volume, sodium balance and blood pressure further supports the theory
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that ANP is likely to play a physiological role in the regulation of 
these parameters (Chapter 2).
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SECTION 3.
RENAL ACTIONS OF ATRIAL NATRIURETIC PEPTIDE: 
INTERACTION WITH THE RENIN ANGIOTENSIN SYSTEM.
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Chapter 4.
Renal actions of Atrial Natriuretic Peptide: 
Effects of Angiotensin II and ACE inhibition.
Introduction:
Although the kidney appears to be the target of the major actions 
of ANP including natriuresis, diuresis and suppression of renin 
release, the underlying mechanisms are incompletely understood 
(Chapter 2, Ziedel (1989); Raine et al.,(1989)). There is still debate 
over the relative importance of direct glomerulo-tubular effects (i.e. 
mediated by ANP receptors in the kidney) and indirect effects (e.g. 
those mediated indirectly by suppression of other hormonal systems 
such as the renin-angiotensin system and vasopressin), and secondly, 
the importance of factors which are known to modulate the renal 
actions of ANP. For example, it is known that increased renal 
sympathetic nerve activity (Koepke and diBona (1987), Koepke et 
al.,(1987)), reduced renal perfusion pressure (Seymour et al.,(1987), 
Davies and Briggs (1987a), Firth et al.,(1987)) and increased 
Angiotensin II (Ang II; McMurray and Struthers (1988b), Showalter et 
al.,(1988)) levels all reduce the effect of ANP, but the physiological
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relevance of these observations is not clear.
The study in the present chapter was designed to examine the
renal effects of low dose ANP infusion in the dog and the role of the 
interaction between the renin-angiotensin system and ANP. The 
interaction was examined by infusing ANP together with either Ang II 
or an ACE inhibitor (to raise and lower plasma Ang II). The ACE 
inhibitor was given both acutely and chronically, since ACE inhibition
has been reported to augment, attenuate or have no effect on the
response to ANP (Wang and Gilmore (1985), Bie et al.,(1990), Hirata et 
al.,(1987), Richards et al.,(1989), diNicolantonio and Morgan (1987), 
Seymour and Mazack (1988), Gaillard et al.,(1988,1989), Hansell and 
Ulfendahl (1987), Salazar et al.,(1987))), despite the consensus that 
Ang II inhibits the actions of ANP. In addition an attempt was made to 
assess the contribution which reduced Ang II levels (via suppression 
of renin release) make to the renal effects of ANP, by "clamping" 
plasma Ang II levels by co-infusion of Ang II and an ACE inhibitor 
(Mizelle et al.,(1989)), thereby removing any ANP dependent changes in 
endogenous Ang II (via suppression of renin, Chapter 2).
Methods:
These experiments were performed in the Wellcome Surgical 
Institute at the University of Glasgow Veterinary School.
Techniques: Eight beagle dogs with externalised carotid artery loops 
were studied on seven separate occasions at least four weeks apart. On 
each occasion they received a diet containing 30mmoles of sodium and 
30 mmoles of potassium per day for 3 days before each experimental day 
and were fasted on the morning of the study. Cannulae were inserted 
into the bladder (6 FG dog catheter, Portex), externalised carotid
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Group 1. Placebo.
Group 2. ANP infusion alone.
Group 3. ANP infusion plus Enalaprilat (En).
Group 4. ANP infusion on the 4th day of Enalapril treatment.
Group 5. (Supplementary group), Enalaprilat alone.
Group 6. ANP infusion plus Enalaprilat plus Ang II infusion
(1 pmol/kg/min).
Group 7. ANP infusion plus Enalaprilat plus Ang II infusion 
(5 pmol/kg/min).
FIGURE 4.1:
OUTLINE OF PROTOCOL: INTERACTION OF ANP AND ANG II.
A. Study protocol for this series of experiments, indicating 
the timing of infusions, blood sampling and urine collections. 
Time in minutes.
B. Outline of the experimental groups.
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artery loop (20g teflon, "Intraflon 2", Vygon, Sweden) for arterial 
pressure measurements and blood sampling, and in a foreleg vein (30 
cm, 3 FG, Portex, UK) for infusion. The arterial line was heparinised 
continuously by 5% Dextrose containing 10 i.u./ml heparin (Heparin 
Sodium, Evans, UK) per ml at a flow rate of 3 ml/hour, and connected 
to a Strathan P23 ID pressure transducer (Gould Electronics, UK). This 
was connected to a Gould Model 8188-812 Amplifier and data digitalised 
using the Gould DASA 4600 analog-digital data aquisition system on an 
IBM PC AT computer. Blood pressure was measured intermittently and 
averaged over the final 150 seconds of each collection period (see 
below). The dogs stood throughout the experimental period supported 
in a hip sling.
Protocol: After cannulation 0.9% NaCl was infused at 0.83ml/min via 
the peripheral vein to replace blood and urine losses. Para amino 
hippuric acid (PAH, MSD, Rahway, NJ) and Inulin (Gesselbad, Germany) 
were administered as bolus injections (0.1mg/0.5ml saline PAH, 6.5 ml 
10% Inulin in 5% Dextrose) and were therafter added to the saline 
infusion to give a final infusion rate of 8.3mg/min Inulin, 6mg/min 
PAH. After a 30 minute equilibration period the bladder was emptied 
and seven 30 minute urine collections made, the urine volume was 
measured volumetrically and urine stored for determination of PAH, 
Inulin, Na and K. At the end of each collection period samples were 
taken (14ml blood) for measurement of ANP, renin, Ang II, aldosterone, 
Na, K, PAH and inulin. Following the first collection period the dogs 
were given either Enalaprilat (3mg/kg in 10 ml 0.9% NaCl) or placebo 
(0.9% NaCl, 10ml). Thereafter the 0.9% NaCl infusion was either 
continued unaltered or Ang II added to given a final infusion rate of 
1 or 5 pmol/kg/min. Finally during the 4th-6th collection periods ANP
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was infused by separate pump at 5pmol/kg/min in 0.9% NaCl (0.5ml/min). 
For this ANP (ahANP, Bachem, UK) was prepared as previously descibed 
(Richards et al.,(1988a)) by dissolving the peptide in Haemaccel 
(Polygeline 3.5%, Hoechst, UK) containing glacial acetic acid and 
bovine serum albumin. Aliquots (2ml) were stored at minus 20°C until 
use, being diluted in 50ml 0.9% NaCl for infusion.
The protocol was subdivided into three major steps to examine 
firstly the effects of ANP alone (compared with placebo); then the 
effects of ACE inhibition or Ang II on the response to ANP were 
compared with the response to ANP alone. Finally, an additional step 
was included to look at the effects of acute ACE inhibition alone.
In total, therefore, there were seven separate study limbs for 
each animal (see Figure 4.1): (1) Placebo, (2) ANP alone, (3) ANP + 
acute Enalapril (3mg/kg), (4) ANP + chronic Enalapril (5mg b.d. for 
three days), (5) ANP + Enalaprilat + Ang II ("pressor", 5pmol/kg/min),
(6) ANP + Enalaprilat + Ang II ("non-pressor", lpmol/kg/min), and 
finally, (7) Enalaprilat alone.
Samples and Assays: Samples for ANP were collected into tubes
containing EDTA and aprotonin (Trasylol, 100 k.i.u./ml, Bayer, UK) on 
ice. The samples were rapidly separated at 4°C and stored at -20°C for 
assay. ANP was determined on pre-extracted samples by RIA as 
previously described for hANP (Richards et al.,(1987a), Appendix 1). 
Renin (Millar et al.,(1981)), Ang II (Morton and Webb (1983)) and 
Aldosterone (Fraser et al.,(1973)) were measured by standard methods; 
Na and K were measured by ion electrode (Beckman model 2A, Beckman 
Instruments, Ireland). ERPF and GFR were determined by the urinary 
clearances of PAH and inulin using the standard clearance equation. 
Statistics: Statistical Analysis was performed using the SPSS/PC+
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package (SPSS Inc. II, USA). Overall analysis was by MANOVA with 
repeated measures and where significant post-hoc analysis at 
individual time points was by paired T-test. Three effects were 
studied in a stepwise manner: (a) the effect of ANP alone, compared 
with placebo; (b) the effects of ACE inhibitor + ANP, compared with 
ANP alone (the Enalaprilat alone limb was included after the initial 
design and was included only to detail the pattern of effects of ACE 
inhibition and was not included in the statistical analysis); (c) the 
effects of Ang II + ANP, compared with ANP alone. Comparisons between 
groups for single variables (e.g Area Under the Curve, AUC) was by 
ANOVA (ONEWAY, SPSS) with post hoc analysis using Student’s T-test 
with the Bonferoni correction (Wallenstein et al.,(1980), Godfrey 
(1981)). Where necessary (eg active renin concentration) large 
variations in baseline values were corrected for by analysis of 
transformed data. Full MANOVA analysis is shown in Appendix 2.
Results: 
Effects of ANP alone:
Plasma ANP: ANP infusion caused an increase in circulating levels of 
ANP from around 40 pg/ml to around 200 pg/ml (Figure 4.3, Table 4.1). 
Urinary effects: The renal effects of ANP are summarised in Figure 4.2 
(and Figure 4.9). There was a gradual increase in urinary sodium 
excretion over the 90 minutes of the infusion from a basal level of 
16.8±3.7 pmol/min (period 2, P2) to a peak value of 52.8±10.1
limol/min; sodium excretion remained unchanged in the placebo limb. 
Urine volume showed a similar increase from 344±36 [ll/min (P2) to a 
peak level of 543±68 pl/min. In contrast urine volume fell from 346±44
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FIGURE 4.2:
RENAL EFFECTS OF LOW DOSE ANP IN DOGS.
Effects of infusion of ANP (5pmol/kg/min) on urinary sodium 
(UNaV, pmol/min) and potassium (UKV, pmol/min) excretion, and 
urine volume (UVol, jil/min). Each period represents a 30 minute 
collection period; ANP was infused during periods 3-5. 
Asterixes indicate significance levels (* PC0.05, ** P<0.01 by 
paired T-test where overall differences were established by 
MANOVA).
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FIGURE 4.3:
HORMONAL RESPONSE TO ANP INFUSION IN DOGS.
Changes in plasma hormone levels with infusion of 5pmol/kg/min 
ANP .or placebo during periods 3-5. Each period represents a 30 
minute time interval. ANP (pg/ml), Renin (active renin 
concentration, pU/ml), Ang II (pg/ml), Aldo (ng/dl). Asterixes 
indicate significance level (*P<0.05, **P<0.01, by paired T- 
test where overall differences between groups present by MANOVA 
- see Appendix 2).
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to a nadir of 228±26 pl/min in the placebo limb. Potassium excretion 
showed a downward trend in both groups but rose again during ANP 
infusion from 14.7±3.0 pmol/min (period 2) to 19.7±1.9 pmol/min, while 
continuing to fall on placebo.
Clearance Data: Changes in GFR and ERPF are shown in Figure 4.5 and 
in Table 4.3. The ANP-induced natriuresis was associated with a rise 
in GFR but this was highly variable and, as a consequence, non­
significant. ERPF showed a downward trend in both the active and 
placebo groups, and filtration fraction (FF) an upward trend, but 
again with no significant differences. However, fractional sodium 
excretion, which gives some indication of tubular function, was 
significantly increased by ANP infusion.
Haemodynamic Effects: Blood pressure and pulse were stable during 
placebo infusion and showed a small downward trend during ANP (Figure 
4.4, Table 4.2). Neither effect was significant and there was no 
observed change in haematocrit.
Hormonal Effects: The hormonal effects of ANP infusion and placebo are 
shown in Figures 4.3, 4.8 and in Table 4.1. Basal plasma ANP levels 
were around 40 pg/ml (14 pmol/1) and infusion caused an increase in 
plasma levels to between 140 and 220 pg/ml. In these normal dogs 
plasma active renin concentration (Table 4.2) was approximately 8 
pU/ml and fell during ANP infusion by about 50% reaching a nadir of 
3.4±0.7 pU/ml at the end of the infusion. Ang II showed a similar 
reduction during ANP infusion but, due largely to baseline 
variability, this failed to achieve statistical significance. No 
effect of ANP on aldosterone was evident. However, plasma aldosterone 
levels fell during both placebo and ANP treatment presumably 
reflecting the superimposed diurnal rhythm (since the studies were
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FIGURE 4.4:
BLOOD PRESSURE, PULSE AND HAEMATOCRIT CHANGES DURING LOW DOSE 
ANP INFUSION IN DOGS.
Effects of 5pmol/kg/min ANP or placebo on MAP (mean arterial 
pressure, mmHg), pulse rate (/min) and haematocrit (HCT, %). 
ANP was infused during periods 3-5, each period representing 30 
minutes. There were no statistically significant effects.
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FIGURE 4.5:
RENAL FUNCTION INDICES DURING ANP INFUSION IN DOGS.
Renal function data during infusion of ANP or placebo. Data are 
given as mean±SEM, the time scale represents 30 minute 
collection periods, and ANP was infused during periods 3-5. GFR 
(glomerular filtration rate, ml/min), ERPF (estimated renal 
plasma flow, ml/min), FF (filtration fraction, %) and FeNa 
(fractional excretion of sodium, %). Asterixes indicate 
significance by paired t-test where overall differences 
established by MANOVA; * P<0.05, ** P<0.01K
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carried out in the morning).
ACE Inhibition:
Plasma ANP: Basal plasma levels of ANP were not altered by pre­
treatment with ACE inhibitor, either acutely or chronically, and the 
levels achieved during infusion of ANP were similar to those achieved 
by infusion of the peptide alone - in the range of 150-200 pg/ml 
(Table 4.1).
Renal Effects: Acute administration of Enalaprilat (3 mg/kg, Figures 
4.6, 4.9) caused an increase in sodium excretion from 14.7±2.9 (basal, 
period 0) |imol/min to 35.9±10.1 nmol/min (P2); infusion of ANP caused 
a further increase to a peak of 118.3±25.4 pmol/min, more than double 
the increase produced by ANP alone. Urine volume showed a similar 
pattern increasing from a basal value of 364±33 to 675±141 pl/min 
after En (P2), with a further rise to 1104±158 fil/min during ANP 
infusion. Potassium excretion showed a downward trend across the 
protocol with no effect of ANP infusion. After pre-treatment with 
Enalapril (5mg b.d.) for three days basal levels of urine volume, 
potassium and sodium excretion were marginally higher than the placebo 
limb. ANP infusion caused a similar natriuresis to that of ANP alone, 
reaching a peak value 67.8±15.3; the diuresis was larger than that due 
to ANP alone (peak urine flow 888±267 pl/min). Although urine flow 
and, to a lesser degree sodium excretion, were greater than ANP alone 
at all times this failed to achieve statistical significance (Figures 
4.5 & 4.9).
In the additional limb where Enalaprilat was given alone there 
was a sustained increase in sodium excretion to around 50 pmol/min, 
lasting for 3 hours after treatment. This observation is important
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since it confirms the original assumption that Enalaprilat pre­
treatment has a stable effect on sodium excretion. Furthermore it can 
be seen (Figures 4.6, 4.9) that the total increase in sodium excretion 
during combined treatment with ANP and Enalaprilat at each time point 
(Periods 3-5) is greater than the sum of the individual contributions 
of ANP and Enalaprilat; this finding is more clearly shown in the 
summary diagram (Figure 4.9).
Clearance data: Renal plasma flow (ERPF) was marginally higher during 
ACE inhibition, but there was a large degree of variability and no 
statistically significant effects. Glomerular filtration rate (GFR), 
tended to be lower but was similarly variable and did not achieve 
statistical significance. Fractional excretion of sodium was, however, 
greatly increased during pre-treatment with ACE inhibitor and mean 
levels were twice as high during co-administration of ANP and 
Enalaprilat (or Enalapril) as they were during infusion of ANP alone 
(Table 4.3). However, once more because of the large SEM these effects 
failed to achieve significance by repeated measures analysis. The FeNa 
during treatment with Enalaprilat alone increased by approximatley 50% 
and remained at this level for three hours, once again re-inforcing 
the original assumption that acute ACE inhibition causes a sustained 
and constant effect.
Haemodynamic Effects: Enalaprilat pre-treatment caused a small
reduction in mean arterial pressure (Table 4.2, 5.5 mmHg), with a 
further marginal reduction occuring with the addition of ANP (2 mmHg). 
After 3 days of treatment with Enalapril mean arterial pressure tended 
to be slightly lower, but only by a few mmHg, and in the additional 
limb Enalaprilat alone caused a sustained fall in blood pressure of 
about 5 mmHg. None of these effects achieved statistical significance,
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FIGURE 4.6:
INFLUENCE OF ACE INHIBITION ON RENAL EFFECTS OF ANP.
Effects of infusion of ANP 5pmol/kg/min on sodium and potassium 
excretion (UNaV, UKV, pmoles/min) and urine volume (UVol, 
p.l/min) either given alone, in the presence of Enalaprilat 
(3mg/kg), or on the fourth day of treatment with Enalapril 5mg 
b.d. The effects of Enalaprilat alone are also shown but were 
not subject to statistical analysis (see text). Treatments were 
compared with ANP alone by MANOVA, with post hoc analysis by 
paired T-test *P<0.05, ** P<0.01. X axis shows 30 minute time 
periods, ANP was given during periods 3-5.
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suggesting that blood pressure is relatively independent of renin in 
these salt replete animals.
Hormonal Effects: Renin concentration responded appropriately to
pretreatment with ACE inhibitors. The basal level was three times 
higher at 25.7±4.7 after chronic Enalapril and rose sharply following 
intravenous Enalaprilat to a similar level (P2) - 24.1±7.1 l^U/ml. 
Levels fell during ANP infusion to about one third pre-infusion
values, and rebounded quickly to pre-infusion levels during the
recovery period (Table 4.1, Figures 4.8, 4.9). In the additional limb 
Enalaprilat alone caused a sustained increase in renin concentration.
Angiotensin II levels are not shown. In a series of preliminary 
experiments in four dogs (data not shown) Enalaprilat caused complete 
suppression of circulating Ang II for three hours to levels below the 
limit of detection of the radio-immunoassay (0.5-1.0 pg/ml). It was 
not possible to repeat these measurements here because the volume of 
blood taken did not allow for measurement of Ang I, which is greatly 
elevated by ACE inhibition and which interferes with Ang II 
estimation. However, one would predict that Ang II would be suppressed 
below the limits of detection for the full 3 hour period. Aldosterone 
levels fell over the three hour period during which samples were
taken. These changes were similar to those seen in the placebo limb
and were not significantly different from levels seen during ANP 
infusion. The pattern of aldosterone levels again presumably reflects 
diurnal variation in hormone levels and the absence of a significant 
reduction during ACE inhibition suggests that aldosterone levels are 
only partially dependent on Ang II in these animals.
Effects of Angiotensin II:
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Plasma ANP: Plasma ANP levels during peptide infusion were again
similar in this limb of the protocol (Table 4.1).
Renal Effects: In this part of the study (Figures 4.7, 4.9)
Enalaprilat was followed by infusion of two doses of Ang II: a "non- 
pressor” dose designed to restore plasma levels close to normal 
(lpmol/kg/min) and a "pressor” dose (5pmol/kg/min). Basal sodium 
excretion was lower in the limb receiving 1 pmol/kg/min and showed a 
small increase from 9.0±1.9 (period 2) to 16.3±3.4 pmol/1 during ANP 
infusion. Overall sodium excretion, even when corrected for baseline 
variability, was significantly lower than than ANP alone (P<0.001, 
MANOVA). 5 pmol/kg/min Ang II caused a marked antinatriuresis, UNaV 
falling from 18.7±4.5 (PO) to 10.0±2.3 (P2) (imol/min and remaining 
between 8 and 10 pmol/min despite subsequent infusion of ANP, 
potassium excretion showed a similar trend and although there was no 
evidence of antidiuresis, there was also no evidence of a diuretic 
response to ANP.
Clearance data: ERPF was significantly reduced during high dose Ang 
II infusion. GFR values were surprisingly (for "low" dose Ang II) also 
reduced (Table 4.3) but this failed to achieve statistical 
significance. However, there was no suggestion of an increase in GFR 
during infusion of ANP in either of the Ang II "clamp" groups. Basal 
levels of FeNa were not significantly lower in the Ang II limbs than 
in the placebo limb but values were much lower during ANP infusion, 
reaching statistical significance (by repeated measures analysis) with 
high dose Ang II. Furthermore, infusion of ANP was associated with a 
small rise in FeNa in the low dose Ang II group, albeit non­
significant, but no change was evident in the high dose group. 
Haemodynamic Effects: Mean arterial pressure was almost identical in
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FIGURE 4.7:
INFLUENCE OF ANG II ON RENAL EFFECTS OF ANP.
Effects of ANP (5pmol/kg/min) on sodium excretion (UNaV, 
pmoles/min), potassium excretion (UKV, pmoles/min) and urine 
volume (UVol, pl/min), given alone or with plasma Ang II 
"clamped" by co-infusion of lpmol or 5pmol/kg/min Ang II 
(periods 1-6) after the administration of Enalaprilat (3mg/kg) 
following period 0. Treatments were compared with ANP alone by 
MANOVA, with post hoc analysis by paired T-test *P<0.05, ** 
P<0.01. Periods represent 30 minute collections, ANP infused 
during periods 3-5.
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the low dose Ang II and placebo groups, suggesting that Ang II had 
been clamped within the physiological range (although plasma levels 
were subsequently found to be slightly higher than basal - see below). 
High dose Ang II caused a modest, sustained rise in MAP of about 10 
mmHg. In neither group was there any suggestion of a reduction in 
blood pressure during ANP infusion, in contrast to the trend towards 
blood pressure reduction in the group receiving ANP alone.
Hormonal Effects: When Ang II was infused following Enalaprilat renin 
levels did not rise but remained "normal" with the low dose infusion 
and suppressed (from 8.9±1.8 [P0] to 4.5±1.1 [P2] pU/ml) during the 
high dose infusion. When ANP was then infused there was a similar fall 
in renin - to that observed with ANP alone - during low dose Ang II 
infusion, and a small but perceptible decrease during high dose 
infusion., with a rebound rise in both Ang II limbs after 
discontinuing ANP. When the renin levels are e^qpressed as a percentage 
of pre-ANP infusion levels (i.e. P2) the percentage fall in renin was 
similar in all limbs (Figure 4.8), with a significant reduction in the 
corrected area under the curve for renin during ANP infusion (Figure 
4.9). The raw data are given in Table 4.1.
Ang II and aldosterone results are given in Table 4.1. Plasma 
Ang II levels achieved during low dose Ang II infusion were slightly 
higher than baseline (circa 14 pg/ml) and levels of around 60pg/ml 
were achieved during high dose infusion. There were no changes during 
the ANP infusion confirming that co-administration of En and Ang II 
produced an effective "clamp". Aldosterone levels were similar in all 
except the high dose Ang II group where they were approximately twice 
basal. Infusion of ANP caused a small reduction in these high 
aldosterone levels although they remained much higher than those seen
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FIGURE 4.8:
RENIN RESPONSE TO ANP INFUSION: INFLUENCE OF ANG II AND ACE 
INHIBITION.
Plasma active renin concentration expressed as a percentage of 
the level at the end of period 2 to compensate for the 
differing effects of Ang II and ACE inhibition on basal levels 
(see text for details). Absolute values are given in Table 4.1. 
Renin was significantly suppressed by ANP (vs Placebo, * 
P<0.05, ** PC0.01), but in none of the other treatment groups 
was there any difference compared with the effects of ANP 
alone. The effects of Enalaprilat alone are also shown.
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during infusion of ANP alone and the absence of an ideal control group 
(i.e. Ang II without ANP) makes the significance of this observation 
uncertain.
Discussion:
Several previous reports (Wang and Gilmore (1985), Bie et
al.,(1990), Hirata et al.,(1987), Richards et al.,(1989a), 
diNicolantonio and Morgan (1987), Seymour and Mazack (1988), Gaillard 
et al.,(1988,1989), Hansell and Ulfendahl (1987), Salazar et
al.,(1987)) have examined the interaction between ANP and Ang II on 
renal function in intact animals and man. Although there is almost 
universal agreement that Ang II can attenuate the natriuretic and 
diuretic actions of ANP, removal of circulating Ang II by
administration of an ACE inhibitor has also been reported to attenuate 
these actions of ANP. The present experiments address some of the 
inconsistencies in previous studies by using conscious animals, 
physiological doses of ANP, modest doses of converting enzyme 
inhibitor and attempting to establish the animals on a "normal" sodium 
diet. Under these circumstances ACE inhibition clearly enhances the 
actions of ANP and Ang II attenuates it, suggesting a modulatory role 
for renal Ang II on the renal actions of ANP.
Actions of ANP.
Basal plasma levels of ANP were around 40 pg/ml, similar to most 
previous reports in dogs (Mizelle et al., (1990), O'Hanian et al.,
(1988), Zimmerman et al.,(1987). Infusion of 5pmol/kg/min ANP caused 
plasma levels to rise 4-5 fold, achieving plasma levels close to 
previous reports using similar dose infusions (OHanian et al., (1988), 
Pichet et al. (1987), Cernacek et al., (1988), Bie et al., (1988)).
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FIGURE 4.9:
SUMMARY OF EFFECTS ON RENIN AND RENAL FUNCTION OF ANP INFUSION 
AND INFLUENCE OF ANG II AND ACE INHIBITION.
Summary of the effects of ANP in each of the different limbs of 
the protocol (see Figure 4.1 and text for details). 
AUC=calculated area under the curve for renin, corrected for 
baseline variation (see text for details), UNaV (sodium 
excretion, mmoles), UKV (potassium excretion, mmoles), UVol 
(urine volume, ml) for the 90 minute period during which ANP 
was infused.
* v? AN*3 alone and + vs placebo (*
There was marked variability in the final plasma levels achieved (140- 
220 pg/ml) despite identical infusion rates (Table 4.1), presumably 
reflecting interindividual differences in clearance rate. However, 
there was no evidence of higher plasma levels in the presence of 
Enalaprilat (as others have suggested, Wilkins et al.,(1987)). 
Overall, the differences in effect between increments in plasma 
levels of four or five-fold are likely to be slight (Cernacek et al.,
(1988)). ANP caused sodium excretion to rise two to three fold, urine 
volume doubled and there was a minor increase in potassium excretion. 
These observations are consistent with similar findings in other 
species infused with physiologically relevant doses of ANP (Human: 
Richards et al, (1988a,b), Soloman et al.,(1989), Anderson et 
al.,(1987), Morice et al.,(1988), Cottier et al.,(1988)); Rat: Soejima 
et al.,(1987) & Chapter 6) and a similar study in conscious dogs 
infused with approximately 3.3 pmol/kg/min ANP (Pichet et al.,(1989)), 
but conflicts with the findings of O ’Hanian (O'Hanian et al., (1988)) 
who failed to show any renal effects during infusion of 3.3 
pmol/kg/Min ANP in conscious dogs. There is no obvious explanation for 
these differences but the overall balance of evidence confirms a role 
for ANP at physiological/ pathophysiological levels. In the study of 
Pichet et al., (1989) absolute values for sodium excretion were 
substantially higher than the values reported here (basal levels 50 
vs. 20 [iEq/min) probably reflecting the higher dietary intake of their 
animals (110 vs. 30 mmoles Na/ day). There was a modest, non­
significant, fall in mean arterial pressure and heart rate (table 4.2) 
consistent with previous observations that the hypotensive effects of 
ANP are only clearly seen at higher doses (Pichet et al.,(1989), 
O'Hanian et al.,(1988), Cernacek et al.,(1988), Bie et al.,(1988)) or
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during chronic administration of ANP (Janssen et al.,(1989), Mizelle 
et al.,(1990)). Active renin concentration fell during ANP infusion 
(consistent with the known actions of ANP in man (e.g. Richards et 
al.,(1988)) and in dogs (Richards et al.,(1988), Burnett et 
al.,(1984)) and although there was a similar trend in Ang II 
(presumably secondary to the changes in plasma renin) this failed to 
achieve statistical significance due to baseline variability (Figure 
4.3). Aldosterone fell in both active and placebo limbs, the fall in 
the placebo limb presumably reflecting diurnal variation; there was no 
significant effect of ANP over the short time interval studied.
This mechanism underlying the renal actions in this study, with 
an upward trend in GFR, a downward trend in renal plasma flow and a 
significant increase in FeNa almost exactly parallel the consensus 
view from low dose studies in man (Richards et al, (1988a,b), Soloman 
et al.,(1989), Anderson et al.,(1987), Morice et al.,(1988), Cottier 
et al.,(1988))). From these data one would predict that the observed 
natriuresis is due to inhibition of tubular sodium reabsorption 
(Chapter 2) but, since no attempt was made to dissect out 
contributions from the proximal and distal tubules (for example by 
lithium clearance), it is not possible to say where in the tubule 
these effects occur. Furthermore, measurement of GFR by inulin 
clearance (Maack (1986)) is relatively inaccurate with up to 10% 
error. The upward trend seen in the present study may thus mask a true 
small effect on GFR, and increased GFR is certainly seen with higher 
infusion rates of ANP (Chapter 2; 2.7). Thus from this data the 
natriuresis due to low dose infusion of ANP appears to be mediated 
predominantly by reduced tubular reabsorption of sodium.
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Effects of ACE inhibition:
Acute administration of Enalaprilat caused a small, sustained 
natriuresis and diuresis with small reduction in mean arterial 
pressure, reflecting the tonic basal activation of the renin- 
angiotensin system in these salt-replete animals (Hall (1986), 
Mitchell and Navar (1989)). Furthermore, the natriuresis - in the 
absence of a change in plasma aldosterone - is consistent with the 
modern view that many of the effects of the renin-angiotensin- 
aldosterone system are mediated by the direct actions of Ang II on the 
renal tubule rather than through aldosterone (Hall (1986), Mitchell 
and Navar (1989)). Subsequent administration of ANP resulted in a 
greatly increased diuresis and natriuresis, when compared with the 
actions of ANP alone. There was no significant alteration in potassium 
excretion. However, in the group pre-treated with Enalapril (5mg 
b.d.), basal urine volume and sodium excretion were increased and 
although ANP administration caused sodium excretion and urine volume 
to rise the effect was not significantly greater than ANP alone. These 
findings contrast with previous studies where ACE inhibition blunted 
the effects of ANP (e.g. Gaillard et al.,(1988, 1989), Seymour and 
Mazack (1988), Wilkins et al.,(1987)), but only acute ACE inhibition 
significantly increased the actions of ANP. There are several possible 
reasons for this, the most likely being that ACE inhibition causes a 
fall in arterial pressure. It is known from studies on the isolated 
kidney (Firth et al.,(1987) and experimental animals (Seymour et 
al.,(1987), Davies and Briggs (1987)) that reductions in renal 
perfusion pressure attenuate the natriuretic actions of ANP. The 
mechanism of this effect is not understood but does not appear to 
involve activation of the intra-renal renin-angiotensin system, since
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infusion of saralasin does not restore the natriuresis (Redfield et 
al., (1989)). In fact, restoration of perfusion pressure by infusion 
of Ang II can restore the natriuretic effects of ANP (Redfield et 
al.,(1989), Davies and Briggs (1987)). Activation of the renal
sympathetic nervous system can also attenuate the natriuretic effects 
of ANP (Koepke and diBona (1988)) and will tend to be activated during 
systemic hypotension and in anaesthetised preparations. The use of 
conscious animals in the present study should avoid sympathetic 
activation and although circulating catecholamines were not measured 
there was no change in heart rate. Richards et al.,(1989) also 
reported an increase in cortisol during ACE inhibition which may 
indicate activation of a "stress" response perhaps associated with 
activation of the sympathetic nervous system. If we accept that 
hypotension (with associated reduction in renal perfusion pressure and 
sympathetic activation) is the factor most likely to inhibit the
natriuretic response to ANP (above) then it is obvious that the dose
of ANP used is important - since hypotension is a dose dependent 
effect (Bie et al.,(1988)) in dogs. The use of low dose ANP in the 
current study - in contrast to previous reports (above) - removes some 
of this effect, since only a small fall in blood pressure was
produced. The dose of ACE inhibitor is also important. Polonia et 
al.,(1990) found that the natriuretic effects of 50pmol/kg/min ANP 
were enhanced by a low dose of Captopril but when combined with high 
dose Captopril (where BP fell) the effects were blunted. Sodium 
balance is also important, and was not controlled in many studies. 
Richards et al.,(1989) studied volunteers on a high salt diet (300 
mmol/day) which will tend to suppress renin activity and thereby make 
ACE inhibition superfluous. The fact that these authors found any
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enhancement of the natriuretic actions of ANP (albeit minor, and non­
significant) is surprising. A greater enhancement might have been seen 
had ACE inhibitor been administered against a background of an active 
renin-angiotensin system. Finally, there are clear differences between 
the effects of acute administration and chronic administration of ACE 
inhibitor on the actions of ANP. In the present study acute 
administration caused a marked enhancement whilst "chronic" 
administration caused only a minor non-significant enhancement. The 
reasons for this are not clear. There were no differences in BP 
between the groups, nor was there any evidence of adaptation within 
the circulating renin-angiotensin system since renin activity and 
aldosterone levels were similar before administration of ANP (i.e. P2) 
in both ACE inhibitor limbs. It may be that the intra-renal renin 
angiotensin system "escapes" from ACE inhibition during chronic 
administration or that these animals are in relative negative sodium 
balance having presumably undergone a natriuresis on the first day of 
treatment. Whatever the expalnation, it it may explain some of the 
observed differences between acute studies and studies of chronic pre­
treatment with ACE inhibitors (Wilkins et al.,(1987), Gaillard et 
al.,(1988,1989)).
Recently, Bie et al.,(1990) have published findings in conscious 
dogs infused with ANP in the presence of ACE inhibition plus 
aldosterone blockade with Canrenoate showing potentiation of the 
actions of ANP. The present findings suggest that ACE inhibitors would 
explain the major part of this potentiation. The observation that ACE 
inhibition enhances the renal effects of ANP fits well with 
observations made during non-pharmacological manipulation of the 
renin-angiotensin system. For example when renin is suppressed by
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volume expansion (Metzler and Ramsay (1989)) or mineralocorticoid 
excess (Gaillard et al.,(1988), Parkes et al.,(1988)) then ANP is more 
potent. The overall consensus from the present study and previous 
reports must be that ACE inhibition potentiates the actions of ANP as 
long as antinatriuretic mechanisms are simultaneously activated. 
Interaction with angiotensin II.
Having established the effects of ACE inhibition (above), Ang II 
should inhibit the renal effects of ANP and this is well established 
(Salazar et al.,(1987), Showalter et al.,(1987), McMurray and 
Struthers (1988a,b), Lang and Struthers (1990)). The purpose of the 
present study was to examine the interaction between ANP and Ang II 
using physiologically relevant doses of both peptides, and to remove 
the effects of ANP on endogenous Ang II by the combination of Ang II 
and ACE inhibitor (Mizelle et al.,(1989)). In the present experiments 
high dose Ang II (which increased plasma Ang II ten-fold (Table 4.1) 
and increased blood pressure (about 10 mmHg, Table 4.2). There was no 
effect on baseline sodium excretion. Renin levels were suppressed 
(Figures 4.8, 4.9, Table 4.3) and aldosterone increased approximately 
three-fold (although due to SEM this did not achieve statistical 
significance, Table 4.1, Appendix 2). The effects of ANP on the kidney 
and on arterial pressure were completely abolished, although the 
effect on renin suppression remained (Figure 4.8, see below). In the 
low dose Ang II group, despite the fact that blood pressure was 
controlled at "normal11 levels as intended, plasma Ang II subsequently 
turned out to be approximately twice normal (Table 4.1). The pattern 
of renal effects is virtually identical to that of high dose Ang II 
except that blood pressure remained "normal" and during infusion of 
ANP there was a small upward trend in sodium excretion which, although
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not statistically significant suggests that the response to ANP is not 
completely abolished. These data confirm that Ang II opposes the renal 
actions of ANP and it is apparent that the effects of the 
antinatriuretic hormone are more potent since doubling plasma levels 
virtually abolishes the response to a five-fold increase in ANP.
Site of the ANP-Ang II interaction:
Having established that increased Ang II attenuates, and ACEi 
(reduced Ang II) augments the effects of ANP, the measurements made 
in this study allow us to make limited judgements regarding the intra- 
renal site of this ANP-Ang II interaction. There is little evidence of 
an interaction in renal blood flow. Although ERPF is lower during Ang 
II infusion, it also falls during treatment with ANP alone and the 
small increase seen during treatment with ACE inhibitor is not 
statistically significant. The data on glomerular blood flow is 
similarly difficult to interpret due to the large variability. ANP 
caused an increase in mean GFR, although this failed to achieve 
statistical significance. Ang II infusion caused a reduction in GFR 
which would not be predicted to occur, at least at this dose of Ang 
II, which is usually reported to increase or preserve GFR (see Hall
(1986), Mitchell and Navar (1989) - for review). When infused
together, GFR remained low and there was no evidence of an upward 
trend in GFR during ANP infusion. However, the greater natriuresis 
during treatment with Enalaprilat and ANP was not accompanied by 
increases in GFR, suggesting that an interaction at the level of the 
glomerulus is not of major importance. Fractional excretion of sodium 
gives some indication about tubular function, although it does not 
localise the effect to any particular tubule section. For this 
variable the pattern of change does follow the observed changes in,
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for example, total sodium excretion. ANP alone caused a rise in FeNa; 
the greater natriuresis seen with combined ACE inhibition and ANP was 
associated with mean values of FeNa twice those seen with ANP alone 
(although once more not statistically significant); and the reduced 
natriuresis during Ang II treatment was associated with a reduced 
FeNa. The balance of evidence therefore points to an interaction at 
the level of the renal tubule, although one can only speculate on the 
tubule segments involved. The main antinatriuretic effects of Ang II 
occur in the proximal tubule (Hall (1986)), those of ANP seem best 
characterised in the distal tubule and collecting duct (Chapter 2). 
Therefore the simplest model might involve Ang II acting as a "gate", 
regulating the delivery of sodium to the distal tubule where ANP can 
then act (Mizelle et al.,(1989), Bie et al.,(1990)). This simple model 
alone might account for all the observed effects. However, it is more 
likely to involve a mixture of effects at different sites in the 
nephron. For example ANP and Ang II have opposing effects in the 
isolated glomerulus (Appel et al.,(1986)) in vitro and, since 
glomerular receptors for both are present (Martin and Ballerman
(1989)), such an effect may well occur in vivo. Minor changes in GFR 
may be missed by the relatively imprecise measurement of inulin 
clearance (Maack (1986)). A trend towards increased GFR with ANP was 
evident in the present study and was absent when Ang II was infused. 
Other workers have suggested that the effects of ANP in the distal 
tubule are quantitatively inadequate to account for the observed 
effects of ANP (Harris and Skinner (1990)) and suggest instead that 
there is an interaction between ANP and Ang II within the proximal 
tubule - where Harris et al.,(1987, 1988) have shown in careful
micropuncture studies that ANP opposes the effects of Ang II on sodium
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reabsorption through disruption of glomerulotubular balance.
Overall, the data points to a physiologically relevant 
interaction between ANP and Ang II which is predominantly tubular and 
may simply involve Ang II regulating the passage of sodium to the 
distal tubule where ANP is effective, but it is not possible to 
exclude effects at other sites within the nephron.
Renin release:
There is abundant evidence that ANP suppresses basal and
stimulated renin release in vivo (Chapter 2, Burnett et al., (1984), 
Maack et al.,(1984), Scheuer et al.,(1987), Richards et al.,(1988)) 
and in vitro (Deray et al.,(1987)). The current findings confirm that 
physiological levels of ANP are effective in the dog, and cause
approximately 50% reduction in circulating active renin. Debate 
continues as to whether the effects of ANP on renin are direct or 
indirect (i.e. acting directly on the renin-secreting cells or 
indirectly through a macula densa mechanism) and, for example, ANP has 
been shown to have no effect in t he non-filtering kidney (Chapter 2, 
Opgenorth et al.,(1987)). However, in this study the percentage
reduction in renin is similar in all the limbs of the protocol even 
when the natriuresis is abolished by Ang II, suggesting a direct 
action, independent of the distal delivery of sodium. Many of the 
actions of ANP persist after infusion has stopped implying 
continuation of action at a post-receptor level (eg Singer et
al.,(1987)), since the plasma half-life of ANP is only a few minutes 
(Chapter 5). For example the natriuresis caused by ANP alone (Figure 
4.2) persisted into the recovery period. However, in all limbs of the 
study renin activity had returned to the appropriate baseline (period 
2) with 30 minutes of cessation of the ANP infusion, again suggesting
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a mechanism of action independent of sodium delivery to the macula 
densa and possibly acting through an short-lived intracellular post­
receptor mechanism.
Contribution of renin suppression to the natriuretic effects of ANP:
One of the original aims of this study was to assess the role of 
suppression of the renin-angiotensin system to the natriuretic actions 
of ANP. To some extent it is not possible to answer this question for 
the simple reason that despite normal arterial pressure the low dose 
Ang II clamp resulted in twice normal plasma levels of Ang II. 
However, some information can be salvaged from the data. Figure 4.10 
shows the relationship between the ratio of plasma ANP/Ang II and 
UNaV. Individually Ang II is inversely related to sodium excretion 
and, under circumstances where Ang II suppressed (ACE inhibition) ANP 
is directly related to UNaV. Overall, the relationship between log 
(ANP/Ang II) and log UNaV is linear:
Log UNaV = 0.27 Log [ANP/ Ang II] + 1.01.
4
From this simple relationship it is possible to predict the 
natriuretic response to ANP from the plasma levels of ANP and Ang II 
(Table 4.1). With infusion of ANP alone the estimated sodium excretion 
during ANP infusion is 2.8 mmoles/90 minutes; compared with an actual 
value of 3.7, and a calculated "placebo" value of 1.2 mmoles/90 
minutes. When a constant value of Ang II (equal to basal levels) is 
put into the equation then a value of 2.4 mmoles/ 90 minutes is 
obtained, thus suppression of Ang II would be predicted to contribute 
approximately 15% to the natriuresis during ANP infusion, with the 
major actions of ANP being due to direct effects on the kidney (Bie et
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FIGURE 4.10:
RELATIONSHIP BETWEEN ANG II AND ANP CONCENTRATIONS AND SODIUM 
EXCRETION IN DOGS.
Relationship between the ratio of ANP/Ang II (both pg/ml) and 
sodium excretion (pmol/min). Data from 32 dog studies, from the 
placebo, ANP alone, and high and low dose ANG II limbs of the 
study (n=8 for each). Each point represents.the mean value for 
8 dogs at a single time point, with 7 time points from each 
experimental limb. r=linear correlation coefficient.
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al.,(1990). In order to confirm this estimate it would be necessary to 
repeat the experiments with different levels of Ang II "clamp". 
However, without an instantaneous measurement of Ang II (other than 
blood pressure) this ideal may be difficult to achieve.
In conclusion this series of experiments demonstrates that modest 
increments in Ang II can attenuate or abolish the renal effects of ANP 
and, as one would predict (but in contrast to much of the published 
literature), that inhibition of the renin-angiotensin system by 
administration of Enalaprilat augments the action of ANP. The failure 
of other workers to demonstrate this is due in part to the confounding 
effects of changes in renal perfusion pressure produced by ACE 
inhibitors but mainly to the differences between acute and chronic 
administration of ACE inhibitors on the subsequent actions of ANP. 
These findings are consistent with a modulatory role for Ang II on the 
actions of ANP in the kidney, with the large ANP-induced natriuresis 
in the presence of Enalaprilat reflecting the maximum "potential" ANP 
effect. Since ANP can reduce renin release and, as a consequence, 
reduces circulating and intrarenal Ang II, the question arises (Bie et 
al.,(1990)) of the extent to which this reduction in Ang II 
contributes to the natriuresis of ANP. In the present series of 
experiments "clamping" Ang II by co-infusion of ANP and Ang II was 
able to blunt the effects of ANP suggesting that reduction in Ang II 
is a necessary component of the natriuresis. However, it was clear 
that modest increments of Ang II have more potent antinatriuretic 
actions than larger increments in ANP have natriuretic. Due to 
difficulty in "clamping" plasma Ang II at absolute levels it was only 
possible to estimate the contribution of suppressed Ang II to the
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natriuretic actions of ANP - at 15%. With respect to renin, debate has 
surrounded the mechanism by which ANP inhibits renin release. The 
ability of ANP to produce a fall in renin in the face of a reduction 
in urinary sodium excretion favours a direct rather than a macula 
densa mediated mechanism.
Finally, from a therapeutic point of view (Section 4) these 
studies suggest that suppression of the renin-angiotensin system may 
offer a mechanism for enhancing the effects of ANP.
ANP
Time 0 1 2 3 4 5 6
Placebo 33.4±6.9 43.6*5.9 42.0*53 39.1*7.6 33.0*6.6 36.0*6.2 343*6.0
ANP alone** 44.0*6.0 52.9*9.1 523*11.7 1923*30.1” 179.9*273“ 180.6*26.1" 49.7*10.1
ANP+EN 38*6.4 313*5.2 45.2*20.1 147.2*29.1 1903*333 180.5*34.5 53.0*15.-
ANP+Chr EN 35.6*6.1 343*7.1 33.6*6.6 153.7*14.9 136.7*9.9 158.3*27.7 30.8*23.1
EN alone 32.4=33 30.9*3.9 343*5.7 37.4*11.4 32.7*6.9 35.6*9.1 37.9*10.:
ANP+EN+Ang 1 53-8*8.6 513*8.1 54.6*8.1 1443*11.1 137.8*4.7 150.0*9.0 46.4*5.9
ANP+EN+Ang 5 34.9*6.7 323*7.2 293*4.1 180.1*18.7 
RENIN
197.7*153 204.2*23.7 45.0*11.1
Time _ 0 1 2 3 4 5 6
— — — ' 1 ' ' '
Placebo 8.6*1.6 7.2*13 7.4*13 6.9*1.2 63*1.2 6.2*1.1 7.2*13
ANP alone** 7.4*1.4 8.4*1.6 7.4*13 4.6*1.0* 3.9*0.8* 3.4*0.7* 73*1.1
ANP+EN*** 83=23 17.4*6.1 24.1*7.1* 133*3.6* 8.0*2.2 6.9*1.9 22.8*4.2'
ANP+Chr EN*’* 25.7*4.7* 25.4*4.0” 28.6*53” 17.1*3.0“ 11.8*2.1* 9.6*13* 20.6*3.1'
EN alone’** 6.0±1.1* 13.0*3.9 19.1*53* 18.7*5.0* 203*5.7* 19.0*43* 21.7*5.6'
ANP+EN+Ang 1 9.0*2.2 10.1*33 12.2=3.9 7.2*23 5.2*1.7 3.9*1.0 8.2=2.9
ANP+EN+Ang 5 8.9*1.8 83*2.6 43*1.1 3.0*03 
ANG 2
33*0.4 2.7*03 33*0.6
Time 0 1 2 3 4 _5 6' " * r
Placebo 10.7*3.0 8.2=1.6 8.7*13 8.1*1.0 7.0*03 7.4*03 8.0*1.4
ANP alone 63*1.6 9.1*23 63*1.9 3.9*1.0 3.7*1.0 33*0.8 5.9*1.1
ANP+EN+Ang 1** 93*1.4 15.9*2.1 14.8*2.5 143*23“ 14.4*23* 13.1*13" 153*2.4'
ANP+EN+Ang 5*** 63 *13 60.6*4.6*” 643*53*” 58.9*3.9“* 613*5.7*“ 65.4=53 583*3.8
ALDO
Time 0 1 _2 _3 _4 5 6
Placebo 5.6*03 4.6*1.0 4.4*03 3.9*0.7 23*0.7 1.6*03 1.9*0.7
ANP alone 63*1.1 53*1.0 4.4*13 23*0.9 2.1=03 1.1*0.6 1.0*03
ANP+EN* 33*0.9* 23*0.4* 23*0.7 2.1*0.6 13*0.4 0.9*04 03*03
ANP+Chr EN 33*0.9 43*1.0 3.4*0.9 23*1.0 2.4=0.6 1.4=0.7 13*0.7
EN alone 4.6*03 4.9*1.2 2.0*0.6 1.4*0.6 0.1*0.1 0.1*0.1 03*0.2
ANP+EN+Ang 1 6.0*0.9 6.6*1.01 6.4*1.7 4.0*0.9 43*1.6 2.4*03 2.4=0.7
ANP+EN+Ang 5 14.0*8.6 153*6.6 17.6*5.4 14.6*4.6 12.4*3.6 8.6*23 11.6*3.1
TABLE 4.1:
PLASMA HORMONE LEVELS.
Levels of ANP (pg/ml), Ang 2 (pg/ml), Renin (jiU/ml), Aldo 
(ng/dl) in each of the treatment groups against time interval. 
Data are. shown as meaniSEM. Significance by MANOVA of ANP vs 
Placebo and of all other groups against ANP illustrated by 
asterixes on label. Where significant, individual time points 
compared by T-test. * P<0.05, ** p<0.01, *** PC0.001.
BP (MAP)
Time 0 1 2 3 4 5 6■ ■ ' '
Placebo 109.5*2.8 110.9*3.1 1123*4.1 112.9*2.8 113.4*3.6 112.4*3.1 114.9*4.7
ANP alone 109.3*2.3 113.0*3.2 114.1*1.9 110.6*1.9 1073*1.7 108.0*1.5 111.9*1.0
ANP+EN** 114.0*4.5 108.5*3.8 1083*3.5 106.4*33 1063*2.7 105.9*4.1 104.9*3.7
ANP+Chr EN 107.4*3.1 108.4*2.6 109.4*2.7 107.5*2.8 104.6*2.2 103.1*2.2 107.9*4.7
EN alone 113.1*2.3 1083*3.4 108.1*2.8 107.4*3.5 110.9*3.6 110.0*3.9 108.9*4.5
ANP+EN+Ang 1 111.0*53 113.4*3.1 114.8*3.5 112.8*2.8 1143*2.7’ 118.1*2.8“ 116.5*3.4
ANP+EN+Ang 5" 112.4*3.0 118.4*2.8 124.5*3.5“ 123.5*3.1“ 
PULSE
121.8*2.7’” 122.6*2.7“* 123.6*2.6*
Time 0 1 2 3 4 _5 _6
Placebo 82*4 81*5 85*4 88*6 87*4 86*3 84*5
ANP alone 91*5 87*3 87*6 83*4 76*4 80*4 86*3
ANP+EN 89*7 90*6 85*6 80*4 85*4 83*6 87*4
ANP+Chr EN 90*5 93*6 90*4 91*6 84*5 87*5 90*
EN alone 72*11 88*3 85*5 85*4 92*4 86*5 84*4
ANP+EN+Ang 1 89*9 96*7 94*7 84*6 92*7 91*5 93*5
ANP+EN+Ang 5 91*6 90*6 91*6
HCT
91*4 88*5 91*6 94*5
Time 0 1 2 3 4 5 6
Placebo 35.7*1.6 35.2*2.1 34.7*2.2 343*2.4 34.0*23 333*23 33.2*2.4
ANP alone 35.0*1.9 343*1.6 343*1.9 33.6*1.9 343*1.6 333*1.6 333*1.7
ANP+EN 353*13 363*13 363*1.6 37.0*1.9 373*1.6 37.9*1.9 36.0*13
ANP+Chr EN 37.1*23 37.1*2.4 36.6*2.0 36.6*2.0 36.6*2.0 35.7*2.1 36.0*2.1
EN alone 353*1.4 353*13 35.4*1.2 353*1.6 353*1.4 353*1.1 353*1.1
ANP+EN+Ang 1 35.5*2.2 353*1.0 353*5.1 353*13 353*13 353*13 353*13
ANP+EN+Ang 5 35.0*1.8 363*13 353*13 353*1.9 353*13 343*13 343*13
TABLE 4.2:
PULSE/ BLOOD PRESSURE AND HAEMATOCRIT:
Mean arterial pressure (MAP), pulse rate (beats per minute) and 
haematocrit (HCT, %) in each of the treatment groups against 
time interval. Statistical significance indicated by asterixes 
as in Table 4.1 (Data are shown as meaniSEM).
Time 0 1 2
ERPF
3 4 _5 _6
Placebo 211*21 201*20 198*21 194*21 183*17 179*17
ANP alone 201*16 200*16 186*15 174*14 164*16 162*16
ANP+EN 254±21 228*23 214*24 203*22 204*20 209*21
ANP+Chr EN 248±12 235*13 213*14 219*16 202*14 204*13
EN alone 221±22 235*24 239*24 235*23 223*21 218*19
ANP+EN+Ang 1 211*13 202*15 184*15 163*12 159*12 179*22
ANP+EN+Ang 5** 221*15 192*15
GFR
170*13 159*11* 150*11 147*11
Placebo 76*10 92*20 95*25 82*16 77*17 56*5
ANP alone 85±17 85*18 76*16 86*31 120*42 90*29
ANP+EN 74±12 84*14 82*12 83*10 84*7 87*8
EN+Chr EN 44*5 51*8 63*15 62*15 77*17 80*17
EN alone* 51*5 48*4 54*9 59*12 69*16 67*17
ANP+EN+Ang 1 52*4 57*7 58*6 54*5 53*5 54*6
ANP+EN+Ang 5 57*7 62*7
FF
60*7 56*8 62*8 65*7
Placebo - 38*6 51*10 51*13 46*9 42*8 29*2
ANP alone - 45*10 45*10 42*8 47*12 76*26 54*12
ANP+EN f 34*8 39*8 38*3 42*5 42*3 43*4
ANP+Chr EN - ■ 18*3 22*4 31*9 30*9 39*10 40*9
EN alone - 23*4 20*2 26*6 29*8 36*10 34*8
ANP+EN+Ang 1 - 24*3 28*4 32*4 34*4 33*5 31*7
ANP+EN+Ang 5 27*3 34*4
FeNa
36*3 36*5 42*5 45*4
Placebo 0.16*0.03 0.13*0.03 0.15*0.04 0.17*0.03 0.19*0.03 0.28*0.07
ANP alone** 0.15*0.02 0.16*0.04 0.24*0.05 0.47*0.07“ 0.46*0.14* 0.27*0.06
ANP+EN 0.30*0.14 039*0.16 0.77*031 1.07*038 0.97*030 0.94*036
ANP+Chr EN 0.46*0.16 0.43*0.22 0.67*036 0.94*033 0.91*031 038*0.16
EN alone 0.46*0.17 037*0.08 0.49*0.10 0.68*0.17 0.66*0.19 0.66*0.21
ANP+EN+Ang 1 0.17*0.04 0.13*0.05 0.15*0.04 0.22*0.04 0.21*0.03 0.19*0.03
ANP+EN+Ang 5** -
TABLE 4.3: 
RENAL FUNCTION
0.18*0.03*
INDICES:
0.12*0.02 0.12*0.03 0.15*0.05* 0.11*0.03* 0.09*0.02
Estimated renal plasma flow (ERPF, ml/min), Glomerular 
filtration rate (GFR/ ml/min), Filtration fraction (FF, %), 
Fractional excretion of sodium (FeNa, %) in each of the 
treatment groups against time interval. Statistical 
significance indicated by asterixes as in Table 4.1 (Data are 
shown as meantSEM).
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Section 4.
NEUTRAL ENDOPEPTIDASE AND ATRIAL NATRIURETIC PEPTIDE.
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Chapter 5.
Harnessing the Therapeutic Potential of ANP: 
Neutral Endopeptidase and NEP Inhibitors.
The unique combination of actions produced by infusion of ANP - 
natriuresis, diuresis, vasorelaxation and suppression of the renin- 
angiotensin system (Chapter 2) - quickly aroused interest as a
potential therapeutic combination in hypertension, heart failure and 
other oedematous states (Jardine et al., (1989), Fried (1989). 
However, since ANP is not orally available, investigation of this 
therapeutic potential was limited by the need for parenteral infusion. 
In theory, there are several ways to circumvent this problem. Firstly, 
it may be possible to synthesise ANP analogues which are stable to 
enzymatic degradation, by modifying the parent ANP molecule. This 
approach was partially responsible for identifying the C-ANP receptor 
(Maack et al., (1987), Scarborough (1989), Koepke et al.,(1989) and, 
although C-receptor analogues are available (eg 4_23ANP, see Chapter 
2), which potentiate the effects of ANP by blocking receptor mediated 
clearance, they are mostly large peptides (Okolicany et al.,(1990)),
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and to date no specific analogues to the guanylate cyclase-linked 
receptor have been identified. An alternative approach is to increase 
production of ANP and, although some agents such as dexamethasone 
(Shields et al.,(1987)), a and B-adrenoceptor agonists (Schiebinger & 
Linden (1987); Schiebinger et al.,(1987)) stimulate the release of ANP 
in vitro, no agents which specifically release ANP have been 
identified. A further alternative is at the subcellular level by the 
inhibition of cGMP degradation. Recent reports suggest that cGMP 
phosphodiesterase inhibitors are potent antihypertensive agents 
(Wilkins et al.,(1990)) but the actions of these compounds is not 
specific to ANP and may potentiate the effects of agents acting 
through soluble guanylate cyclase (eg EDRF). Although this is an 
interesting and potentially important antihypertensive mechanism it 
will not be considered further here.
Finally, ANP's actions may be potentiated by the inhibition of 
enzymatic degradation of the peptide. Although it has been known for 
some time that ANP is rapidly cleared from the circulation (Espiner et 
al., (1986), Richards et al.,(1986)) it was not until 1987 that an 
enzyme responsible for ANP degradation was identified. This enzyme, 
Neutral Endopeptidase (NEP, EC 3.4.24.11) is found principally in the 
renal brush border. Almost simultaneously in 1987 a number of groups 
(Stephenson & Kenny (1987), Olins et al (1987), Sonnenberg et al 
(1987)) reported that ANP was degraded by preparations of renal brush 
border membrane which are rich in peptidases, and that the principal 
site of attack is at the Cys-Phe bond of ANP (Figures 2.2 & 2.3). This 
enzymatic degradation co-purifies with purification of NEP from renal 
brush border membranes (Sonnenberg et al.,(1987)), and is blocked by 
specific enzyme inhibitors (Stephenson & Kenny (1987), Olins et
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al,(1987), Sonnenberg et al., (1987), Bertrand and Doble (1988)). The 
identification of a specific enzyme degrading ANP stimulated the 
development of inhibitors of NEP, and the re-evaluation of earlier 
enzyme inhibitors, drawing on the technology used in the design of ACE 
inhibitors. In 1987, when the present studies were started, this 
appeared to be the most reproducible way of elevating plasma ANP, and 
the most promising line of research. The remainder of this chapter 
describes the characteristics of NEP, and the development of NEP 
inhibitors.
Neutral Endopeptidase:
First discovered by Kenny in Leeds, NEP is a Zinc containing 
metallo-endopeptidase localised the brush border of the proximal 
tubule (Kerr & Kenny (1974), Booth & Kenny (1974)), a site rich in 
peptidase enzymes. At the time of its discovery no specific role for 
NEP was apparent. However, the discovery of endogenous opiates or 
enkephalins in the late 1970’s was followed by the demonstration of a 
specific enzyme "enkephalinase” (Malfroy et al (1978)), which degraded 
these peptides at the Gly3_Phe4 amide bond (Figure 5.1). Later 
enkephalinase activity was detected in other organs including the 
kidney (Llorens & Schwartz (1981)) and was subsequently demonstrated 
to be identical to NEP (Malfroy & Schwartz (1984)). The enzyme has 
since been shown to be present to a varying extent in most tissues 
(Table 5.1) and to have a bewildering collection of substrates (Table 
5.1) to which ANP was added in 1987 (Stephenson & Kenny (1987)).
In their initial study these authors found that ANP was degraded 
by kidney micro-villous membrane in vitro and the pattern of 
hydrolysis was similar with purified NEP. A number of degradation
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products were identified with several potential sites for hydrolysis 
within the ANP structure, the most important site appearing to be 
within the 17 AA ring of ANP at the Cys-Phe bond (Cys1 0 5 , Phel o e ; 
Figures 2.2, 2.3). Phosphoramidon, an inhibitor of NEP caused 80-100% 
suppression of degradation, with no affect of either ACE or 
aminopeptidase inhibitors (Stevenson & Kenny (1987). Other groups 
subsequently published similar findings (Sonnenberg et al., (1987), 
Olins et al., (1987), Koehn et al., (1987), Bertrand & Doble (1988)), 
that kidney membrane preparations degraded ANP at the Cys-Phe bond, 
that ANP degrading activity co-purified with NEP, was pH sensitive and 
was inhibited by the existing NEP inhibitors Thiorphan and 
Phosphoramidon.
Properties of NEP:
The gene for NEP has recently been cloned (Malfroy et al.,(1988)). 
The gene sequence shows a high degree of conservation (with 93% 
homology between rat and rabbit, NEP's and a similar degree of 
homology with human enzyme) and encodes for a protein of around 62,000 
daltons. By hydrophobic analysis this can be shown to have a small 
hydrophobic membrane spanning region near the amino terminus, and a 
large hydrophillic region, containing the active site, projecting from 
the cell surface (Devault et al.,(1987), Malfroy et al.,(1987)). The 
enzyme contains 5 or 6 potential N-linked glycosylation sites, and 
estimates for the molecular weight of the glycosylated enzyme vary 
around 87-95,000 (Devault et al.,(1987)). NEP shares a highly 
conserved nucleotide consensus sequence with other metallo- 
endopeptidases including Thermolysin (Schwartz (1989), Devault et al.,
(1987), Erdos & Skidgell (1989)), particularly in the residues co­
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ordinating the position of the zinc atom in the catalytic site.
Distribution of NEP:
NEP is a widely distributed enzyme (Table 5.1; Erdos and Skidgell
(1989)). In the brain it is found in the globus pallidus and 
substantia nigra and in centres responsible for pain perception, the 
distribution being similar to that of endogenous opiate receptors 
(Malfroy et al., (1978), Llorens et al., (1982). The density of 
enkephalinase in the brain is appropriately regulated by exogenous 
opiates, and inhibition of NEP activity using specific inhibitors 
potentiates the effects of endogenous opiates. In the kidney small 
amounts of NEP are found in the glomerulus, but the densest 
concentration appears in the brush border of the proximal tubule, 
where its presumed role - like that of other peptidase enzymes - is to 
conserve the protein content of peptides filtered by the glomerulus 
(Kenny and Stephenson (1988)). The enzyme is also present in other 
brush border membranes including the gastrointestinal system and in 
the placenta (Erdos and Skidgell (1989)), and in the male in 
seminiferous tubules and spermatozoa (Erdos et al., (1985)). In 
pulmonary tissue (Johnstone et al.,(1985)), NEP is found in the 
alveoli and in the airways, but there is little enzyme in vascular 
endothelium. Recent work has demonstrated that NEP is identical to a 
cell surface marker expressed on lymphocytes - Calla - and neutral 
endopeptidase at this site may be involved in the degradation, and the 
regulation of the local micro environment of chemotactic peptides 
(Kenny et al.,(1989)).
Substrates for NEP and Design of Enzyme Inhibitors:
A Distribution of NEP.
Kidney (Brush border of proximal tubule).
Central Nervous System (Neuronal & synaptic membranes). 
Lung (Epithelial cells).
Male Genital Tract (Testis, epididymus, prostate).
Human Neutrophils and Fibroblasts.
Thyroid.
Adrenal.
Placenta.
Gut.
B Hormones Cleaved by NEP.
Atrial Natriuretic Peptide.
Insulin B chain.
Enkephalins.
Endorphins.
Bradykinin.
Substance P.
Oxytocin.
LHRH.
Angiotensins I & II.
Gastrin.
Cholecystokinin.
TABLE 5.1:
SUBSTRATES AND DISTRIBUTION OF NEP.
(A) Distribution and (B) Substrate specificity of NEP. 
(After Erdos & Skidgell (1989), Connell & Jardine (1990).
In addition to enkephalins, endorphins and a number of other 
neurotransmitter substances have been shown to be substrates for NEP. 
The distribution of the enzyme at nerve terminals and on axonal 
membranes suggest it has a functional role in the regulation of 
neurotransmitter substances. Other substrates have also been 
identified, and these are listed in Table 5.1 (Erdos and Skidgell 
(1989)). Most peptides have a molecular weight of less than 3000 
daltons, similar to ANP (approximately 3100), although NEP may degrade 
larger peptides, such as Interleukin I. The enzyme cleaves peptides at 
the amino side of hydrophobic amino acids. Table 5.2 shows 
diagrammatically, the predicted active site of neutral endopeptidase. 
Using the terminology of (Schechter and Berger (1967)), where binding 
sites (S) and amino acid substrates (P) are labelled by their position 
relative to the cissile bond with e.g. S^, S2 ... . towards the amino 
terminal end of the molecule and Sa.1 , S2 ' .... towards the carboxyl 
terminal end of the molecule, NEP requires a hydrophobic amino acid at 
the Sa.' position (Schwartz (1989)). This knowledge about subsite 
specificity for neutral endopeptidase has been used to design specific 
inhibitors. Since it is known that the natural substrate Met- 
enkephalin has the amino acid composition tyr-gly-gly-phe-met and is 
cleaved at the gly-phe bond one can see that phenylalanine fits into 
the hydrophobic subsite (Figure 5.1), and it seems unlikely (since 
glycine does not possess a side chain) that there is any specificity 
likely to be attributed to the Px and P2 amino acids. Llorens et 
al.,(1980) used this rationale to explore the requirement for 
inhibitory dipeptide on NEP. They demonstrated that peptides the with 
sequence X-Ala were most potent inhibitors when X-Phe, and when 
dipeptides of the form Phe-X were introduced into their system then
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those with a short side chain, and with a potentially charged group 
(carboxylate) were the most potent. Phe-Ala was the most potent 
inhibitor with an IC5Q of l^M. Similar technology led to the design 
of Thiorphan (Roques et al.,(1980)) and a number of other agents 
(Erdos & Skidgell (1989), Schwartz (1989)). With the discovery of ANP 
as a substrate there has been renewed interest in NEP inhibitors, and 
a number of newer agents are now available including SQ 29,072 
(Seymour et al.,(1989a,b)), SCH 34,086 and SCH 39,370 (Sybertz et 
al.,(1989), Sybertz et al.,(1988)) UK 69,578 (Danilewicz et 
al.,(1989), Northridge et al.,(1989)). The structures of the available 
NEP inhibitors are shown in Figure 5.1. These molecules share a 
hydrophobic side chain corresponding to the hydrophobic S^1 pocket of 
neutral endopeptidase, and a carboxyl molecule to bind to the 
positively charged arginine in NEP. The P^,1-amino acid seems to be of 
lesser importance, and to date there has been little work on exploring 
the importance of peptides or the structure of the inhibitor towards 
the amino terminal binding regions of NEP. Danilewich et al.,(1989) 
describing the development of UK 69,578 (UK 73,967), noted that 
lengthening the molecule towards the amino terminal probably had 
little effect in terms of specificity other than affecting the stereo 
chemistry of the S^.1 and S2 ’ binding sites. The relative potency of 
the available neutral endopeptidase inhibitors is given in Figure 5.1. 
These values have been obtained in vitro and can only be interpreted 
in broad terms as a guide to the possible inhibitory potency of these 
agents. It is known that neutral endopeptidase is pH sensitive 
(Schwartz (1989), Bertrand and Doble (1988)), and similarly the 
actions of Thiorphan as an inhibitor shows a large pH difference. The 
inhibitors were all tested in separate systems (with widely different
Neutral Endopeptidase
\ Ara+
(Met) Enkephalin Tyr-G iy— n— ch2- c - n — ch— c — n — c h — CO2H
H H H
Phe-Ala
o ch,
n I
H2N— CH—C—N— CH —COjH 
H
1.0±0.2pM
(Llorens et al.,(1980))
Thiorphan
Phosphoramidon
HS—CHj—CH—C— N— CH2—COjH 
H
o-l
V— CH,
NH
(Rhamnose—O—P—NH — CH— C—N— CH—C02H
O
2 nM
(Schwartz (1989).
13 pM-.
(Danilewicz et al.,(1990)) 
2 nM
(Schwartz (1989),
SQ 29,072
O 
11
h s —c h 2— Ch — c — N' 
H
26 nM
(Seymour et al.,(1989))
SCH 39370
SCH 32615
CO2H OHI 11.2 nMN— CH— C—N—CH2—CH—CO2H
H H (Sybertz et al.,(1989))
19 nM
(Sybertz et al.,(1990))
UK 73,967 MeO,
COjH
^ ^ ^ C  — N — COgH
14 nM
(Danilewicz et al.,(1990)) 
(Shepperson et al.,(1991))
FIGURE 5.1:
STRUCTURE OF NEP AND NEP INHIBITORS.
Diagrammatic representation of the active . site of Neutral 
Endopeptidase and some of the available NEP inhibitors, with 
estimates of Ki.
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results e.g. Thiorphan - Figure 5.1), and until they are compared one 
against the other in a standardised preparation with careful attention 
to pH and buffering changes then one cannot compare these values 
absolutely.
Studies with NEP inhibitors on ANP:
Following the in vitro work described above (Sonnenberg et al., 
(1988), Olins et al.,(1987, 1989); Stephenson & Kenny (1987)) showing 
that NEP inhibitors prevent the degradation of ANP in vitro, a number 
of groups have gone on to study these compounds in vivo, with the aim 
of elevating endogenous ANP in the hope of finding an effective agent 
for hypertension and heart failure. The following four chapters 
describe work with UK 69,578 in rats and human, the effects of 
prolonged oral administration of an orally active derivative of UK
69,578 (UK 79,300) and the antihypertensive effects of NEPi using SCH 
34,826. The results of in vivo studies with these agents and recent 
work with novel NEP inhibitors are discussed in Chapter 10.
Chapter 6.
Acute Inhibition of Neutral Endopeptidase in Rats.
Introduction.
The demonstration (Chapter 5) that NEP degrades ANP led to the 
development of specific NEP inhibitors (NEPi). In 1987 one such NEPi 
(UK 69,578, developed by Pfizer Central Research, UK) became available 
for human studies. This inhibitor prevents the degradation of ANP in 
vitro (Danilewicz et al., (1989), Northridge et al., (1989), Samuels 
et al., (1989)) but, at that time, although sufficient data was 
available for approval of the drug for human studies, there was no 
published data^on UK 69,578. The purpose of the present study was to 
assess the effect of UK 69,578 using the anaesthetised rat as a simple 
experimental model. The effects on urine volume, electrolyte excretion 
and plasma ANP were assessed and compared with low-dose infusion of 
ANP (5 pmol/Kg/min).
Methods.
Male Sprague-Dawley rats (350-420 g, Olac, UK) were anaesthetised
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with Pentobarbitone Sodium (60 mg/ml, Sagital, RMB Animal Health Ltd., 
UK.) 0.1 ml/kg intraperitoneally and anaesthesia maintained by 
intravenous administration of 0.05 ml as required (approximately
0.2ml/hr). The left carotid artery and jugular vein were cannulated 
using PE 30 tubing, the bladder with PE 50 tubing (10 cm, and the 
trachea with PE 240 tubing (3cm). 0.45% sodium chloride solution
(2ml/hr) was infused into the jugular vein by infusion pump (Vial 
Medical, France), and drugs administered through a 3-way tap in the 
tubing. The arterial cannula was connected to a pressure transducer 
(Stratham PD 23, Gould Electronics, UK) and intra-arterial pressure 
monitored continuously on a chart recorder (Elcomatic 720A, Elcomatic 
Ltd., UK.). Urine was collected into pre-weighed 1ml tubes and the 
experiment abandoned if there was blood staining. The cannulation 
procedure took approximately 30 minutes after which the rat was 
allowed to equilibrate for 60 minutes. Thereafter, the following 
protocol was followed. After the 60 minute mn-in period ten 15 minute 
urine collections were made. Following the first two (basal) a blood 
sample was taken (0.5 ml from the arterial line, replaced with an 
equal volume of 0.45% saline) and drug/ placebo (in 0.5 ml 0.45% 
saline) administered via the venous line. Over the next eight urine 
collections 0.45% saline was administered as before or replaced with 
ANP (rANP, Bachem Ltd., UK,[5 pmol/Kg/min]; prepared as in Chapter 4, 
Richards et al.,(1988a)) dissolved in 0.45% saline. At the end of the 
sixth collection period a 0.5 ml blood sample was taken and replaced 
with an equal volume of 0.45% saline, and at the end of the tenth 
period 3-5 mis of blood were withdrawn through the arterial line and 
the animal killed by injection of 1.0 ml Sagital. The blood samples 
were collected into tubes containing 100pl 50mM EGTA + Trasylol 100
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i.u. on ice. Blood was separated at 4°C and plasma stored at -20°C 
until assay for ANP (Appendix 1). Urine volume was calculated by 
weighing tubes and electrolytes (Na,K) measured using a Beckman model 
2A analyzer (Beckman Instruments, Ireland).
Overall there were five treatment groups: Placebo (n=6), ANP 
alone (n=6), and UK 69,578 alone (1,10,100 mg/Kg; n=5 in each group).
Statistical analysis. Urinary data were analyzed as area under 
the curve (periods 3-10) and compared against placebo by t-test with 
the Bonferroni correction for repeated comparisons. For the plasma ANP 
data, overall treatment effects were compared with placebo using 
ANOVAR with repeated measures and subsequent comparison by dose at 
individual time points by t-test with the Bonferroni correction 
(Godfrey (1981), Wallenstein et al.,(1981)).
Results:
The results are summarised in Figure 6.1. Urine volume, sodium 
and potassium excretion were stable during the placebo limb, and there 
were no differences in these parameters during the baseline periods 
(1-2) between experimental groups. During infusion of 5 pmol/kg/min 
ANP there was a gradual increase in sodium excretion which reached a 
peak after 60 minutes and which persisted, declining slowly, 
thereafter. Urine volume and potassium excretion showed similar 
trends. After administration of lmg/kg UK 69,578 there was a gradual 
increase in urine volume and sodium excretion which failed to achieve 
statistical significance, but there was a rise in potassium excretion. 
Sodium and potassium excretion and urine volume were all increased 
following 10 and 100 mg/kg UK 69,578. The temporal pattern of these 
changes and their magnitude was very similar to that produced by
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FIGURE 6.1:
EFFECTS ON RENAL FUNCTION OF ANP AND UK 69,578 IN THE 
ANAESTHETISED RAT.
Urinary sodium and potassium excretion (UNaV, UKV, |imol/min) 
and urine volume (UVol, jil/min) in response to treatment with 
ANP 5 pmol/kg/min given during periods 3-10 (left panel), or UK
69,578 (UK 69, 1, 10 or 100 mg/kg) given as a bolus after 
period 2. Data are shown as meanSEM. Statistical analysis is by 
comparison of area under the curve (Periods 3-10) by T-test, * 
PC0.05, ** P<0.01 vs. Placebo.
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infusion of ANP in the 10 mg/kg group. However, the highest dose of UK
69.578 produced a more rapid rise in urine volume and sodium 
excretion, which began to decline after 30 minutes. Arterial pressure 
(not shown) was not significantly altered by any treatment. Plasma ANP 
remained stable in the placebo group with levels similar to those 
reported by other workers in rats (see chapter 9) between 50-100 
pg/ml. Only in the group receiving 100 mg/kg UK 69,578 was there a 
significant effect of treatment with UK 69,578 with time (ANOVAR 
P=0.042), but no significant effect of ANP or individual doses of UK
69.578 at individual time points (Figure 6.2).
Discussion.
This was a preliminary study aimed at addressing the question of 
whether NEP inhibition, and specifically UK 69,578, has any in vivo 
effects on renal function and plasma ANP. Only a small group of 
animals was studied and this is reflected by the large variability 
shown in Figure 6.1. Simple statistical methods (analysis of area 
under the curve) were employed, with the aim of establishing the 
presence or absence of effect, and the time course data are 
essentially descriptive. Even with these reservations it is clear that 
NEP inhibition by UK 69,578 can increase plasma ANP and that there is 
an increase in urine volume and sodium excretion which, especially in 
the mid-dose group, closely parallels the effects of ANP infusion.
Effects of ANP: The plasma levels of ANP in the control periods 
of each experimental group are broadly similar to those reported in 
other studies in normal rats (Soejima et al.,(1988)). Infusion of 
5pmol/kg/min ANP produced a modest, two to three-fold increase in 
circulating hormone levels well within the reported pathophysiological
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FIGURE 6.2:
EFFECTS ON PLASMA ANP OF ANP INFUSION AND UK 69,578 IN THE 
ANAESTHETISED RAT.
Plasma ANP (pg/ml) before and during infusion of ANP 
(5pmol/kg/min,A , periods 3-10), UK 69,578 (1,^ ,10,4 ,100,* 
mg/kg , given as a bolus after period 2) or placebo (• ).
All treatments started at time 0. Data are shown as mean±SEM, 
n=5 for each of the UK 69,578 limbs and n=6 for the ANP and 
placebo limbs.
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range in the rat (Soejima et al.,(1988), chapter 9). The response seen 
with a slowly rising natriuresis and diuresis is similar to that 
reported by other workers in the rat (Soejima et al.,(1988)), dog 
(Chapter 4, Pichet et al.,(1988), Cernacek et al.,(1987)) and in man 
(Richards et al., (1988a,b), Morice et al.,(1988), Anderson et 
al.,(1987), Cottier et al.,(1987), Solomon et al.,(1988)). The 
increase in potassium excretion is greater than predicted from these 
studies but has been well documented in all species with high dose 
infusion (Chapter 2, eg deBold et al.,(1981), Richards et al.,(1986)), 
and in the rat is known to be dose related (Soejima et al.,(1986)). In 
the present series of experiments dietary electrolyte intake was not 
controlled and may contribute to the kaliuresis.
Effects of UK 69,578: There is a striking similarity in the pattern of 
urine volume and electrolyte excretion produced by bolus 
administration of UK 69,578 and the infusion of ANP in the present 
series of experiments. The sequence of changes at 10 mg/kg/min almost 
paralleled the response to ANP infusion. At 1 mg/kg little effect was 
apparent except on potassium excretion and lOOmg/kg there was a more 
rapid onset of effect. While it is difficult to infer much from such 
a small series, it may potentially reflect a more rapid rise in plasma 
ANP, or a local effect at extravascular sites perhaps in the kidney. 
Alternatively, higher doses may conceivably be less specific and the 
different time course may reflect the involvement of, for example, 
intrarenal kinins (Ura et al.,(1987), Scicli and Carretero (1989)) in 
the natriuresis. Although there was a significant treatment effect 
on plasma ANP, hormone levels were not significantly elevated by 
individual doses. This absence of a significant dose effect is likely 
to reflect the small sample size and the large variability in ANP
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levels in this study (Figure 6.2) rather than a genuine absence of 
effect. There was no hypotensive effect of NEPi in the present study, 
but this is not surprising in view of the modest increment in 
circulating ANP, significant effects on blood pressure having been 
reported only with higher plasma levels in the rat (Soejima et 
al.,(1988)).
In conclusion, two findings emerge from this study. Firstly, that 
NEP inhibition causes renal effects similar to ANP and secondly, there 
is a strong suggestion that plasma ANP is increased, providing 
circumstantial evidence that NEP inhibition acts via ANP. Similar 
findings have since been reported by other workers in experimental 
animals (Chapter 10) and justify the investigation of the effects, and 
potential therapeutic actions, of these agents in man (Chapters 7 & 
8).
Chapter 7.
Acute administration of UK 69,578 in normal man.
Introduction.
The demonstration that NEP inhibitors reduce the degradation of 
ANP in vitro (Chapter 5) and in experimental animals (Chapter 6) 
raises the question of whether similar (potentially therapeutic) 
effects occur in man. UK 69,578 (Pfizer UK) was approved for 
experimental studies in man in 1987. This chapter describes the first 
study of this compound, and of the effects of NEP inhibition, in human 
subjects.
With a novel type of compound such as UK 69,578 there are 
particular problems in study design. First, the list of substrates 
for NEP is large, and inhibition of degradation of (for example) 
neuropeptides and kinins might be predicted to cause haemodynamic and 
psychotropic effects not detectable in experimental animals. For this 
reason this study was designed to cautiously explore the dose-response 
relationship, the main objective being to establish the safety of this 
compound in man. The other aims were to examine the effects of NEP
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inhibition on plasma ANP and the components of the RAAS; effects on 
renal function and arterial blood pressure. At the outset it was 
intended to examine renal function in detail using PAH and inulin 
clearance methods. However, it was not possible to establish that 
either inulin or PAH did not interfere with infusion or assay of UK
69,578 until after the lower dosage groups were completed. For this 
reason studies with PAH and inulin were only included in the higher 
dosage groups, and the analysis of these data is viewed as a separate 
study within the context of the large dose ranging study (see below, 
Figure 7.1).
Methods.
Sixteen normal male volunteers were studied. The subjects were 
between 21 and 49 years, were within 10% of the predicted normal body 
weight for height, and had no abnormality in medical history, clinical 
examination, biochemical profile, full blood count, ECG and dipstick 
urinalysis. All subjects gave informed written consent prior to 
involvement in the study, which was approved by the hospital Ethical 
Committee.
Each subject was studied on four separate occasions at least one 
week apart. The subjects were divided into four groups of four and 
each subject received three doses of the compound plus a placebo. 
Within each group the doses were arranged in ascending order, but the 
placebo was randomly inserted. The four dosage groups were also 
studied in ascending order, and the doses were arranged so that the 
highest dose in one group overlapped with the lowest dose in the 
subsequent group, providing data on eight subjects at these dosage 
levels for subsequent statistical analysis. The dose-range of 0.025
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FIGURE 7.1:
PROTOCOL FOR ADMINISTRATION OF UK 69,578 IN MAN.
Outline of protocol (A) and dosage groups (B). Dose of UK
69,578 in mg/kg, P=placebo. Inulin and PAH clearance were 
studied in groups 3 & 4 (see text for details).
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to 10.0 mg/kg was studied, and the dosage schedule is illustrated in 
Figure 7.1.
On each occasion the subjects were studied on the 4th day of a 
diet containing 150 mmols of sodium and 70 mmols of potassium per day, 
provided by the hospital dietician. They continued on this diet until 
the morning following the study day. On the day of study the subjects 
were admitted to the Investigation Ward at 6am; two heparinised 
cannulae (venflon, Viggo, Sweden) were inserted into opposite forearm 
veins, one for blood sampling, the other for infusion, and following 
this subjects remained supine (except to pass urine) for the duration 
of the study. After a short period of acclimatization, they received 
an oral loading dose of 350 mis tap water, and thereafter hourly urine 
collections were made for 13 hours, the urine volume being replaced by 
an equal volume of drinking water. Urine volume was measured, and 
aliquots taken for measurements of sodium, potassium and ANP. After 
one hour, basal blood samples were taken for measurement of 
electrolytes, haematocrit, active renin concentration, angiotensin 
II, aldosterone and ANP. UK 69,578 or placebo (normal saline) were 
then administered by a 20 minute intravenous infusion and blood 
sampling was repeated at 2, 8 and 24 hrs post-dosing. In addition, 
blood samples were taken for pharmacokinetic analysis at 0.3, 0.5, 1, 
1.5 and 4 hrs post-drug administration, and for ANP at 0.5, 1 and 4 
hrs. The electrocardiogram was monitored continuously during the first 
4 hrs, and blood pressure measured using a digital semi-automatic 
sphygmomanometer (Copal, Takeda, Japan). The subjects were allowed 
home 12 hours after dosing, and returned to the Unit at 24 and 96 hrs 
when after a period of supine rest for 30 mins, blood pressure was 
recorded and blood samples repeated.
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In the two higher dosing groups PAH (MSD, Rahway, NJ, USA), 0.5g 
and inulin (Laevosan-Gesellschaft, Linz, Germany), 3.0 g were given by 
bolus injection 1 hr before administration of the drug and followed by 
a constant infusion of PAH (0.5 g/h and inulin 1.0 g/h) for 5 hrs 
(i.e. until 4 hrs after administration of the compound.) Renal plasma 
flow (ERPF) and glomerular filtration rate (GFR) were calculated from 
the plasma levels of PAH and inulin respectively according to the 
method of Schnurr et al.,(1980)). In these dosage groups the subjects 
received both placebo and 2mg/kg UK 69,578 and this subset of the 
study was analysed separately as a simple comparison between 2mg/kg UK
69,578 and placebo in eight subjects.
Assays: Active renin concentration (Millar et al.,(1981)), angiotensin 
II (Morton & Webb (1985)), and aldosterone (Fraser, Guest & Young 
(1973)), Inulin (Varley et al.,(1980), PAH (Waugh and Beall (1974)) 
were measured by standard methods. Samples for ANP were collected into 
chilled tubes containing aprotonin (Trasylol, Bayer UK 100 IU/ml) and 
were measured by radioimmunoassay with pre-extraction of plasma 
samples as described in Appendix 1 (Richards et al.,(1987)). Full 
blood count and haematocrit were measured by coulter counter (Coulter 
Electronics, Miami, USA), plasma electrolytes and liver enzymes by 
autoanalyser. Urea and electrolytes were measured by ion sensitive 
electrode (Beckman Model 2A, Beckman Inc., Ireland) and urine ANP was 
measured by a modified version of the plasma method (Richard et 
al.,(1987), Appendix 1). This involved extraction of 10ml of urine 
(mean recovery 84%, n=16), with a lower limit of detection of 2pg/ml 
urine.
Pharmacokinetics: These estimations were performed by Dr. NJ Cussans 
of Pfizer (UK)). Plasma concentrations of UK 69,578 were assayed using
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EC 3.4.24.11 prepared from rat kidney as standard. Unknown drug 
concentrations in diluted plasma and urine were calculated from the 
inhibition of hydrolysis by the endopeptidase of X4C-labelled 
Hippuryl-L-phenylalanyl-L-arginine. Hydrolysis was quantified by the 
release of labelled uric hippuric acid, determined by liquid 
scintillation counting. Plasma and urine samples were assayed against 
known concentrations of UK 69,578. The area under the plasma 
concentrations versus time curve (AUC) was calculated using the 
trapezoidal rule for measured plasma levels up to 8 hrs post-dose and 
the term in elimination rate concentration (B) calculated from the 
slope of the curve at 8 hrs.
Statistical Analysis: Statistical analysis for the dose ranging study 
is by crossover analysis of variance (ANOVAR), using the GENSTAT 5 
computer package (GENSTAT (1984)) and was performed by Dr. Glen 
Andrews of the Statistics Department at Pfizer (UK). Subject, period 
and treatment where included as factors in the model. In addition to 
compensate for baseline variation the baseline measurements for each 
subject- were used as covariates in the analysis and treatment means 
adjusted for baseline variation in the subsequent analysis. Where 
significant differences were apparent by Anovar, individual timepoint 
comparisons were made using Dunnet’s procedure (Dunnett (1955)).
In the subset where inulin and PAH clearance were measured 
comparison between 2mg/kg UK 69,578 and placebo is by repeated 
measures analysis of variance (MANOVAR, SPSS/PC+, SPSS Inc, USA), with 
post-hoc analysis by paired t-test.
Results:
Dose Ranging Study:
AN
P 
(p
g/
ml
)
6O -1
50 -
40 -
0.5mg/Kg30 -
__jj ^ Placebo
0.1mg/Kg 
2.0mg/Kg
20 -
8 24
Time (hrs]
B 2 0 0  -i
~  100
j=
E
d>ex.
O  
ZD 
< 0 -
-100 — I--- r
0.01
i >1111—  
0.1
T V )"l Ill] 
1
AUC 2 hours
AUC 8 hours
i i 11111 
10
Dose UK 69.578 (mg/Kg)
FIGURE 7.2:
PLASMA ANP RESPONSE TO UK 69,578 IN MAN.
(A) Mean plasma levels of ANP (pg/ml) following infusion of UK
69,578 at 0.1 (A), 0.5 (A), and 2.0 (O) mg/Kg or placebo (• 
). N=16 (placebo) and n=8 (all other groups). See Table 7.1 for 
complete data.
(B) Area under the plasma ANP curve (pg.hr/ml) against dose of 
UK 69,578 (mg/kg). N=16 (placebo), n=8 (0.1, 0.5, 2.0 mg/Kg) 
and n=4 (all other groups). * PC0.05, ** P<0.01 by ANOVAR; data
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The administration of UK 69,578 was well tolerated in all 
subjects, and there were no reported side effects attributable to the 
compound. There were no significant changes in plasma electrolytes, 
liver transaminases, blood count, haematocrit, ECG or blood pressure 
at anytime after administration of UK 69,578.
Plasma ANP:
Plasma ANP rose rapidly after administration of the compound 
reaching peak levels of between two and three times basal value within 
120 mins of drug administration. The levels then slowly returned to 
normal within 8 hrs (Figure 7.2). There were no changes in plasma ANP 
following placebo. A clear effect of the compound on plasma ANP was 
evident at doses of 0.1 mg/kg and above. Above this dose there was 
little effect on the peak levels of plasma ANP achieved although there 
is an impression that the effect may have been prolonged. Analysis of 
the area under the curve (AUC) for plasma ANP (0-8 hrs) revealed a 
significant increase in AUC at 0.5 mg/kg and above (Figure 7.2, Table 
7.1). However, at doses above 0.5 mg/kg there was no evidence of 
further significant increase in AUC, suggesting that a near maximal 
effect had been achieved at this dose, although the true dose-response 
relationship may be obscured by the differing numbers of subjects in 
each dosage group, interindividual variation in response to UK 69,578, 
and the limited number of sampling times.
Renal function:
Sodium excretion: Compared with the placebo group, urinary sodium 
excretion increased following UK 69,578 with maximal changes in the 
slope with a cumulative sodium curve over the first 6hrs post-dose, 
and the curves tending to run parallel thereafter (Figure 7.3). The
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FIGURE 7.3:
RENAL EFFECTS OF UK 69,578 IN HAN.
Mean cumulative urine volume (UVol), sodium (UNaV) and 
potassium (UKV) excretion for 12 hours following administration 
of UK 69,578 0.1 (A ), 0.5 (A ), and 2.0 ( o ) mg/Kg or placebo •
(n=16, placebo; n=8 all other groups). See Figure 7.5 for full 
data.
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mean cumulative 8 hour excretion of sodium rose from 64.9 mmols in 
placebo (appropriate to a dietary intake of 150 mmols/day) to 116.1 
mmols on a maximum dose (Figure 7.5). Statistically significant 
increases were evident to doses above 0.3 mg/kg, and the pattern of 
increase with dose was similar to that for ANP with near maximal 
increases being achieved at 0.3 mg/kg and only a small upward trend 
thereafter.
Figure 7.6 shows a relationship between area under the curve for 
plasma ANP and cumulative urine sodium excretion over 8 hrs. It is 
clear from this that there is an approximately linear relationship 
between the area under the curve for ANP and urinary sodium excretion, 
between doses of 0.025 mg/kg and 0.5 mg/kg, but there is little 
further increase in either area under the curve for ANP or urinary 
sodium excretion at doses above this.
Potassium excretion: There were no significant alterations in
potassium excretion following UK 69,578 (Figures 7.3, 7.5).
Urine volume: increased following UK 69,578 with doses above 2mg/kg 
(Figure 7.3). Although there is a clear increase in a cumulative urine 
volume (Figure 7.5), it is difficult to quantify beyond the first part 
of the curve since oral water loading will have reinforced the 
prolonged the early  ^diuresis (this is more clearly shown in Figure 
7.8).
Urinary ANP excretion: The limit of the detection of the urinary ANP 
assay was 2 pg/ml. A high urinary output caused by waterloading and 
UK 69,578 diluted ANP to below the limit of detection in some 
patients, particularly in the lower dose groups. However, despite the 
increased urine flow with higher doses of UK 69,578, ANP was 
detectable in the urine and at doses of 2mg/kg and above urinary ANP
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FIGURE 7.4:
HORMONAL EFFECTS OF UK 69,578 IN MAN.
Changes in mean plasma active renin concentration (pU/ml), Ang 
H  (P9/ml)/ and aldosterone (ng/dl). Data are shown as change 
from basal following 0.1 (&),0.5 (A ) and 2.0 (o) mg/Kg UK
69,578 or placebo (• ). N=16 for placebo group and 8 for the 
other groups. See Table 7.1.
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FIGURE 7.5:
DOSE RESPONSE RELATIONSHIP BETWEEN UK 69,578 AND URINE VOLUME, 
ANP AND ELECTROLYTE EXCRETION.
Summary of the dose-response relationship between dose of UK
69,578 and Cumulative urine volume (UVol, ml/8hrs), sodium 
(UNaV, mmoles/8hrs), potassium (UKV, mmoles/8hrs) and ANP 
(UANP, ng/8hrs). Data are given as Mean±SEM, n=16 (placebo, 0), 
n=8 (0.1, 0.5, 2.0 mg/kg), n=4 (all other doses). * P<0.05, ** 
P<0.01 by ANOVAR against paired placebo values.
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excretion was higher than placebo (Figure 7.5; the timing of the 
changes is more clearly shown in Figure 7.8).
Plasma renin, angiotensin and aldosterone (Figure 7.4, Table 7.1):
Plasma concentration of active renin was relatively unchanged 
after placebo, but showed a downward trend following UK 69,578 for up 
to 8 hrs post-dose in the higher dosage groups. The suppression of 
plasma renin at 2 hrs was statistically significant at the 2mg/kg doge 
(p<0.01) and there was a rebound rise in renin at 24hrs, which was 
statistically significant in the 0.3 and 1 mg/kg dosage groups. Plasma 
angiotensin II and aldosterone showed similar trends, although neither 
reached statistical significance.
Pharmacokinetics:
Pharmacokinetic data for UK 69,578 were derived by fitting the 
data to a one compartment model. The elimination half-life of the 
compound was 1.1±0.2 hrs (mean±SD). The volume of distribution was 
0.25±0.05 kg with 56±8.2 % of the excretion being renal within the 
first 12 hrs. The plasma area under the curve (p.g.hr/ml; 0-8 hrs) was 
6.1±1.0 pg/ml/mg/kg. Full pharmacokinetic data is given in Appendix 
3.
Renal Function Study (2 mg/kg subgroup):
The data presented in Figure 9-12 comes from the subset of 
subjects in whom renal function was studied using inulin and PAH 
clearance. I have taken the opportunity to present illustrative data 
on blood pressure, urine volume, ANP and electrolyte excretion in 
addition to GFR, ERPF and fractional excretion of sodium.
Figure 7.7 shows systolic blood pressure, diastolic blood
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FIGURE 7.6:
RELATIONSHIP BETWEEN DOSE OF UK 69,578, PLASMA ANP AND SODIUM 
EXCRETION.
Relationship between area under the plasma ANP curve and 
cumulative urinary sodium excretion in the 8 hours following 
administration of UK 69,578 or placebo. Doses of UK 69,578 as 
marked; n=16 placebo, solid squares represent n=8, solid 
circles n=4. Data are given as mean±SEM.
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FIGURE 7.7:
CHANGES IN BLOOD PRESSURE AND PULSE IN RESPONSE TO UK 69,578 (2 
mg/Kg).
Systolic blood pressure (SBP, mmHg), diastolic blood pressure 
(DBP, mmHg) and pulse (beats per minute) for 2mg/kg UK 69,578 
vs matched placebo (n=8). Data are given as mean±SEM. There 
were no statistically significant effects.
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pressure and pulse for the 24hrs following administration of 2mg/kg UK
69,578 or placebo. Although blood pressure and pulse were slightly 
lower on the active limb this was clearly not significant. Figure 7.8 
demonstrates the time course of urinary electrolyte excretion in this 
group of subjects, more clearly than the cumulative graphs 
demonstrated in Figures 7.3 and 7.5. Urinary sodium excretion 
increased by 2hr post-administration of UK 69,578, and remained 
elevated until 7hrs post-dose. Potassium excretion was unchanged, and 
the increase in urine volume was more variable. The time course of 
urinary ANP excretion is shown and clearly parallels the changes in 
plasma hormone levels (Figure 7.2, Table 7.1.).
Renal Function Indices: Glomerular filtration increased in both active 
and placebo limbs. Analysis of the absolute GFR data was non­
significant, although the active limb was slightly higher when 
percentage increases in GFR were studied (Connell and Jardine (1990)). 
ERPF showed a similar rise in both groups which failed to reach 
statistical significance. There was no difference in filtration 
fraction, and although fractional excretion of sodium was higher in 
the active group, by analysis of variance, this reached significance 
only at the 2hrs post-dose time point.
Discussion:
At the time of publication (Jardine et al.,(1989,1990)) this was 
the first study to report the effects of NEP inhibition in normal 
subjects. It demonstrates that acute administration of NEP in man 
causes a rise in plasma ANP, in a dose-related manner, associated with 
diuresis and natriuresis and a pattern of renal function in 
neurohumoral effects characteristic of ANP. Plasma ANP concentrations
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FIGURE 7.8:
TIME COURSE OF CHANGES IN RENAL FUNCTION IN RESPONSE TO UK
69,578 (2mg/Kg).
Time course of changes in urinary sodium excretion (UNaV, 
mmols/hr), potassium excretion (UKV, mmols/hr), urine volume 
(UVol, mls/hr) and urinary ANP (UANP, pg/hr) against time for 
12hrs post-administration of UK 69,578 or placebo. Data shown 
as meantSEM, * P<0.05, ** P<0.01 (paired T-Test after MANOVA).
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were increased for more than 4hrs in the high-dose group, with peak 
levels 2-3 times basal values being achieved. These data confirm the 
findings in animals (Chapter 6) and suggest that degradation of ANP by 
NEP is a major route of elimination of circulating ANP. Although the 
circulating half-life of UK 69,578 is only 1.1 hours, plasma ANP 
levels were elevated for more than 4 hrs (Figure 7.2), and urinary ANP 
excretion prolonged for a similar period (Figure 7.8). This may be 
interpreted in a number of ways. Firstly, plasma levels of UK 69,578 
may not reflect the levels of drug at the active site, either in the 
renal tubule or at an extravascular site. Alternatively, only low 
plasma levels may be required to inhibit the enzyme completely, and 
the dose-response relationship, with near maximal effects (on plasma 
ANP and renal function, Figure 7.5) being achieved with intermediate 
doses would support this suggestion.
Renal Actions: Urinary sodium excretion and volume rose in parallel in 
with the changes in circulating ANP (Figures 7.3, 7.6). While the 
extent of the increase in circulating levels of ANP produced by UK
69,578 were relatively modest, there is evidence from a number of 
recent studies that similar small increases in circulating ANP (of 
between 50-100 pg/ml (18-30 pmol/1)) during low-dose infusion are 
similarly associated with significant natriuresis and diuresis 
(Richards et al., (1988a,b), Cottier et al.,(1987), Anderson et 
al.,(1987), Solomon et al.,(1988), Morice et al.,(1988)). Both the 
magnitude of the natriuresis and diuresis achieved by UK 69,578, and 
the absence of an effect on potassium excretion are consistent with 
the effects of ANP. The confirmation of the findings in Chapter 6, of 
the similar pattern of renal effects produced by ANP or NEPi provides 
further evidence that the effects of NEP inhibition are likely to be
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FIGURE 7.9:
RENAL FUNCTION INDICES AFTER TREATMENT WITH UK 69,578 (2
ing/Kg).
Urine function data during treatment with UK 69,578 (2 mg/Kg). 
Glomerular filtration rate (GFR, mls/min), estimated renal 
plasma flow (ERPF, mls/min), filtration fraction (FF), 
fractional excretion of sodium (FeNa, %). * P<0.05, ** P<0.01 
by paired T-test where overall differences identified by 
repeated measures MANOVA.
mediated by ANP. The relationship between ANP and sodium excretion 
provides further evidence for this (Figure 7.6). Although such 
evidence is circumstantial, more direct evidence comes from the 
observation that, in animal studies, the effects of UK 69,578 are 
greatly attenuated by co-administration of ANP antisera ((Samuels et 
al.,(1989), Shepperson et al.,(1991), Northridge et al.,(1989), 
Chapter 10).
From our knowledge of the renal mechanisms of action of ANP (Chp. 
2), it is possible that NEP inhibition may act on the kidney either by 
increases in plasma ANP or, because NEP is a tubular ectoenzyme, on 
ANP levels within the tubule. In fact both urinary and plasma hormone 
levels were increased, indicating that both mechanisms may operate. 
There was no evidence of either mechanism predominating, the 
differences in the dose-response relationships between plasma and 
urinary ANP being largely technical, due to the difficulty in 
measuring urinary hormone (see Methods, Figure 7.5.).
Renal function indices:In the subset of patients in whom PAH and 
inulin clearances were performed, there were no demonstrable changes 
in glomerular filtration, renal plasma flow or filtration fraction but 
the fractional excretion of sodium was increased. However, GFR and 
ERPF both rose in both the active and placebo limbs of the protocol. 
There are several e^lanations for this. It may reflect the timing of 
the study, with a 6am start, and a diurnal variation in GFR and ERPF, 
or, alternatively, it may reflect the water replacement and initial 
water loading in the experimental protocol. Alternatively, although 
a standard regime was employed, and the samples taken 5 mins prior to 
the commencement of UK 69,578/placebo infusion suggested that steady- 
state levels of inulin and PAH were achieved, this may not have been
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the case. Even if this were the case, since the same regime was used 
in each part of the study, it is still possible to compare the effects 
of active and placebo treatment.
In fact, just as the overall pattern of renal effects is similar 
to the effects of low dose ANP, so are the more detailed measurements 
of renal function. The consensus from the studies of ANP infusion 
rates less than 2 pmol/kg/min (Richards et al., (1988a,b), Cottier et 
al.,(1987), Anderson et al.,(1987), Solomon et al.,(1988), Morice et 
al.,(1988)) is for no change in GFR, either a downward trend or no 
change in ERPF, an upward trend in filtration fraction and a rise in 
FeNa. The results of the present study with NEP inhibition are 
therefore consistent with the effects of ANP.
Dose-response relationship: There was little change in plasma ANP 
(either peak levels, 2hr levels or area under the curve), urine volume 
of sodium excretion and doses below 0.1 mg/kg, but clear increases in 
ANP and urinary sodium excretion at 0.5 mg/kg, and only modest changes 
thereafter (Figures 7.2, 7.3 and 7.5). These findings suggest that 
maximal inhibition of the enzyme may be achieved at quite low doses 
with little effect on further increases.
Hormonal Effects: Despite the natriuresis observed following
administration of UK 69,578 there was no activation of the renin- 
angiotensin system, consistent with the known physiology of ANP, 
(Chapters 2&4, Figures 1.1, 4.3.), and the results of low-dose
infusion studies (Richards et al., (1988a,b), Cottier et al.,(1987), 
Anderson et al.,(1987), Solomon et al.,(1988), Morice et al.,(1988)). 
Indeed plasma active renin concentration fell significantly in the 8 
hrs after administration of the compound, and there was a rebound 
activation of renin at 24 hrs which could be explained by the effects
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of the preceding natriuresis, but (at 24 hrs) in the absence of 
sustained elevation in ANP. Indeed, a virtually identical pattern t 
with a dramatic rebound rise in renin - following ANP infusion, has 
previously been described (Bie et al.,(1988)). Angiotensin II and 
aldosterone levels showed a similar trends which failed to achieve’ 
statistical significance. Although the Ang II levels were stable in 
the placebo limb, aldosterone levels fell during the day, presumably 
reflecting the diurnal variation in aldosterone levels (Richards et 
al.,(1987)), and the greater fall in aldosterone levels at 8 hours in 
the active limbs was not statistically significant. It is therefore 
not possible to comment further on the changes in aldosterone other 
than to suggest that a number of influences might be contributing to 
the downward trend, including diurnal rhythm, elevated ANP (Chapter 2, 
Cuneo et al.,(1987), McMurray and Struthers (1988c)) and indirectly 
via reduced plasma Ang II.
Overall, the pattern of changes in the renin-angiotensin system 
is similar to those achieved in low dose infusion studies with ANP, 
where renin is generally reduced but the effects on Ang II (where 
measured) and aldosterone.more variable, but showing a downward trend.
General Effects: The remaining effects of treatment with UK 69,578 
were essentially negative, confirming the safety of this compound at 
least for acute administration. The were no effects on mood or 
conscious level, despite the fact that a number of neuropeptides are 
metabolised by NEP. This may be due to failure of UK 69,578 to pass 
the blood brain barrier as has been suggested for other NEPi (Schwartz 
(1989)). No changes were observed in the heart rate or blood pressure 
(illustrated in Figure 7.7). Infusion of ANP is generally reported not
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to alter blood pressure - measured non-invasively (e.g. Richards et 
al.,(1988a)) - but more recent work (Richards et al., (1988c))
suggests that intra-arterial pressure in seated subjects may fall 
during ANP infusion at physiological doses. Such an effect would have 
been missed by the present study, and therefore a modest hypotensive 
effects cannot be excluded.
There were also no changes in plasma electrolytes, liver enzymes, 
full blood count or haematocrit. The latter finding conflicts with 
studies of ANP infusion (e.g. Richards et al.,(1988), Tonolo et 
al.,(1989)), where haematocrit is usually increased, and may reflect 
the automated measurement of haematocrit in the present study or the 
waterloading protocol which may mask a genuine rise in haematocrit.
In conclusion, this study demonstrates that acute administration 
of a neutral endopeptidase inhibitor in man is safe. Infusion of UK
69,578 elevates circulating levels of ANP, presumably through 
inhibition of degradation of the peptide by NEP, and produces a 
combination of diuresis, natriuresis, suppression of the renin- 
angiotensin system, all of which are consistent with an action of NEPI 
through ANP. Furthermore, the changes in plasma ANP and sodium 
excretion were related to the dose of UK 69,578 and there was a clear 
relationship between the effects of NEPi on plasma ANP and urinary 
sodium excretion.
In man, as in the rat (Chapter 6), acute NEP inhibition therefore 
appears to fulfil its potential by increasing plasma ANP, and 
justifying the investigation of the effects of prolonged treatment 
(Chapter 8).
HORMONE DOSE N TIME
(mg/kg) (hrs)
24
ANP Placebo 16 25.0*33 223±3.1 19.1±2.1 23.1*3.3 23.7*3.7
Renin 33.9*5.2 38.6*6.6 29.6*5.4 39.1*5.6
Ang II 8 2 *1 3  8.4*13 7 .9 *12 123*1.5
Aldo 1 1 3 *2 3  83*1.4 8.6*1.9 11.8*1.1
ANP 
Renin 
Ang II 
Aldo
0.025 1 1 3 *1 3
30.0*73
21.1*6.9
12.0*4.0
193*2.7
293*4.6
18.0*83
5 3 *0 3
12.5*23 11.0*13
283*7.0
9.1*1.6
73*0 .7
15.0*2.4
3 1 3*43
15.6*6.8
11.5*4.5
ANP 
Renin 
Ang II 
Aldo
0.05 183*3.4  
25.0*7.5 
4.8*1.4 
8 3 *1 3
23.0*4.7
323*5.7
103*3.9
53*0.6
21.8*4.7 173*2.9
22.0*7.7
13.1*9.0
4 3 *0 3
15.0*2.5
34.8*11.8
92*4.4
6.8*03
ANP 
Renin 
Ang II 
Aldo
0.1 23.4*4.6
25.6*7.6
8.7*6.1
16.0*3.8
41.4*7.3
18.8*5.7
6.1*12
14.4*3.0
29.1*4.6 183*2.5
283*7.6
7 .6 *12
8.9*2.0
20.5*3.4
45.1*11.9
11.8*3.3
14.6*32
ANP 
Renin 
Ang II 
Aldo
0 3 29.0*6.9
333*14.6
8.6*3.8
17.8*33
70.0*14.8
13.0*4.9
5.1*1.6
25.0*63
3 1 3 *5 3 34.8*11.6
323*21.9
9.1*5.1
13.0*0.6
25.8*6.7 
92.8*24.1 * 
23.3*6.7 
233*6.7
ANP 0 3  8 21.1*2.1 52.8*9.8 * *  303*4.7 24.6*4.6 30.6*2.4
Renin 403*13.0 28.6*8.0 343*11.0 47.4*7.0
Ang II  1 0 3 *2 3  82*1 .8 8.6*2.8 9 .9 *12
Aldo 14.1*3.4 12.6*33 10.8*3.9 17.6*3.0
ANP 1.0 4 28.6*11.6 353*4.7 243*4.9 21.8*3.8 15.4*2.1
Renin 49.4*5.0 40.4*4.8 39.6*1.6 73.2*92 *
Ang II 9.6*2.1 10.6*23 5.9*1.4 133*3.1
Aldo 14.4*1.8 8.6*1.4 6.8*0.8 14.6*2.8
ANP 
Renin 
Ang II 
Aldo
2.0 21.8*2.7
35.6*6.4
6.9*13
11.0*2.0
45.8*6.2 * *  
23.0*2.7 *  
6.1*0.7 
6 3 *1 3
41.0*73 * * 22.4*3.0
16.8*2.8
5.6*0.7
6.6*1.4
17.9*2.1
55.1*7.9
11.7*13
133*1.9
ANP 
Renin 
Ang II 
Aldo
5.0 23.0*63
2 4 3 *6 3
6.9*2.8
8 3 *2 3
41.0*15.8
233*7.2
6.9*0.9
4.0*2.7
37.0*82 193*6.2
193*16.9
43*1 .0
4.0*0.4
183*6.2
42.8*12.7
10.9*0.5
13.0*2.1
ANP 
Renin 
Ang II 
Aldo
10.0 143*4.2  
243*4.8  
73*1 .8  
8.0*1.8
313*13.8 
193*53  
5.9*1.0 
43*1.0
323*113 22.0*8.1 
9.8*0.9 
4.8*0.8 
43*1 .0
18.5*3.2
493*12.0
93*1 .4
123*2.1
TABLE 7.1:
Concentrations of active renin (pU/ml), angiotensin II (pg/ml), 
aldosterone (ng/dL) and ANP (pg/ml) for all dosage groups. 
Values given as meaniSEM, pre-dose and 2, 8 and 24hrs post­
dose. Data from groups where n>4 are shown in Figures 7.2-7.4. 
Statistical analysis by ANOVAR with individual time points 
being compared with matched placebo by Dunnett1s procedure (*
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Chapter 8.
Effects of prolonged NEP inhibition:
10 day administration of UK 79,300 in normal subjects.
Introduction.
The early problem in determining the effect of long term changes 
in plasma ANP was that sustained elevation in plasma ANP could only be 
achieved by infusion of exogenous peptide. However, the demonstration 
that acute NEP inhibition increases plasma ANP (Chapters 6 & 7) 
offered a potential mechanism for producing sustained increases in 
endogenous ANP. In 1988, UK 79,300 an orally bioavailable prodrug of 
the active enantiomer of UK 69,578 became available for human use 
(Danilewicz et al.,(1989)) and was subsequently shown to cause a 
pattern of changes in plasma ANP similar to that of UK 69,578 
(O’Connell et al.,(1989)) and to offer a mechanism for chronically 
elevating endogenous ANP by oral drug therapy.
The study described in this chapter was designed to look at the 
effects of administration of UK 79,300 (Candoxatril, Pfizer UK) in 
normal subjects. This compound is a prodrug of the active enantiomer 
of UK 69,578 (i.e. UK 73,967) and has an oral bioavailability of
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approximately 40% in animal studies (NJ Cussans, personal 
communication). Based on this, a dose of 200mg UK 79,300 (which is 
equivalent to 2-3mg/kg UK 69,578 i.v. at which dose clear effects are 
seen, Chapter 7) twice daily was used. The primary aim of this study, 
as in the previous one (Chapter 7), was to establish the safety of UK
79,300 and to measure a number of simple parameters including blood 
pressure, urine volume and electrolyte excretion and plasma hormone 
levels. In addition investigations were performed to look for specific 
effects of NEP inhibition. First, since it was assumed that an effect 
through ANP would involve changes in sodium balance, this was examined 
in two ways - by a metabolic balance study and the measurement of 
exchangeable sodium. Secondly, on the final day of each limb of the 
protocol subjects were infused with graded doses of phenylephrine and 
Ang II to look for potential antipressor effects of NEP inhibition 
and, by the measurement of hormone levels during Ang II infusion, to 
examine the interaction with the renin-angiotensin system and effects 
on aldosterone synthesis. Finally, the effects of treatment on 
platelet ANP receptors was measured both as a marker of effect and 
since changes in receptor affinity or number may potentially alter the 
effectiveness of chronic therapy.
Methods:
Eight normal human volunteers were studied. Subjects were aged 
21-49 years, had no abnormality on clinical examination, ECG, 
biochemical profile, full blood count or urinalysis and gave informed 
written consent before participating in the study. The study lasted 
six weeks and consisted of two two-week experimental periods separated 
by a two week "washout period". On one limb of the study the subjects
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received active treatment (UK 79,300 - 200 mg b.d. p.o.) and on the 
other placebo (one capsule b.d.); the design being randomised and 
double-blind. The study limbs were identical and lasted from a Sunday 
(9 a.m.) until the following Friday (2 p.m.). During this period the 
subjects took a diet containing 200 mmoles sodium and 80 mmoles 
potassium per day. Urine was collected throughout each 24 hour period 
from the start (9 a.m. - 9 a.m.) in thymol containers and urine 
volume, Na and K measured. Each morning between 9 and 9.30 a.m., after 
a 15-30 minute period of rest blood pressure and pulse were measured 
(in duplicate, lying and standing) using a semi-automatic 
sphygmomanometer (Copal, Takeda, Japan). After a three day 
equilibration period, during which the subjects received only placebo 
capsules, drug/placebo were given for the following ten days 
(Wednesday a.m. - Friday a.m. inclusive). Immediately before the first 
active/placebo dose, and after one, three, five, seven and nine days 
of active/placebo treatment blood samples were taken for measurement 
of biochemical profile, full blood count, renin, angiotensin II, 
aldosterone and ANP after 30 minutes rest and before the morning dose. 
Sampling technique (Chapter 7), collection and assay methodology were 
as previously described (Appendix 1, Richards et al., (1987), Millar 
et al., (1981), Morton and Webb (1983), Fraser, Guest and Young 
(1973), Chapter 7). On the eighth day of active/placebo treatment an 
extra 50 ml of blood was collected into sodium citrate and platelet 
ANP receptors measured (see below). The subjects then received Na-22 
and exchangeable body sodium measured by the method of Davies and 
Robertson (1973)) from a plasma sample taken after 18 hours 
equilibration and urinary Na-22 excretion.
On the final day of each limb of the study subjects were admitted
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to the investigation ward at 7.30 a.m. Heparinised cannulae (Viggo, 
Venflon) were inserted into opposite forearm veins for infusion and 
sampling and the subjects remained supine thereafter. Fasting, pre­
dose samples were taken (as above) and the subjects received UK 79,300 
or placebo. After 45 minutes a saline infusion was begun and changed 
at 45 minute intervals to contain incremental doses of Ang II (Ciba- 
Geigy; final dose: 2, 4 and 8 ng/Kg/min Ang II). The total volume of 
infusion was less than 50mls. At the end of each phase of the infusion 
blood was taken (as above) for measurement of renin, Ang II, 
aldosterone and ANP and supine blood pressure recorded. At the end of 
the Ang II infusion subjects were given lunch and allowed a 90 minute 
"washout11 before receiving an incremental infusion of Phenylephrine 
(Boots Pharmaceuticals, UK). Saline alone was infused for 15 minutes 
followed by 6 five minute infusions of Phenylephrine at 0.3, 0.6, 0.9, 
1.35, 2.0, 3.0 |ig/Kg/min. Blood pressure was recorded at the end of 
each dose and the ECG monitored continuously. The infusion was stopped 
if the heart rate fell below 40/min.
Platelet Receptor Assay: Platelet ANP receptors were assayed using a 
modification of the method of McQueen et al.,(1990 a,b) and Schiffrin 
(Schiffrin (1988), Schiffrin et al.,(1989,1991)). 45mls of blood were 
taken into tubes containing 5 mis 3.8% sodium citrate, and platelets 
obtained by differential centrifugation (Dominiczak et al.,(1990)) but 
centrifugation for 5 mins at 1000 g, the supernatant removed, EGTA 
added to a final concentration of 5 mM and a platelet pellet obtained 
by centrifugation for 10 mins at 1000 g, the pellet was then 
resuspended in 10 mis Medium 199*+" (Gibco Ltd., UK). All steps were 
performed at room temperature. The platelet concentration was then 
measured (Coulter Counter, Coulter USA) and the sample diluted in
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Medium 199'*" to give a final concentration of 500 x 109/1. ANP binding 
was then determined by displacement of radio-labelled ANP (125I-ANP, 
Amersham, UK) in incubation volumes of 1 ml containing 100 x 10s 
platelets, 17 pM 125I-ANP and increasing concentrations of unlabelled 
ANP (0-800 pM). Specific binding was determined after incubation for 
1 hr at 22 °C. The incubation was terminated by diluting the 
incubating mixture with 7 ml 50 mM TRIS/120 mM NaCl/0.05% BSA, pH 7.4 
and filtered under vacuum through Whatman GS/F glass fibre filters 
prewet with 1% NaCl/1% BSA/5% Tween 20/1% phenylethanylimine. The 
filters were dried, removed and trapped radioactivity determined. 
Under these conditions there was no detectable ligand degradation 
under standard assay conditions, in contrast to findings in other 
tissues (McQueen et al., (1990 a,b)), presumably reflecting the
absence of peptidase enzymes in this assay system. ANP binding 
increased linearly up to 1.5 x 10s platelets/tube and in time course 
studies the plateau was reached at 40 mins. Receptor affinity (Kd) and 
density of binding sites (Bmax) were determined using a weighted least 
squares non-linear regression method (McQueen et al.,(1984). In the 
absence of detectable ligand degradation by HPLC (in contrast to other 
tissues - McQueen et al., (1990b)) equilibrium conditions were 
assumed. Statistical comparison of binding parameters and 
determination of the number of binding sites was as previously 
described (McQueen et al., (1984), McQueen et al., (1990a,b)). 
Materials: 125I-ah-ANP was obtained from Amersham UK, unlabelled ah- 
ANP from Penninsula Laboratories, UK, Medium 199 plus (containing 25 
mM HEPES, 0.4% BSA, 0.1% bacitracin, 0.5 mM phenylmethylsulphonyl 
fluoride (PMS), 100 KlU/ml Trasylol) from Gibco, UK, and all other 
chemicals from Sigma (UK).
Statistical analysis is by repeated measures analysis of variance 
(MANOVA, SPSS/PC+, IBM) and where significant by MANOVA, post hoc 
analysis is by paired t-test at individual time points.
Results:
Prolonged administration of UK 79,300 was well tolerated by all 
subjects with no reported side effects, and in keeping with the 
previous findings with acute administration of UK 69,578 (Chapter 7). 
There were no observed changes in blood pressure, plasma electrolytes 
or liver enzymes (see Table 8.1 for summary data). The only 
significant effects were that there was a fall in haemoglobin and in 
body weight in both limbs of the study, reflecting venesection <— J
dietary restriction.
Urinary sodium and potassium excretion and urine volume are shown 
in Figure 8.1. There were no significant changes in potassium 
excretion, but both urinary sodium excretion and volume were 
significantly different in the active limb by repeated measures 
MANOVA. Post-hoc analysis revealed that this was due to a natriuresis 
and diuresis in the first 24 hours after starting treatment (Day 1) 
and that there was a subsequent antinatriuresis and diuresis on Day 3, 
with variable changes in each thereafter. Cumulative measurements of 
urinary sodium excretion, based on the balance study were not 
significantly different at the end of the study (1687±56 [UK] vs. 
1703±83 [Pi] mmoles/9 days, P=NS). Measurement of exchangeable sodium 
similarly showed no difference in exchangeable body sodium, measured 
between the 7th and 8th day of drug/placebo administration (3043±107 
[UK] vs. 30681119 [PI] mmoles, P=NS).
In contrast to the findings with acute NEP inhibition there were
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FIGURE 8.1:
RENAL EFFECTS OF UK 79,300 IN MAN.
Urine volume (ml/24 hours), sodium arid potassium excretion 
(UNaV, UKV mmoles/24 hours) during treatment with UK 79,300 
(200mg b.d., days 1-9) after a three day control period (days - 
2 - 0). Data are shown as mean±SEM. * P<0.05, ** P<0.01 by 
paired T-test where overall difference between active and 
placebo established by MANOVA.
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FIGURE 8.2:
HORMONAL EFFECTS OF UK 79,300.
Plasma ANP (pg/ml), active renin concentration (Renin, pU/ml), 
angiotensin II (Ang II, pg/ml) and aldosterone (Aldo, ng/dl). 
UK 79,300 was administered (200mg b.d.) from day 0 onwards. 
Data are shown as mean±SEM, there were no statistically 
significant effects.
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only minor alterations in plasma hormone levels shown in Figure 8.2. 
Plasma ANP was marginally higher in the first day of administration, 
and on days 5,7 and 9 but this failed to achieve statistical 
significance. Plasma levels of active renin concentration, angiotensin 
II and aldosterone were also marginally higher during active 
treatment, but again there were no significant statistical changes.
Figure 8.3 shows the hormonal data from the final day of the 
study. Basal ANP levels were slightly higher in the active limb and 
showed a greater increase during infusion of the pressor agent Ang II, 
although again this was not statistically significant. Plasma ANP was 
also higher before infusion of phenylephrine and, although ANP 
increased during Phe infusion, there was no significant difference in 
the response during active or placebo treatment. There were unexpected 
changes in the other hormonal measurements during Ang II infusion. 
Active renin concentration was suppressed in both phases of the study. 
However, Ang II levels were significantly higher when infused in the 
presence of Uk 79,300, although post-hoc analysis did not identify a 
specific time point. Repeated measures MANOVA also identified a 
significantly greater rise in plasma aldosterone during Ang II 
infusion in the active limb of the study; with paired t-tests being 
significant in the highest two dosage groups (Figure 8.4). Blood 
pressure increased to a similar extent in both limbs of the study 
during Ang II infusion but there was a significantly reduced pressor 
response to Phenylephrine infusion in the active group (PC0.001, 
MANOVA; Figure 8.3).
Platelet binding data is shown in Figure 8.5. There was no 
difference in the affinity of ANP receptor (Kd=55.6±12.3 [placebo], 
42.4±14.1 [UK 79,300], pM) but there was a significant reduction in
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FIGURE 8.3:
HORMONAL RESPONSE TO ANG II INFUSION DURING TREATMENT WITH UK
79,300 IN MAN.
Changes in active renin concentration (Renin, ^iU/ml), 
angiotensin II (Ang II, pg/ml) and aldosterone (Aldo, ng/dl) 
with infusion of angiotensin II (0,2,4 and 8 ng/kg/min) on the 
tenth day of treatment with UK 79,300 or placebo. Plasma Ang II 
levels were significantly higher in the active limb by repeated 
measures MANOVA (P=0.009), but there was no significance at 
individual time points. * P<0.05 ** P<0.01 indicate
significance by T-test where overall significance first 
established by MANOVA.
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FIGURE 8.4:
ANP AND BLOOD PRESSURE RESPONSE TO ANG II AND PHENYLEPHRINE 
INFUSION DURING TREATMENT WITH UK 79,300.
Plasma ANP (pg/ml), blood pressure (BP, mmHg) and pulse rate 
(Pulse, beats per minute) during graded infusion of Ang II 
(ng/kg/min) and Phenylephrine (pg/kg/min) on the tenth day of 
treatment with UK 79,300 or placebo. * P<0.05, ** P<0.01
indicate significance by paired t-test where overall 
significance identified by repeated measures MANOVAR.
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the number of binding sites in the active limb of the study (39±4 vs 
22±3 fmol/109 platelets, p=0.0034; t-test).
Discussion.
This study was the first to examine the effects of prolonged 
administration of NEPi in normal man. As was seen with acute 
administration of the related compound UK 69,578 there were no adverse 
effects and no changes in resting blood pressure, plasma electrolytes, 
liver enzymes or full blood count (other than a fall in haemoglobin 
due to blood sampling and weight loss due to dietary restriction).
Renal Effects:
Overall, there was a signfificant difference in sodium excretion 
during active treatment. The pattern of natriuresis - with an effect 
only on the first day of treatment - is similar to that seen during 
low dose infusion of ANP in man (Janssen et al., (1989)) and animals 
(Kivlign et al., (1988), Mizelle et al.,(1988)) where a natriuresis 
was only evident during the first 24 hours of ANP infusion. In 
contrast to these studies however, there was no evidence that the 
subjects remained in negative sodium balance. From the metabolic 
balance data, there was a rebound antinatriuresis on day three of the 
active limb and, overall, there was no significant difference in total 
calculated sodium balance over nine days of treatment with UK 79,300 
or placebo. Exchangeable body sodium was lower in the active limb but 
the difference was not statistically significant, and the magnitude of 
the difference found is at the limit of detection for this method 
(Davies and Robertson (1973)) and is much less than would be seen with 
diuretic agents such as frusemide.
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Urine volume showed a similar pattern to sodium excretion. MANOVA 
demonstrated a significantly higher urine volume on the active limb, 
and post hoc analysis revealed that there was a significant diuresis 
only on day one, with a relative antidiuresis on day three. Overall 
total (9 day) urine volume was not different in the active limb. In 
keeping with the findings from acute administration of the related 
NEP-I UK 69,578 there was no change in potassium excretion (Chapter 
6).
These results demonstrate that in the first 24 hours after the 
start of treatment UK 79,300 has similar effects to UK 69,578 and 
acute administration of ANP. However, these effects are not sustained 
during prolonged treatment. Possible reasons for this are discussed 
below.
Hormonal Effects:
Although plasma levels of ANP were slightly higher in the active 
limb, this failed to reach statistical significance. There are several 
possible reasons for this. From the earlier study (Chapter 7), and the 
findings of O'Connell et al., (1989) that UK 79,300 has similar acute 
effects to UK 69,578 and the finding of a natriuresis during the first 
24 hours of active treatment it is surprising that ANP was not 
elevated. From a statistical viewpoint this is at least partly due to 
the fact that baseline (Day 0) levels of ANP were inexplicably higher 
in the active limb. From a methodological point of view, limiting 
blood sampling to the pre-dose period may have missed a rise in ANP 
since plasma levels had returned to normal or near-normal levels 8 
hours after administration of UK 69,578. There is some evidence to 
support this. Firstly, plasma levels were higher on the final day of 
the study 90 minutes after administration of UK 79,300. During
154
infusion of Ang II there was the expected rise in plasma ANP 
(presumably as a result of increased arterial pressure [Chapter 3, 
Uelinger et al.,(1987)]). In the presence of UK 79,300, there is an 
exaggerated; rise in plasma ANP, implying at least some inhibition of 
ANP degradation. Secondly, the down-regulation in platelet ANP 
receptors is consistent with a sustained increase in plasma ANP. 
Furthermore, two recent preliminary reports of long term NEP 
inhibition (with UK 79,300) in man have found a sustained increase in 
urinary cGMP (O'Connell et al.,(1990)) or persistent increase in 
plasma ANP (Bevan et al.,(1991)) suggesting that the failure to find 
an elevated ANP in the current study may be methodological.
The tendency for plasma active renin concentration to be higher 
in the active limb would be consistent with the findings from the 
acute dosage (Chapter 7) where there was a rebound rise in renin 
following an initial suppression, after administration of UK 69,578. 
The predose sampling in this study with UK 79,300 would tend to pick 
up these rebound rises in hormone. The trend for angiotensin II and 
aldosterone levels to be higher could be explained in a similar way, 
although the effect of NEPi on Ang II degradation (see below) will 
also increase Ang II.
ANP binding: showed a significant reduction in the number of binding 
sites on the active limb of the study, similar to the pattern seen in 
patients with elevated plasma ANP due to heart failure (Schiffrin
(1988) or hypertension (Schiffrin et al.,(1988)). The nature of 
platelet receptors has recently been clarified (Schiffrin et 
al.,(1991)). Human platelets contain a mixture of high and low 
molecular weight receptors. The low molecular weight receptor appears 
to be the C-ANP receptor (Chapter 2) but the high molecular weight
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FIGURE 8.5:
PLATELET ANP RECEPTORS - DURING UK 79,300 TREATMENT.
A. Scatchard analysis and B. binding curves for platelet ANP 
binding from samples taken on the 8th day of treatment with UK
79,300 or placebo. Data are shown as mean±SD, see text for 
details.
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form, although similar to the B-ANP receptor is not functionally, 
linked to guanylate cyclase. However, regardless of their nature these 
receptors do behave appropriately in a number of conditions, such as 
heart failure (Schiffrin (1987)). The down regulation of platelet ANP 
receptors in the current study is therefore consistent with a 
sustained rise in plasma ANP during treatment with UK 79,300. The 
balance of evidence from platelet binding and the initial natriuresis 
and diuresis would suggest that plasma ANP levels are elevated, but 
that increased plasma levels have been missed by sampling prior to 
administration of the drug (and plasma hormone levels have returned to 
normal. Although platelets receptors have no proven biological 
significance they are likely to act as markers for the biologically 
active ANP receptor, and one would therefore predict down regulation 
of this receptor subtype in other tissues. Such an effect may 
partially account for the failure of sustained hormone elevation to 
produce a sustained natriuresis and diuresis.
Infusion data: The infusions on the final day had two aims. Firstly to 
identify possible antihypertensive effects in normal subjects in case 
there were no changes in blood pressure during the study (as was 
found, Table 8.1) and secondly to examine the effects of NEP 
inhibition on the adrenal response to Ang II since ANP has been shown 
to inhibit adrenal function both in vitro (Chapter 2) and in vivo 
(Cuneo et al.,(1987)). The Ang II infusion protocol was similar to 
that employed by Cuneo et al.,(1987) where ANP was found to inhibit 
the aldosterone response to Ang II infusion. In contrast to the clear 
inhibition of aldosterone production in these studies UK 79,300 
resulted in an increased aldosterone response to Ang II. The reason 
for this is clear, if unexpected, in that Ang II levels were also
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increased presumably reflecting the fact that NEP degrades Ang II 
(Chapter 5). Even when the elevated levels of Ang II were taken into 
account by examining the ratio of Aldo/Ang II there was no evidence of 
any inhibition of aldosterone production (data not shown). This 
disappointing observation suggests that the non-specific actions of 
NEPi may render them ineffective as antihypertensive agents at least 
in circumstances where Ang II is elevated. The blood pressure response 
to infusion confirms this with an exaggerated pressor response to Ang 
II in the presence of UK 79,300. However, the pressor response to 
Phenylephrine was reduced confirming that NEPi may have 
antihypertensive actions under some circumstances. It should be noted 
that this pattern of effects - with a greater inhibition of Phe than 
Ang II - contrasts with previous reports that ANP specifically 
inhibits the pressor effects of Ang II (Proctor and Bealer (1987)).
The effects of NEP inhibition on Ang II may explain the limited 
renal effects of NEP inhibition. If we accept that plasma ANP is 
raised during prolonged treatment with UK 79,300 (above) then the 
transient natriuresis, rebound antinatriuresis and absence of any 
effect on overall sodium balance must be due either to activation of 
antinatriuretic mechanisms or of factors which modulate the renal 
actions of ANP (Chapter 4). Catecholamines were not measured in this 
study, and there was no increase in heart rate to suggest sympathetic 
activation (Koepke and diBona (1987)); nor was there a significant 
fall in blood pressure (Seymour et al.,(1987)). Activation of the 
renin-angiotensin system therefore seems the most likely mechanism. In 
keeping with this, Ang II levels were higher during active treatment 
and we have established that Ang II degradation was inhibited, which 
will magnify any Ang II-mediated effects. In fact, although the early,
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transient natriuresis (Figute 8.1) is similar to the effects of ANP 
(Janssen et al.,(1989), Kivlign et al.,(1988)), the rebound 
antinatriuresis and lack of overall effects on sodium balance is not. 
Inhibition of Ang II degradation may explain this, by amplifying the 
effects of activation of the renin-angiotensin system.
A further relevant question is whether or not NEP inhibition has 
any effect on baroreceptor function, since ANP is thought to attenuate 
the baroreceptor response to a variety of stimuli (Chapter. 2). 
Baroreceptor function was not formally assessed in the present study, 
although the heart rate/systolic pressure relationship did not differ 
between active and placebo treatment groups for either Ang II or 
phenylephrine. Figure 8.4). Further studies are required to assess any 
effect of NEPi on baroreceptor function.
In conclusion, this study confirms the safety of NEP inhibition 
in man, but fails to achieve the initial potential of these agents 
(Chapter 7). The renal effects are modest, but consistent with low 
dose infusion studies of ANP in man and animals (Janssen et al.,,
(1989), Kivlign et al.,(1989)) with a diuresis and natriuresis only on 
the first day. Plasma ANP was probably elevated, although this was not 
clearly established from the plasma measurements, but the finding of 
most concern from the present study is that NEP inhibition is non­
specific and can also inhibit Ang II degradation. As a result of this, 
although there appeared to be some anti-pressor potential against the 
effects of phenylephrine infusions, the pressor response to Ang II was 
increased. Although this does not completely exclude a therapeutic 
role for NEPi, it is likely to limit its use to situations where the 
renin-angiotensin system is not activated.
0______1_______ 2_______ 3_______ 4_______ 5_______6 7_______ 8_______ 9
SBP P 11915 11513 12615 11714 11915 11613 11715 11615 12115 11414
UK79 11713 11513 11615 11815 11815 11214 12014 11115 12013 11414
SBP P 10615 11014 11314 10514 10716 10813 10915 10113 11015 10815
(S)
UK79 11615 10614 11013 10314 10914 10513 10615 10714 10813 10713
DBP P 7014 6714 6912 6713 6713 6213 6313 6415 6814 6814
UK79 69+3 6914 6913 6614 • 6714 67+3 6814 6313 6214 72+4
DBP
(S)
P 7614 7215 6616 6715 6715 6814 6615 6913 6915 75+4
UK79 7813 7615 7315 7313 6614 7014 6714 6913 7014 7513
wr P 73.4
13.1
73.4
13.0
73.3
+2.9
73.0
♦3.0
72.7
+2.9
72.9
±2.9
UK79 74.2
13.1
73.8
13.1
73.6
13.2
73.4
13.2
72.9
12.9
72.9
±2.9
HCT P 4211 41U 4111 4111 4111 3911
UK79 4311 4311 4211 42ll 42±1 4011
Ha P 140.3
10.6
140.4
+0.8
140.0
+0.6
140.6
10.8
140.9
10.5
140.9
±0.6
UK79 140.4
+0.4
139.8
10.5
139.8
+0.4
139.9
10.5
140.8
+0.3
140.9
±0.5
K P 4.110.1 4.010.1 4.010.1 4.110.1 4.110.1 4.010.1
UK79 4.210.1 4.210.1 4.210.1 4.210.1 4.210.1 4.110.1
U P 5.710.3 6.110.5 5.510.3 6.0+0.3 5.410.3 6.2+0.4
UK79 5.610.3 5.310.3 5.810.3 6.010.3 5.410.3 5.510.3
Ct P 96.0
13.7
95.0
+5.1
91.9
14.0
98.8
14.3
100.6
♦5.4
93.8
±5.7
UK79 99.4
+5.8
89.9
+5.5
94.7
12.7
91.8
15.4
91.1
±7.0
94.4
±4.4
TABLE 8.1
BLOOD PRESSURE, WEIGHT AND BIOCHEMICAL DATA.
Blood Pressure (systolic supine (SBP) and standing SBP(S);
diastolic supine (DBP) and standing DBP(S); mmHg, meaniSEM). 
Weight in Kg (Wt), Haematocrit (Hct, %), and plasma sodium, 
potassium and urea (Na, K, U, mmol/1) and creatinine (nmol/1). 
There were no differences between active (UK79) and placebo (P) 
for any of these variables. Data shown as meaniSEM (n=8)
against time in days; UK 79,300 started after day 0.
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Chapter 9.
Antihypertensive Effects of NEP inhibition:
Studies with SCH 34826 in normal and DOCA-salt rats.
Introduction.
The findings in the previous chapter (Chapter 8) suggest that 
chronic administration of NEPi may inhibit ANP degradation but that 
the effects on sodium homeostasis are short lived and modest. Despite 
the absence of a fall in resting blood pressure, this does not exclude 
a potential antihypertensive effect of NEP inhibition, particularly as 
ANP is reported to cause more pronounced effects in hypertensive 
subjects (Richards et al., (1989), Cusson et al., (1987)). The 
attenuation of the pressor response to phenylephrine (Chapter 8) 
during NEPi treatment suggests some potential antihypertensive effect 
(albeit with the caveat that NEPi are unlikely to be effective in 
situations where the RAAS is activated (Chapter 8)). The study 
described in this chapter was therefore undertaken to examine the 
effects of SCH 34826 (see chapter 5, a NEP inhibitor of comparable 
potency to UK 69,578) on plasma ANP, sodium balance and blood pressure 
in normal and DOCA salt hypertensive rats.
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Methods.
Twenty four male Sprague Dawley rats (weight 200-250g, OLAC Ltd., 
UK) were used. Two separate studies were performed in normal rats and 
in rats made DOCA-salt hypertensive by unilateral nephrectomy and the 
implantation of 25mg DOCA pellet subcutaneously (Russo et al.,(199Q)). 
The animals were housed singly in metabolic cages allowing 
quantification of dietary intake and urine output. They received a 
’’sodium free” diet (Special Diet Services, Essex, UK., containing 
approximately 6mmoles‘Na/Kg) and 1% NaCl containing 74 pBq/1 Na-22 to 
drink (Harrap (1986), Brown (1981)). After a four week equilibration 
period during which blood pressure was measured twice weekly by the 
tail-cuff method (BP recorder 8005, W&W Electronics, Basel, 
Switzerland), the experimental phase of the study began. Urine volume 
was measured daily and Na and K concentration measured (Beckman model 
2A analyzer, Beckman Inc., Ireland). Urinary excretion of cGMP was 
determined by radioimmunoassay (Lyall et al.,.(1987)), using a 
commercially available kit (Amersham, UK); the inter and intra-assay 
coefficients of variation were 1.4 and 0.8% respectively. Intake of 
of food and saline was measured. The experimental part of the study 
lasted 14 days. The first 3 days were a control period, the next three 
days the rats received either 10 mg/Kg SCH 34826 or placebo 12 hourly 
by subcutaneous injection, then 30mg/kg SCH 34826 or placebo and 
finally 90 mg/kg SCH 34826 for five days (after Sybertz et al.,(1989), 
Janssen et al., (1989), Kivlign et al.,(1988)) to allow time for a 
maximal effect to appear. Blood pressure was determined at the end of 
each phase by the tail cuff method and exchangeable body sodium 
measured by the method of Brown (1981). Briefly the rats were placed
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in a perspex frame and radioactivity measured in an ARMAC counter. 
Exchangeable body sodium (NaE) was estimated by comparison with a 
standard "ghost" containing 150 mis of Na-22/1% NaCl using the 
equation.....
NaE(nnnol/Kg) = (Counts per rat) x 26.7
Standard Counts Weight of rat
On the final day the rats were sacrificed by guillotine exactly 
two hours after the final dose and trunk blood collected in chilled 
tubes containing EDTA/Trasylol for determination of plasma ANP 
(Appendix 1).
Statistical analysis is by repeated measures ANOVAR of active 
versus placebo within normal and hypertensive groups (SPSS/PC+, SPSS 
Inc., USA). Where significant (P<0.05) post hoc analysis at individual 
dose or time points was by Student's t-test.
Results.
Metabolic Balance. The normal rats had stable 24 hour urine volume, 
sodium and potassium excretion throughout the study period, without 
evidence of any changes at any dose of SCH 34,826 (Figure 9.1). The 
DOCA salt rats (Figure 9.2) had slightly higher baseline levels of Na 
and K excretion and, in particular, urine volume, but again there was 
no difference between active and placebo during treatment with SCH 
34826. In the DOCA salt rats there was a downward trend in Na 
excretion in both active and placebo groups during the 14 day 
experimental period perhaps because these animals had not achieved a 
stable equilibrium (i.e. intravascular volume and total body sodium
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FIGURE 9.1:
RENAL EFFECTS OF SCH 34,826 IN NORMAL RATS.
Urinary sodium excretion (UNaV, nmoles/day), potassium 
excretion (UKV, nmoles/day), urine volume (UVol, ml/day) and 
dose of SCH 34,826 (mg/kg b.d.) against time in days. Normal SD 
rats, n=6 in each group. Data are given as meaniSEM and there 
were no statistically different effects.
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FIGURE 9.2:
RENAL EFFECTS OF SCH 34,826 IN HYPERTENSIVE RATS.
Urinary sodium excretion (UNaV, nmoles/day), potassium 
excretion (UKV, nmoles/day), urine volume (UVol, ml/day) and 
dose of SCH 34,826 (mg/kg b.d.) against time in days. DOCA salt 
hypertensive rats, n=6 in each group. Data are given as 
meaniSEM and there were no statistically different effects.
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were still expanding) during the first few days of the experimental 
period. In both the normal and DOCA salt rats there was a non­
significant tendency for Na excretion and urine volume to be higher in 
the rats treated with SCH 34826 but this was also evident in the 
control period, and there is therefore no evidence that NEPi had any 
effect. In all groups urinary Na excretion approximated to 70-80% of 
the calculated Na intake, a finding similar to that observed by others 
using this method.
Exchangeable Sodium. In the normal rats exchangeable body sodium 
levels of between 35 and 40 mmoles/kg were found, similar to previous 
reports in normal animals (Mannheim et al.,(1986), McAreavey et 
al.,(1984)). However, measurement of exchangeable sodium gave no 
further indication of activity of the NEPi (Figure 9.3). Indeed, NaE 
tended to be higher during active treatment in both normal and DOCA 
salt groups with the DOCA salt rats showing approximately 20% 
expansion of NaE (Simpson et al.,(1986), McAreavey et al.,(1984)). 
Blood Pressure. The normal rats had high baseline readings but showed 
a downward trend with repeated measurements. As in humans (Chapter 8) 
there was no evidence of a fall in blood pressure in normal rats 
(Figure 9.3) during treatment and, in fact, the mean SBP was lower in 
the placebo group. The baseline SBP was about 20 mmHg higher in the 
DOCA salt hypertensive rats and continued to rise in the placebo 
group. In contrast, those DOCA salt rats receiving SCH 34826 showed a 
downward trend in SBP which was maximal at the highest dose, where 
there was a 40 mmHg difference between the active and placebo groups. 
Plasma ANP. This was determined in trunk blood obtained two hours 
after administration of 90mg/Kg SCH 34826 on the final day of the 
study. ANP was elevated six-fold in the DOCA salt rat compared to the
Na
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FIGURE 9.3:
BLOOD PRESSURE AND EXCHANGEABLE SODIUM IN NORMAL AND 
HYPERTENSIVE RATS DURING TREATMENT WITH SCH 34,826.
(A) Systolic blood pressure (SBP, mmHg) measured by the tail 
cuff method in conscious rats in each of the four experimental 
groups*.as indicated (n=6 in each group). * PC0.05 SCH 34,826 
vs. placebo within the DOCA salt hypertensive rats by T-test 
with the Bonferoni correction.
(B) Exchangeable sodium within the same groups as labelled.
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FIGURE 9.4:
PLASMA ANP AFTER TREATMENT WITH SCH 34,826 IN RATS.
Plasma ANP (pg/ml) measured two hours after the final dose of 
SCH 34,826 (90mg). Significance as indicated by T-test.
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normal animal, where levels of around 50-100 pg/ml were seen. Hormone 
levels were 50% higher in the active treatment groups of both normal 
and DOCA salt animals but, due to small numbers of animal and the 
large SEM, these observations were not significant.
Cyclic GMP excretion, which is used as a marker of ANP activity, 
was increased in DOCA salt rats, paralleling the rise in plasma ANP, 
compared with the normal group. However, although there was a small 
increase in plasma ANP during NEP inhibition there was no eveidence of 
a similar trend in either the normal or the DOCA salt hypertensive 
groups.
Discussion.
The majority of findings in this study simply confim those in 
the previous study (Chapter 8) in normal humans in that there was no 
significant effect on exchangeable sodium during prolonged treatment 
with NEPi (in this case SCH 34826 in rats). Like the preceding study 
it seems likely that ANP degradation was inhibited, although the 
higher values found in both normal and hypertensive rats were limited 
to a single measurement and failed to reach statistical significance. 
The most important finding in the present study was the significant 
antihypertensive effect of SCH 34826 in DOCA salt hypertensive rats. 
Plasma ANP:
Plasma ANP was greatly elevated in DOCA salt hypertension as one 
would predict for a volume expanded state and as has previously been 
shown in this hypertensive strain (e.g Schiffrin and St Louis (1987)) 
and in other volume expanded states (Chapter 2, Chapter 3). The blood 
samples were taken without anaesthetic and were necessarily limited to 
a single time point. However, plasma ANP levels were higher two hours
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after the final dose in both normal and hypertensive rats. The absence 
of statistical significance may reflect the small sample size and the 
magnitude of the rise is similar to that seen after acute 
administration of UK 69,578 in rats (Chapter 6) and to the non­
significant increase seen on the final day of treatment with UK 79,300 
in man (Chapter 8). However, it may be that SCH 34,826 - despite the 
in vitro similarity (Figure 5.1) - is a less potent NEP inhibitor than 
UK 69,578 (Chapter 10).
The pattern of changes in cGMP is interesting, but similarly 
fails to produce any evidence for an ANP-mediated effect. It is known 
that ANP receptors are down-regulated in DOCA hypertension (Schiffrin 
and St-Louis (1987)). In the present study, urinary excretion of 
cyclic GMP was greater in the DOCA salt rats, but only about three 
times higher than in normal rats, compared with a ten-fold increase in 
plasma ANP. The differing increases in plasma ANP and urinary cGMP in 
the hypertensive group are consistent with a reduction in ANP 
receptors. Despite the trend towards an increase in plasma ANP during 
NEP inhibition in each group there was no evidence for an increase in 
cGMP. In recent studies of NEP inhibitors in rats (see Chapter 10 for 
review) acute treatment with NEP inhibitors is almost universally 
accompanied by an increase in cGMP. It is not clear whether the 
findings in the present study mean that NEP inhibition does not act 
via ANP or whether the relationship between ANP and cGMP changes with 
prolonged treatment - perhaps due to a down-regulation of receptor 
numbers as was shown in the human subjects receiving UK 79,300 
(Chapter 8).
Urine volume and electrolyte excretion:
Despite the findings in earlier chapters (Chapters 6-8) there
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were no observed changes in urine volume, sodium or potassium 
excretion. This may be due to the difficulty in quantifying urine 
volume and electrolyte excretion in rats, rather than a difference in 
potency between NEPi, and the small number of rats in each group. In 
a previous study of prolonged treatment with Phosphoramidon and 
Captopril in DOCA salt rats (Nakagawa and Nasjletti (1987)), where ACE 
inhibition should have minimal effects, urinary sodium excretion was 
increased on the last day of a two-week treatment. It is possible 
therefore that a minor effect on renal function may have been below 
the limit of detection of the present experimental protocol. 
Exchangeable Sodium: The failure of exchangeable sodium to show any 
change during NEPi confirms the findings in man (Chapter 8) and, as 
with the metabolic measurements, only excludes a large effect such as 
the differences between normal and DOCA salt animals (Brown (1981), 
Figure 9.3). A minor effect may still be present.
Blood Pressure: The absence of a significant change in sodium balance 
in this study, despite the convincing fall in blood pressure might 
suggest that the actions of these agents is independent of any effect 
on ANP. However, the mechanism by which ANP causes hypotension is not 
clear. Acute reductions in blood pressure, and those caused by 
administration of high dose infusion appear to be mediated by a 
reduction in cardiac output due to reduced filling pressures (Tonolo 
et al.,(1989), Parkes et al.,(1988)), due to a combination of the 
renal actions of the peptide and increased vascular permeability 
(increased haematocrit). The later hypotensive actions of the peptide 
may be independent of any change in sodium balance, the implication 
being that a direct vascular effect is present. For example 
administration of 2 pmol/kg/min ANP to the SHR for 7 days (Garcia et
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al., (1985) produced a 20% fall in BP but no effect on sodium balance, 
and in a subsequent study these authors found no changes in 
intravascular volume during chronic treatment with ANP (Garcia et 
al.,(1985)). ANP can therefore produce antihypertensive effects in 
the absence of changes in sodium balance and the findings in the 
present study are therefore still consistent with a mechanism of 
action through ANP.
In conclusion, prolonged administration of NEPi in the rat - as 
in the human (Chapter 8) - has no demonstrable effects on sodium 
balance. However, treatment with SCH 34,826 (90 mg/kg) for 5 days did 
result in a significant reduction in blood pressure in a renin- 
independent model of hypertension - the DOCA salt rat. These 
observations confirm the possible therapeutic use of NEPi - at least 
in this model of hypertension.
GROUP NORMAL DOCA
PLACEBO SCH 34826 PLACEBO SCH 34826
UNaV
0 4.02±0.18 4.88±0.36 5.69±0.55 6.73±0.54
10 3.88±0.29 4.54±0.29 5.12±0.50 5.89+0.35
30 3.90±0.17 4 .55±0.17 4.39±0.33 4.81±0.65*
100 3.91+0.27 4.66±0.27 4.60=0.45 4.99±0.55
UKV
0 1.92±0.12 2.02±0.06 2.88;0.18 2.S4+0.24
10 1.S6±0.11 2.05+0.11 2.34±0.18 2.45+0.14
30 1.96±0.12 2.15±0.07 2.81±0.35 2.50±0.12
100 1.96+0.09 2.06+0.11 2.32±0.18 2.17±0.08
UVol
0 14.4±1.4 19.2±2.8 31.0+2.4 35.7+4.5
10 14.5±1.4 19.4+2.4 25.4±1.9 31.8±3.0
30 14.0±0.9 19.0±2.0 22.1+0.8 26.2±3.6
100 15.0+1.3 19.4±1.9 24.3±2.8 23.4+4.0
UcGMP
0 10.8±1.3 10.2+1.3 24.0±3.5 19.6+5.6
10 7.3+0.5 7.5+0.8 19.8±4.4 19.0±4.4
30 10.5+0.9 10.4±0.9 33.3+5.6 26.6±7.2
100 14.7±1.5 12.4+1.6 29.1+7.3 23.8±4.5
TABLE 9.1:
SUMMARY OF RENAL EFFECTS OF SCH 34,826 IN RATS.
Summary figure of the mean values of urinary sodium excretion 
(UNaV, mmoles/day), potassium excretion (UKV, mmoles/day), 
urine volume (UVol, ml/day) and cyclic GMP excretion (UcGMP, 
nmoles/day) by treatment (Dose of SCH 34,826 in mg/kg b.d). All 
data shown as meaniSEM, n=6. There were no significant effects 
of treatment of any variable either in normal or DOCA salt 
rats.
166
Chapter 10.
NEP inhibitors in perspective.
Introduction:
In 1987. when first reports emerged that NEP degrades ANP in 
vitro, NEP inhibitors appeared to be a logical means of elevating 
plasma ANP to possible therapeutic benefit (Chapter 5). The studies in 
the last four chapters were designed to examine this hypothesis and 
clearly show that acute NEP inhibition can cause an increase in plasma 
ANP and natriuresis, diuresis and suppression of renin (Chapters 6&7). 
This pattern of effects is exactly what one would predict for an 
inhibitor of ANP degradation. However, although chronic NEP inhibition 
lowers blood pressure in the DOCA salt rat (Chapter 9) there was no 
evidence of a sustained effect on sodium balance (Chapters 8&9), 
despite a probable sustained elevation in plasma ANP. The reasons for 
this appear to be that NEP is non-specific and NEP inhibition may 
potentiate both natriuretic (ANP) and antinatriuretic (e.g. Ang II) 
mechanisms.
In this chapter the results of other studies with NEP inhibitors,
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published since 1987, are reviewed and the relevance of the work in 
this thesis is discussed. The overall aim is to discuss the actions, 
mechanisms of action and therapeutic potential of NEP inhibitors.
Actions of NEPi
Animal Studies:
In chapter 6 acute NEP inhibition was shown to cause elevation 
of plasma ANP and natriuresis and diuresis. The effects of several 
other NEPi have now been investigated by other workers with similar 
findings.
Thiorphan/ Phosphoramidon: Following the demonstration that Thiorphan 
inhibits ANP. degradation in vitro (Olins et al.,(1987)), Olins et 
al.,(1989) have studied the effects of Thiorphan in conscious rats. 
Treatment with Thiorphan, during an ANP infusion, produced a 2-3 fold 
increase in plasma ANP for up to 60 minutes (at a dose of 30mg/kg, 
with doses as low as lmg/kg showing effect). The infusion of high 
doses of ANP was required to show changes in plasma hormone levels, 
and changes in urinary function were not studied. In contrast, Koepke 
et al.(1989) studied the effect of Thiorphan (30mg/kg i.v.), during 
infusion of ANP, but were unable to demonstrate any potentiation over 
the effect of ANP alone at a dose of 50ng/kg/min (approx. 16 
pmol/kg/min of ANP). However, in a further study Smits et al.(1989) 
examined the same dose of Thiorphan 30mg/kg in conscious rats. In this 
case the inhibitor caused non-significant increases in plasma ANP 
levels and those achieved by infusion of the peptide and although 
Thiorphan alone had no effect on renal function NEP inhibition
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greatly augmented the natriuresis and diuresis of infused ANP 
(67ng/kg/min). None of the above studies (in the rat) were able to 
demonstrate a significant rise in endogenous ANP with Thiorphan, 
although the renal and haemodynamic changes are consistent with t he 
actions of ANP. Increased plasma levels have since been shown in the 
rabbit (Marleau et al., (1990)) where Thiorphan (25 pg/kg/min for 90 
minutes) increased plasma ANP from 65±26 to 163±52 pg/ml, lending 
support to the theory that the renal actions of Thiorphan are likely 
to be secondary to inhibition of ANP degradation.
Similar findings have been made with Phosphoramidon (Figure 5.1). 
Ura et al. (1987), in a study designed primarily to examine kinin
metabolism, noted that Phosphoramidon (110 or 330 pg/hr/kg) increased 
urine volume by 15%, and urine sodium excretion by 37%, but without 
change in renal blood flow, GFR or potassium excretion; a pattern of 
changes consistent with the known effects of ANP. Lafferty et al. 
(1989) compared the effects of Phosphoramidon in normal rats and rats 
with 5/6 nephrectomy, a volume expanded state. While Phosphoramidon 
had no effect on plasma ANP in the normal rat, it did double 
fractional excretion of sodium, and in the 5/6 nephrectomy rat it 
caused a 5-fold increase in sodium and fractional sodium excretion, 
with an increase in GFR and a 3-fold rise in plasma ANP. Thiorphan 
had a similar effect, which was also more marked in the rats with 
reduced renal mass. Webb et al.,(1989) have also compared the effects 
of Phosphoramidon and Thiorphan on the renal and cardiovascular 
response to bolus administration of ANP (0.5 nmol/kg) in the 
anaesthetised rat. Thiorphan (0.01, 0.1 and 1 mg/kg/min) and
Phosphoramidon (0.001, 0.05 and 0.01 mg/kg/min) increased urinary cGMP 
excretion (approximately two-fold). Sodium excretion was augmented
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only in the low dose groups and blood pressure (20 mmHg) in the high 
dose groups; the fall in blood pressure presumably attenuating the 
natriuretic effect (Seymour et al., (1987) )■.
New NEPi: A number of newly designed NEP inhibitors (see Figure 5.1) 
have also been assessed in experimental animals.
In mice UK 69,578 (3mg/kg; Danilewicz et al., (1989)) increased 
urine volume and sodium excretion, in response to infusion of 600 fil 
saline, two-fold (from 136±11 to 249±15 }il/min and 10.8±1.1 to
21.8±1.5 pEq/min). In this study the rise in plasma ANP was also 
augmented - the peak level being doubled, and greatly prolonged. A 
doubling of endogenous plasma ANP has also been reported in dogs with 
experimental heart failure (Alabaster et al., (1989) treated with UK 
69,578. Shepperson et al.,(1991) have recently confirmed these
findings and shown that UK 69,578 (1-10 mg/kg) augments the
natriuresis and diuresis due to saline infusion (20 ml/hr) in 
anaesthetised rats. The natriuretic effects of UK 69,578 were 
abolished by co-administration of a polyclonal ANP antisera in
contrast to the effects on a quantitatively similar natriuresis 
produced by hydrochlorthiazide; suggesting that the observed effects 
of NEPi are mediated by ANP. Furthermore, acute administration of this 
NEP inhibitor (3-30 mg/kg) caused a dose dependent fall in BP in the 
DOCA salt rat of up to 30 mmHg for more than 5 hours after a single 
dose.
Another recently developed NEPi SQ 29,072 (Seymour et al.,
(1989a)) has also been shown to prolong the half-life of exogenous ANP 
in the spontaneously hypertensive rat (SHR) and to augment the
hypotensive effects of ANP (3nmol/kg). In a more detailed study with
170
this compound (Seymour et al., (1989b)), SQ 29,072 (100 ^mol/kg)
prolonged the depressor response to ANP for up to two hours and
increased the natriuretic response to 10 and 30 nmol/kg ANP,
approximately five-fold in the first hour. The increase in natriuretic 
response was dependent on the dose of SQ 29,072, as was augmentation 
of the hypotensive effect of ANP. Urinary cGMP excretion was also 
increased, and it was noted that the effects of NEPi were greater in 
volume expanded rats, presumably due either to increased endogenous 
ANP or suppression of antinatriuretic mechanisms.
In a more recent paper (Seymour et al.,(1991)) combined
inhibition of ACE and NEP, either by the use of Captopril and SQ 
29,072, or by SQ 28,133 - a compound which inhibits both NEP and ACE - 
resulted in a reduction in blood pressure in the SHR (-62±9 [both] vs 
-26±5 [SQ 29,072] or -40±10 [Captopril]) which was greater than the 
effect of either agent alone. In the DOCA salt rat - a non-renin 
dependent model of hypertension, ACE inhibition did not enhance the 
natriuretic effects of NEPi. Overall, these suggest that the effects 
of NEPi, like those of ANP (Chapter 4), are potentiated by ACE 
inhibition.
Two studies have examined the effects of acute NEP inhibition 
with the related compound SQ 28,603 (Seymour et al., (1991a)) in dogs 
with experimental heart failure (Marguiles et al.,(1990), Cavero et 
al.,(1990)). Treatment with 30-60 mg SQ 28,603 doubled plasma ANP and 
increased urine volume, and the excretion of sodium and cGMP to a 
greater extent than the infusion of exogenous ANP (to achieve similar 
plasma levels, Cavero et al.,(1990)) suggesting either that an 
alternative mechanism to ANP is involved or the plasma ANP level does 
not reflect levels of ANP at the active site - perhaps within the
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kidney. Infusion of low dose ANP into one renal artery of dogs 
(Marguiles et al.,(1990)), in the presence or absence of SQ 28,603 
given intravenously, again doubled the effects of ANP on urine volume 
and sodium excretion. The NEPi alone also caused a natriuresis in the 
control kidney, due to an increase in FeNa but not GFR, while the 
natriuresis in the supplemented kidney was associated with a rise in 
GFR, FeNa and FeLi (a marker of proximal tubular function). This 
pattern of effects is consistent with the renal mechanism of ANP, 
where GFR is increased only by high doses (Chapters 2,4) and FeNa by 
low doses.
Schering have also developed a series of NEP inhibitors (Ghipkin 
et al., (1988), which prevent the in vitro degradation of ANP (Sybertz 
et al., (1989)). In normal rats SCH 39,370 (30 mg/kg i.v.) caused a 
five-fold increase in plasma ANP during infusion of the peptide at 1 
Hg/kg/min for 30 minutes, with an associated increase in the 
natriuresis and diuresis approximately 50% (Sybertz et al., (1989)). 
SCH 34,826 augmented the rise in plasma ANP following ANP injection 
(30 }ig/kg), with increased natriuresis and diuresis in both the SHR 
and DOCA salt rat (Sybertz et al., (1990)). There was an associated 
increase in urinary ANP excretion (100 fold/3hrs) and cGMP excretion 
(3 fold/ 3 hours) in the DOCA salt rat. SCH 34,826 only reduced blood 
pressure acutely in the DOCA salt rat, and had no effect in the SHR. 
However, after 5 days of treatment with 90 mg/kg SCH 34,826 there was 
a 20 mmHg reduction in blood pressure in the SHR.
From these studies in experimental animals it is possible to draw 
a series of conclusions on the actions of NEPi. Although this pattern 
of effects is consistent with an action through ANP and urinary cGMP - 
a marker of ANP action - is generally reported to be increased,
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plasma levels are not invariably elevated. It is not clear whether 
this is due to difficulty in sampling from small animals, genuine 
species differences or whether there are differences in potency 
between the agents (Figure 5.1). Plasma ANP may be little more than a 
marker for tissue levels of ANP - perhaps within the kidney - which 
may be functionally more important. In the study in chapter 6, plasma 
levels were increased by treatment, and significant increases have 
been seen in other species and agents (Cavero et al.,(1990), Marguiles 
et al.,(199Q), Marleau et al.,(1990), Lafferty et al.,(1989)). The 
demonstration of an increase in ANP in these studies may reflect the 
fact that baseline ANP levels would be elevated by volume expansion in 
the rats (Chapter 6) and heart failure in the dogs (Cavero et 
al.,(199Q), Marguiles et al.,(1990). There is also a suggestion that 
the response to NEPi is enhanced in these conditions, although whether 
this is due to higher ANP levels is not known (Seymour et 
al.,(1989a,b), see below). However, these data do suggest that the 
renal response to NEPi is governed by the same factors as ANP (Chapter 
4) being reduced by a fall in blood pressure (Webb et al.,(1989)), and 
increased by volume expansion (Lafferty et al.,(1989)) and ACE 
inhibition (Seymour et al.,(1991b)).
All the above studies have examined the acute effects of NEPi and 
apart from the observation that blood pressure falls with chronic 
treatment (Sybertz et al.,(1990)) there is no published data on the 
prolonged renal or hormonal effects. The study in chapter 9 failed to 
show any effects on urine volume, electrolyte or cGMP excretion, or 
body sodium of prolonged treatment with SCH 34,826 in either normal or 
DOCA salt rats, despite an upward trend in plasma ANP and a 
significant reduction in blood pressure in the hypertensive animals.
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Why the haemodynamic effects of NEPi should be evident, but the renal 
effects disappear with prolonged is not clear. Similar effects are 
apparent with prolonged dosing in man (see below) and may be due to 
the activation of antinatriuretic mechanisms and the non-specific 
effects of NEP inhibition.
Human Studies:
More recently NEPi have been investigated in man (Chapters 7&8). 
The study described in chapter 7 confirmed that UK 69,578 inhibits the 
degradation of ANP in man, raising plasma hormone levels two-three 
fold and with an associated diuresis, natriuresis and suppression of 
plasma renin. This confirms the renal effects of NEPi in animals but 
the clearer increase in plasma ANP, and the observed suppression of 
renin provide more substantial evidence that these agents work - as 
predicted - through inhibition of ANP degradation. The close 
relationship between changes in plasma ANP and sodium excretion 
(Figure 7.8) following treatment with UK 69,578 supports this 
hypothesis. In patients with heart failure this compound (UK 69,578 
(Northridge et al., (1990); Figure 10.1) and in patients with 
essential hypertension its oral prodrug (UK 79,300 (O'Connell et 
al.,(1990)) have almost identical acute effects on plasma ANP, urine 
volume and sodium excretion and renin concentration. Richards et 
al.,(1990) have recently confirmed this pattern of effects in normal 
subjects given UK 79,300 orally, and shown parallel increases in 
plasma ANP, and urinary sodium and cGMP excretion, with reduced plasma 
renin and aldosterone.
The only other reported studies in man are with Sinorphan (an 
oral prodrug of Thiorphan; Gros et al.,(1989), Kahn et al.,(1990),
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Schwartz et al.,(1990), Dussaule et al.,(1991)). In normal subjects 
and in patients with heart failure or ascites this agent inhibits 
plasma NEP and causes short term increases in plasma ANP. The pattern 
being similar to that of UK 69,578, and is associated with a transient 
increase in sodium excretion. In patients with ascites the natriuresis 
was less marked, but again there was a close association between the 
elevation in plasma ANP and cGMP (Dussaule et al.,(1991)), both of 
whcih were inversely related to NEP activity.
There have been no published reports on the effects of prolonged 
NEPi. The study in chapter 8 confirms the findings with acute NEP 
inhibition, in that a natriuresis and diuresis were seen on the first 
day of treatment. However, in contrast to the effects of prolonged low 
dose ANP infusion (Janssen et al.,(1989), MIzelle et al.,(1988), 
Kivlign et al.,(1988)) this was not maintained for the duration of 
treatment; instead there was an antinatriuresis on third day of 
treatment and overall sodium balance was not altered. Theoretically, 
this may be due either to activation of antinatriuretic "defence" 
mechanism or failure to produced a sustained rise in ANP. In fact, 
although pre-dose plasma ANP levels were not elevated, overall plasma 
levels probably were elevated as shown by the down-regulation of 
platelet ANP receptors (Figure 8.5). It is likely that these effects 
on ANP were offset by the activation of antinatriuretic mechanisms. 
One of the most significant findings in this study was that Ang II 
levels were elevated by NEP inhibition - at least during infusion of 
Ang II - thus antinatriuretic mechanisms may be potentiated by this 
treatment. In these normal subjects there was also no evidence of any 
antihypertensive effects. A preliminary report in hypertensive 
subjects treated with UK 79,300 for 28 days (Bevan et al.,(1991)) has
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reported a sustained increase in ANP (approximately two-fold) 
supporting the view that plasma ANP is likely to be elevated by 
prolonged treatment. Renal function data have not yet been reported 
from this study but a very limited reduction in blood pressure was 
achieved by prolonged treatment.
These studies in man confirm the acute effects of NEPi in 
animals, but the more complex studies have allowed the time course in 
plasma ANP, and other hormones such as renin, to be well 
characterised. The pattern of hormonal and renal changes provide 
further evidence that NEPi act via ANP. Despite the promise of the 
results of acute NEP inhibition, the effects of chronic therapy are 
short-lived at least partly due to the non-specific effects of NEPi on 
Ang II degradation.
Therapeutic effects of NEP inhibition:
Hypertens ion:
Many of the animal studies (above) have examined the acute 
effects of NEP inhibition in hypertensive strains, and the consensus 
from these is that acute NEPi enhances the hypotensive response to 
pharmacological doses of exogenous ANP (in both normal and hypotensive 
rats; Sybertz et al.,(1989, 1990), Seymour et al.,(1989)). Given
alone, the antihypertensive effects of NEPi are less clear. In renin- 
independent models such as the DOCA-salt rat (Sybertz et al.,(1989), 
Seymour et al.,(1989, 1990), Shepperson et al.,(1991)) acute NEP
inhibition lowers blood pressure by up to 40 mmHg. In the SHR model of 
essential hypertension however, there are differing reports on whether 
acute NEP inhibition is equally (Seymour et al., (1991)) or less
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(Sybertz et al./(1990) effective. As noted above there are few studies 
of prolonged NEP inhibition. Sybertz et al.,(1990) found a 20 mmHg 
reduction in blood pressure compared with placebo in rats treated with 
SCH 34,826 (90 mg b.d. for 5 days), which is less impressive than the 
acute actions. A similar antihypertensive effect is seen in DOCA salt j 
rats in Chapter 9. Further studies are required to assess whether or 
not NEPi are more (or only) effective in low renin forms of
I
hypertension such as the DOCA salt rat (as suggested in chapter 8) and ! 
whether high absolute levels of ANP must be achieved (either by
i
infusion or in situations where endogenous ANP is elevated, eg DOCA- |
salt rat). i  -         __
In humans there is only a little preliminary work on the 
antihypertensive effects of NEPi. In normal subjects and patients with 
heart failure, acute or chronic treatment has no effect on blood 
pressure (Chapters 7 & 8, Northridge et al.,(1990), Richards et 
al.,(1990)).. In patients with mild essential hypertension, acute 
administration of UK 79,300 (O'Connell et al.,(1991)) increased plasma 
ANP and sodium excretion but had no effects on blood pressure. The 
only "positive" study of NEPi in humans with hypertension is the 
uncontrolled and therefore uninterpretable study of Lefrancois et 
al.,(1990) where treatment with increasing doses of Sinorphan resulted 
in a 15 mmHg fall in mean blood pressure over a four week period. A 
more recent study (Bevan et al.,(1991)) in which 40 patients were 
randomised to receive either UK 79,300 or placebo for 28 days, found 
a 10/3 mmHg reduction in supine blood pressure in the active group 
compared with 5/4 mmHg in placebo (P=NS). The only significant 
differences were in the standing systolic pressure which fell by 10 
mmHg compared with 1 mmHg in the placebo group; despite a sustained 
rise in basal ANP from 37 to 56 mmHg.
The mechanism of blood pressure reduction cannot be resolved from
177
these studies. However, in the absence of any renal effects of 
prolonged treatment it seems most likely that observed 
antihypertensive effects of chronic treatment are due to direct 
vascular effects of ANP, whilst the acute effects may involve changes 
in intravascular volume. This pattern is also seen during infusion of 
the exogenous peptide (Chapter 9 - Discussion).
Overall, although there are only limited data on the 
antihypertensive effects of prolonged NEPi, these appear modest and 
may be restricted to low renin forms of hypertension.
Heart Failure:
Despite the high circulating levels of ANP in heart failure 
(Cody et al.,(1987)), with down-regulation of ANP receptors (Schiffrin 
(1988)), and. the associated neurohumoral activation, both of which 
might be expected to offset the effects of ANP/NEP, NEP inhibition 
appears to be at least as effective as in normal subjects. In their 
preliminary study of UK 69,578 in six patients with mild chronic heart 
failure, Northridge et al.,(1989,1990; Figure 10.1) found that NEP 
inhibition caused a two to five fold increase in plasma ANP (with
levels of over 1000 pg/ml in some patients), associated with a two to
three-fold increase in urine volume and sodium excretion for 
approximately four hours. Furthermore, there was a significant 
reduction in both right atrial and pulmonary capillary wedge 
pressures, sustained for up to eight hours (see Figure 10.1). This
pattern of changes has since been confirmed, albeit in a very
preliminary form, (Kahn et al.,(1990)) using the oral NEPi Sinorphan. 
In patients with more severe heart failure this compound is reported 
to cause a similar rise in ANP over 2-3 hours, associated with a 20%
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FIGURE 10.1:
EFFECT OF NEP INHIBITION IN HEART FAILURE.
Summary of the effects of UK 69,578 in six patients with mild 
(NYHA grade 1/2) heart failure on plasma ANP (ANF, pg/ml), 
right atrial (RAP) and pulmonary capillary wedge pressure (PWP, 
mmHg) and cardiac output (CO, 1/min) against time in hours. UK 
69,578 was administered over 20 minutes at time 0. (after 
Northridge, Jardine et al., (1990) with permission).
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reduction in renin and in cardiac filling pressures.
There have been no detailed studies of the renal actions of NEP 
inhibition in heart failure in humans. However, the findings of Cavero 
et al.,(1990), in dogs with experimental heart failure (due to rapid 
ventricular pacing), suggest that the renal effects are maintained or 
enhanced (compared to either normal dogs or the infusion of ANP in 
dogs with heart failure). "Why this should be the case when one might 
expect the opposite in a condition where there is activation of the 
renin-angiotensin system and down regulation of ANP receptors is 
unknown and although Marguiles et al.,(1990) have suggested that 
increased degradation of ANP in heart failure may be responsible, the 
involvement of other substrates for NEP must be excluded. A further 
alternative is that the threshold for the venodilator actions of ANP 
is lower than that for the other actions of the peptide (Bie et 
al.,(1988)) and it is these effects which may be particularly useful 
in the treatment of heart failure. The question of whether or not 
these potentially beneficial effects are present during chronic 
treatment are awaited with interest.
How do NEP inhibitors work?:
Having reviewed the effects of NEP inhibition, the questions 
remain of how these effects are achieved and whether the original 
assumption that inhibition of ANP degradation is the likely mechanism 
is correct. In fact, NEP has many substrates (Figure 5.1) and there is 
evidence both for and against an ANP-mediated effect.
Much of the evidence supporting an ANP-mediated effect is 
circumstantial:
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1. Acute NEP inhibition raises plasma ANP, approximately 2-3 fold for 
several * hours (Chapters 6 & 7, Kahn et al.,(1990), Northridge et 
al.,(1990), Lafferty et al.,(1989), Marleau et al.,(1990), Danilewicz 
et al.,(1990), Shepperson et al.,(1991), Marguiles et al.,(1990), 
Cavero et al.,(1990), Sybertz et al.,(1989)). The urinary excretion of 
ANP is also enhanced.
2. Acute (e.g. Chapters 6 & 7) and chronic (Chapter 8) NEP inhibition 
produce a pattern of changes in urine volume, sodium and potassium 
excretion which is similar to that caused by low dose infusion of ANP 
(at plasma levels similar to those achieved by NEP inhibition). The 
natriuresis is directly related to the rise in plasma ANP (Chapter 7) 
and when compared directly - one against the other (Chapter 6, Cavero 
et al.,(1990), Marguiles et al.,(1991)) - NEPi and ANP produce a 
similar pattern of effects.
3. The actions of NEPi are usually associated with an increase in 
urinary cGMP excretion (Dussaule et al.,(1990), Richards et 
al.,(1990), Marguiles et al.,(1990), Sybertz et al.,(1989, 1990) - a 
marker of ANPs cellular effects (Wong et al.,(1988)), even in the 
absence of a demonstrable rise in plasma ANP (Sybertz et al., 
(1989,1990)). Furthermore, the natriuresis is quantitatively related 
to changes in cGMP excretion (Dussaule et al.,(1991)).
4. Although few studies have examined the mechanisms underlying the 
renal effects of NEPi and the results are inconsistent, they are 
similar to those of ANP (Chapter 2). In chapter 7, there was a 
significant rise in FeNa, but not GFR or ERPF, similar to low dose 
ANP. This pattern has been confirmed for NEPi given alone (Cavero et 
al.,(1990), Marguiles et al.,(1990)). However, NEPi given in the 
presence of elevated exogenous (Marguiles et al.,(1989)) or endogenous
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(Lafferty et al.,(1990)) ANP increase GFR, the pattern being similar 
to that of high dose ANP administration (Chapter 2).
5. The endocrine (suppression of renin, Chapter 7) and vascular 
(hypotensive, Chapter 9) effects of NEPi are very similar to those of 
ANP and quite dissimilar to any other diuretic.
6. NEPi potentiate the response to infused ANP (Smits et al.,(1990), 
Seymour et al.,(1989), Olins et al.,(1989)), although whether or not 
this is a specific effect remains to be seen.
7. Finally, the renal response to NEPi is modulated in the same way as 
the response to exogenous ANP by intravascular volume, arterial 
pressure and the renin-angiotensin system (Seymour et al.,(1989, 
1991); Webb et al.,(1988)).
Although the above evidence is circumstantial, taken together it 
provides strong evidence for an ANP-mediated effect. The only evidence 
to date which directly implicates ANP is the observation of Samuels 
(Samuels et al.,(1989), Shepperson et al.,(1991)) confirmed by 
Schwartz et al.,(1990) that polyclonal ANP antisera block the 
natriuretic response to NEPi but not to other diuretics.
The evidence against ANP is less convincing and centres on 
possible alternative mechanisms. Inhibition of kinin degradation is 
the most likely, since kinins are also natriuretic, diuretic and 
vasorelaxant (Scicli and Carretero (1986)) and urinary kinin levels 
are increased by NEP inhibition (Ura et al.,(1987)). Against a role 
for kinins are the observations that kinins stimulate rather than 
suppress renin secretion (Carretero et al.,(1989)) and NEPi does not 
enhance the response to exogenous bradykinin (Sybertz et al.,(1990), 
Gros et al.,(1991)). However, infusion of a kinin receptor antagonist 
(Smits et al.,(1990)) has been shown to abolish the natriuretic
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response to combined treatment with ANP plus Thiorphan in rats. It 
remains to be seen whether this is a specific effect on ANP and/or 
NEPi, or indeed whether this agent is a specific kinin receptor 
antagonist. A similar blunting of the natriuretic response to 
phosphoramidon by a kinin antagonist (albeit in the presence of an ACE 
inhibitor) has been reported by Nakagawa et al.,(1990). However, in a 
similar experiment (Roman et al.,(1988)) a kinin antagonist failed to 
alter the natriuretic response to combined NEP and ACE inhibition in 
rats. Nevertheless, it is impossible to dismiss a contribution from 
increased circulating or intra-renal kinins on the observed renal 
effects.
A further, as yet unconfirmed suggestion (Vane (1990)) is that 
NEPi may inhibit the the conversion of Endothelin to its active form, 
offering another hypotensive mechanism. The balance of evidence,
however, strongly favours the original hypothesis: that NEPi act via 
inhibition of ANP degradation.
One final problem which is difficult to explain is how inhibition 
of an enzyme on the luminal aspect of the proximal tubule can have any 
effect on circulating hormone levels. Two points emerge from this. The 
first is that NEP is found in other tissues and it has recently been 
confirmed that NEP inhibition raises plasma ANP even in anephric rat
(Barclay et al.,(1991)). In this model UK 69,578 reduces the
degradation of exogenous ANP by approximately 40% (T | [B] = 140 vs 
102 secs). The second point is that of the site of action of NEPi 
(Granger (1990)). Inhibition of NEP at its major site - in the
proximal tubule - should only increase hormone levels more distally 
within the tubule, where the hormone may act on luminal receptors.
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Sonnenberg (1990) has recently confirmed that stimulation of these 
receptors results in increased sodium excretion and Stephenson and 
Kenny (1988) have postulated that the role of NEP is to regulate the 
delivery of ANP to this site, rather than to recover the peptide from 
the urine. The findings that cGMP excretion may be increased before 
plasma ANP (Sybertz et al.,(1989,1990)) and that the renal effects of 
NEPi are greater than can be reproduced by infusing ANP to similar 
plasma levels (Cavero et al.,(1990)) are consistent with an 
extravascular action of NEPi -which seems most likely to be within the 
tubule.
Overall, both increased intra-tubular and plasma ANP are likely 
to contribute to the renal effects of NEPi.
Conclusions:
This section cover the time-period from the discovery that NEP 
degrades ANP (1987) to the present. In that short time a variety of 
NEPi (including older "enkephalinase" inhibitors and newly designed 
compounds) have been investigated in animals and in man. To some 
extent these agents have fulfilled their original promise in that they 
raise endogenous ANP and cause a spectrum of renal, endocrine and 
vascular effects similar to infused ANP. However, although they appear 
to have beneficial effects in some forms of hypertension and in heart 
failure, the effects on long term salt and water balance appear to be 
limited. This is partly due to lack of enzyme specificity (with 
inhibition of the degradation of other substrates for NEP including 
the antinatriuretic hormone Ang II), but also to the very modest 
effects that ANP has when increased to the levels produced by NEP 
inhibition in the last four chapters.
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Further work is required to assess the effectiveness and 
acceptability of NEPi in different forms of hypertension (specifically 
non-renin and renin dependent hypertension) and whether or not it is 
more effective in combination with other agents (Chapter 13). Although 
not as potent as was first hoped, the recent work on NEPi has shown 
that it is possible to harness at least some of the therapeutic 
potential of ANP with oral drug therapy. Future work should aim at the 
development of more specific inhibitors of ANP degradation, 
combination of NEPi with other agents (Chapter 13) with the aim of 
increasing plasma ANP levels two to four times those achieved by NEP, 
at which levels sustained haemodynamic and renal effects would be 
expected (Mizelle et al.,(1990)).
SECTION 5 .
CALCIUM AND THE RF.T.F.AS'F! fVF ANP.
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Chapter 11.
Effects of extracellular calcium and calcium antagonists on the release of ANP 
in vitro.
Introduction.
This final section examines aspects of the role of calcium on the release 
of ANP in vitro (Chapter 11) and in vivo (Chapter 12). There were two aims 
behind these studies. Firstly, there are theoretical reasons to believe that 
atrial stretch-secretion coupling is likely to involve calcium (see below) 
and, secondly, following the general theme of this thesis - to examine the 
possible therapeutic interactions between ANP (NEPi, Section 4) and calcium 
antagonists.
ANP is secreted in response to atrial distension. The stretch-secretion 
coupling mechanism is self-contained within the atrial myocyte since the 
isolated heart (Dietz (1987)), atria (Bilder et al.,(1986)) or dispersed 
myocytes (Gibbs (1987b)) release ANP in response to distension. The nature of 
this stretch-secretion coupling mechanism is still unknown but, for a number 
of reasons, may involve intracellular calcium. Stretch-activated ion channels
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are present in other tissues, for example in nerve sensory terminals, proximal 
tubular and choroid plexus epithelial cells (Sackin (1986), Christensen 
(1987)), and endothelial cells (Lansman et al.,(1987)). Stretch sensitive 
calcium channels have been proposed in cardiac muscle (Allen et al.,(1988)) 
to account for part of the classical length-tension relationship in cardiac 
muscle. The simplest model for ANP release would involve similar stretch 
activated channels to elevate intracellular calcium which is a central event 
in exocytosis in other tissues (Rubin (1982)). With regard to ANP a number of 
stimuli other than stretch have been shown to increase hormone release 
including increased heart rate (Schiebinger, Baker and Linden (1987)), a- and 
B-adrenoceptor agonists (Schiebinger and Linden (1988)), Endothelin (Stasch 
et al.,(1989)) and cardiac glycosides (Yamamoto et al.,(1988)). In the heart 
all of these stimuli increase the availability of intracellular calcium by 
differing mechanisms, although other factors which occur as a consequence of 
increased calcium - for example, contractility - may indirectly alter 
secretion (below).
The purpose of this first study was therefore to look at a simple 
experimental model - the isolated rat atrium - and examine the hypothesis that 
ANP release is dependent on intracellular calcium (Ca^), by altering Caj. 
indirectly through changes in extracellular calcium (CaQ ) or calcium 
antagonists.
Methods:
The right atrium was removed from male SD rats (300g) killed by cervical 
dislocation, and rapidly immersed in ice cold physiological solution (below). 
The atrium was then suspended between a stainless steel electrode (Figure
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11.1) and a tension transducer (Elcomatic EM 750, Elcomatic, UK) and 
superfused with physiological solution (PS) at 37°C at a rate of lml/minute. 
The superfusion cannula acted as a second electrode and the preparation was 
electrically paced using an isolated stimulator at 2 Hz using a supramaximal 
square wave stimulus. The preparation was initially suspended under 0. 5g 
resting tension and developed tension was continuously recorded using a 
Washington FC100/FC142 amplifier/chart recorder (Washington Ltd., UK). The 
physiological solution contained 125 mM NaCl, 25 mM NaHC03, 5 mM HEPES, 5 mM 
Dextrose, 1 mM MgS04, and either 1 mM EGTA or 0 mM CaC12 or 2 mM CaC12 
("normal"). In one series of experiments Verapamil (Cordilox, Abbott, UK) was 
added to "normal" PS to a final solution of 1 pM.
The preparation was allowed 60 minutes to stabilise (after Shiebinger et 
al.,(1986)), during which it was superfused with "normal" PS, following which 
three 5 minute control collections of effluent were made. Thereafter there 
were four ejqperimental limbs: in (a) superfusion was continued with normal PS 
for a further 12 five minute collection periods; in (b) the superfusate was 
changed to one containing (nominally) 0 mM calcium for six 5 minute periods 
before returning to "normal" PS for the remaining six 5 minute collections; 
in (c) the superfusate was changed to one containing 1 mM EGTA for five 
minutes before returning to "normal" PS for the remaining 11 periods and in 
(d) superfusate containing ljiM verapamil was given for six 5 minute periods 
before returning to "normal" PS for the remaining six periods. Effluent was 
collected in chilled 5 ml tubes and rapidly frozen at -20°C, being stored at 
this temperature until assay. ANP was measured by direct radio-immunoassay 
(Appendix 1). Pre-extraction is used to remove large molecular weight 
substances from plasma prior to RIA. Isolated atria are reported to release
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mature (28AA) peptide and there were no plasma components present; pre­
extraction was therefore deemed unnecessary-
Results:
Stability of the preparation: Release of ANP was highly variable and fell 
steadily over the first 45 minutes (Figure 11.1) in normal calcium PS. This 
presumably represents leakage from damaged cells and after one hour the rate 
of hormone release was relatively stable.
Manipulation of Calcium: Changing to nominally calcium free PS (OmM Ca) 
resulted in a decline in developed tension over a period of a few minutes 
reflecting the depletion of intracellular calcium and the diffusion of calcium 
from the interstitial fluid into the superfusate (Figure 11.2). When 2 mM 
calcium was restored the developed tension returned to normal. In contrast the 
high dose of verapamil resulted in a slow decline in developed tension to 
about half the basal values, with no evidence of recovery, suggesting 
irreversible, possibly toxic effects on the myocytes with this concentration 
of verapamil. In preliminary experiments, 5 mM EGTA for 30 minutes resulted 
in rapid abolition of tension from which there was no recovery (in contrast 
to the results of deBold and deBold (1989)). As a compromise 1 mM EGTA was 
given for 5 minutes. There was a rapid abolition of tension (over a few 
minutes) representing depletion of intracellular calcium and the diffusion of 
calcium out of the interstitial spaces.
In contrast to the clear and predictable changes in developed tension 
which are produced by manipulation of Ca0 , there were no differences in the 
release of ANP, which gradually declined to between 50 and 70 % of basal 
levels over the 60 minutes of the interventional part of the study.
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FIGURE 11.1:
RELEASE OF ANP BY THE ISOLATED RAT ATRIUM.
A. Schematic representation of the perfusion apparatus for the 
study of the release of ANP from the rat atrium in vitro (see 
text for details).
B. Release of ANP (pg/mg atrial tissue/minute) during 24 5 
minute collection periods. n=8, data shown as mean±SEM.
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FIGURE 11.2:
EFFECTS OF ZERO CALCIUM AND VERAPAMIL ON ANP RELEASE.
Effects on (A) tension - as a fraction of basal tension - and 
(B) ANP release - as a fraction of basal release - of changing 
the superfusate to 0 [Ca] or 10~6 M Verapamil. After 3x5 minute 
control collections in 2mM Ca superfusate, the superfusate was 
changed for 6x5 minute collections before being restored to 
normal for the final 6x5 minute collections. n=8 in each group, 
only mean data points are shown for clarity.
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FIGURE 11.3:
EFFECTS OF EGTA ON ANP RELEASE.
Effects on (A) tension - as a fraction of basal tension - and 
(B) ANP release - as a fraction of basal release - of changing 
the superfusate to 1 mM EGTA. After 3x5 minute control 
collections in 2mM Ca superfusate, the superfusate was changed 
for 1x5 minute collection before being restored to normal for 
the final 11x5 minute collections. n=8 in each group, only mean 
data points are shown for clarity.
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Discussion:
This study was limited in its objectives - to examine the potential 
influence of calcium on unstimulated ANP release in vitro. The results are 
similarly limited - to showing no effect of calcium on ANP release, but a 
clear dissociation between ANP release and developed tension. It is easy to 
criticise the failure to study stimulated ANP release but, in fact, the 
isolated atrium is probably far from the ideal preparation to study the 
release of ANP (see below), there was a large inter-preparation variability 
(necessitating the expression of the data as percentage values - a problem 
reported by other workers e.g. Schiebinger et al.,(1987,1988)) and in 
preliminary experiments it was not possible to produce consistent release 
either by mechanical or hormonal stimulation (not shown). However, the 
observed findings are entirely consistent with the published reports showing 
that calcium can stimulate, inhibit or have no effect on the release of ANP 
in vitro (see below). It does not seem possible to absorb these apparently 
contradictory observations into a single theory and part of the problem lies 
in the absence of an ideal preparation for studying ANP release in vitro. 
Experimental models: The isolated atrium is composed of multiple cell layers, 
the innermost cells dependent on diffusion of nutrients and waste products 
through the extracellular matrix. Thus, these inner layers will be, at best, 
metabolically compromised. The time scale for diffusion is well illustrated 
in the present experiments where it can be seen that the time taken for 
calcium to diffuse out of the preparation (and contraction to cease) is 
several seconds; for larger molecules such as glucose and especially ANP the 
time scale would be expected to be much greater. In fact, contraction of the
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cells may be expected to be important in the circulation of fluid within the 
extracellular space and Cho et al.,(1988) found that distension of the 
isolated atrium only produced an increase in ANP release after distension was 
released, consistent with this suggestion. Another problem relates to the use 
of EGTA to lower Ca. EGTA disrupts cell membranes causing "skinning” of the 
plasma membrane (Miller (1977)) and this disruption is probably important in 
cell viability since the preparation did not recover full contractile strength 
even after a short exposure. Increasing the permeability of the membrane in 
this way may perhaps promote the fusion of vesicles within the cell increasing 
the release of ANP. A further complicating feature is the suggestion by 
Needleman that a calcium dependent enzyme may be involved in the processing 
of pro-ANP to ANP (Ito et al.,(1988)). Finally, many groups have failed to 
control heart rate. Increases in heart rate are known to stimulate ANP release 
(Schiebinger and Linden (1986)) and intracellular calcium is similarly 
dependent on contraction frequency. Schiebinger (1989) found that quiescent 
atria did not release ANP in response to B-adrenoceptor stimulation, in 
contrast to beating atria, therefore the results of studies on unpaced atria 
must be viewed with caution. What then is the evidence for and against a role 
for calcium in ANP release ?
1. Calcium-dependent release. At the level of gene expression, in cultured 
atrial cells, calcium increases ANP mENA (LaPointe et al.,(1990)). Similarly, 
in tissue culture experiments increases in extracellular calcium within the 
physiological range (0-2 mM), or treatment with the calcium ionophore A23187 
(Hirata et al.,(1988), LaPointe et al.,(1990)) increase ANP release and these 
effects can be blocked by the calcium channel blocker verapamil (LaPointe et 
al.,(1990). Infusion of subpressor doses of calcium into normal animals
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(Yamamoto et al.,(1988)) and man (Finn et al.,(1990)) causes an increase in 
plasma ANP. In man Finn et al., (1990) found that increasing plasma calcium 
by approximately 0.3 mM caused a 40 % increase in plasma ANP with a 140% 
increase in urinary sodium excretion; in dogs the rise in calcium was much 
greater (3-fold) and resulted in a 4-fold increase in plasma ANP (Yamamoto et 
al.,(1988)). Ouabain, which increases both intracellular calcium and cardiac 
contractility causes a similar increase in plasma ANP in dogs (Yamamoto et 
al.,(1988)) and in cultured atrial cells in vitro (Bloch et al.,(1988). In 
isolated preparations Schiebinger (1989) found that reducing extracellular 
calcium from 1.8 to 0.2 mM, or the addition of a calcium channel blocker (lOpM 
Nitrendipine), or a blocker of Ca release from sarcoplasmic reticulum 
(Ryanodine lpM) inhibited B-adrenoceptor or adenylate cyclase mediated 
release. The stimulatory effect of Endothelin, which acts through 
phosphotidylinositol turnover, on ANP released from paced isolated atria was 
similarly inhibited by reducing extracellular calcium to 0.2 mM or treatment 
with the calcium channel blocker Nitrendipine but not by Ryanodine 
(Schiebinger and Gomez-Sanchez (1990)). One failing of these studies 
(Schiebinger (1989), Schiebinger and Gomez-Sanchez (1990)) is that 
contractility changes tended to parallel ANP release and since contractility 
may be predicted to influence the rate of appearance of ANP in the superfusate 
(above) this may influence the interpretation of these results.
2. Non-calcium dependent release.: There are few other reports that calcium 
has no role in the release of ANP. However, Gibbs (1987), found that calcium 
removal did not inhibit the effect of osmotic stretch on ANP release in 
isolated perifused atrial cells in keeping with the findings of the present 
series of experiments.
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3. Negative modulation of ANP release by calcium.: Although the rationale for 
calcium dependent ANP release is strong, and much of the above evidence 
convincing, there are a number of studies showing the opposite effect of 
calcium i.e. suppression of release with increased calcium (deBold and deBold 
(1989), Greenwald et al.,(1989)). In deBold1 s study 2 mM EGTA was used to 
remove calcium and caused a sustained increase in hormone release and 
inhibition of contractility. These effects were fully reversed by restoration 
of calcium and are therefore inexplicably different from the present study, 
where the effects of EGTA were irreversible. When nominally Ca free buffer was 
used there was a transient rise in ANP release which may be due to increased 
heart rate as a consequence of removal of extracellular calcium. Greenwald et 
al.,(1989) used cultured myocytes which released only proANP, the release of 
which was stimulated by addition of EGTA - to lower calcium - and increased 
by ionomycin - which increases intracellular calcium. Iida and Page (1989) 
have shown in cultured cells that phorbol ester stimulated ANP release is 
present even when influx of calcium was reduced by EGTA and sarcoplasmic 
reticulum release of calcium by ryanodine, implying that calcium is not 
essential. However, they also found that ANP release was reduced when 
contraction was inhibited by tetrodotoxin, supporting the theory (above) that 
contraction may play a role in the migration and release of atrial granules 
(even in isolated cells).
Overall, these studies have in common the use of EGTA, which may be 
inappropriate (above) but do confirm that ANP release can be stimulated in the 
absence of extracellular calcium in some preparations and experimental 
circumstances.
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In conclusion from the present study reduction in extracellular calcium 
or calcium channel blockers has little effect on ANP release. However, the 
balance of evidence from studies emerging over the last three to four years 
is that ANP release is, at least partially, dependent on calcium. The 
inability of the present study to demonstrate this may be methodological. 
Removal of calcium would be predicted to reduce ANP release and this may be 
difficult to see against the background of a falling baseline (Figure 11.1 -
11.3), and changes in contractility since this may affect the rate of 
appearance of ANP in the superfusate.
Many factors might contribute to the apparently opposite findings of 
different workers regarding the role of calcium in ANP release. Firstly, there 
is no ideal preparation in which to study release is unknown. Secondly, it is 
conceivable (and probably desirable) that contractility and hormone release 
should be regulated independently, perhaps by different calcium pools within 
the cell. There appears to be a consensus that release of calcium from 
sarcoplasmic reticulum is not essential (Schiebinger and Gomez-Sanchez (1990), 
Iida and Page (1989)). Finally, calcium may be a co-factor in release and 
other stretch-sensitive factors may be important. For example, it has recently 
been shown that atrial cell membrane phosphotidylinositol turnover is 
independently increased by atrial stretch (Harsdorf et al.,(1989) and direct 
activation of protein kinase C increases the release of ANP (Iida and Page 
(1989)). However, althoug such a mechanism may be partially calcium- 
independent it cannot explain the the actions of disparate stimuli, including 
B-agonists, which do not act through phosphotidylinositol turnover.
Further work is obviously required to work out the precise mechanism by
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which the atrial cell regulates hormone release and future in vitro studies 
will need to circumvent all the above problems. To remove the problems of cell 
viability (falling baseline release) and diffusion time isolated or cultured 
cells would be the best choice, but these will require to be paced in the 
culture dish, presumably by field stimulation, in order to remove the 
confounding effects of changes in heart rate. The application of a 
physiological stimulus to ANP release in isolated cells is difficult since 
osmotic stretch is non-physiological and may disrupt the cell membrane. 
However, this may be circumvented by culturing cells on a flexible membrane 
(Buck (1983)) allowing the study of factors which modulate release. Finally, 
the use of chelating agents such as EGTA must be used with caution in view of 
their partially irreversible effects on cell membranes.
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Chapter 12.
Effects of Nifedipine on ANP response to saline loading in man.
Introduction:
Although the results of studies on the role of calcium in ANP release in 
vitro are conflicting (Chapter 11) there is a greater consensus from in vivo 
studies. Increasing extracellular calcium by infusion (Yamamoto et al.,(1988), 
Fujimara et al.,(1989), Finn et al.,(1990)) or intracellular calcium using 
ouabain (Yamamoto et al.,(1988), Bloch et al.,(1989)) increases plasma ANP 
with an associated increase in sodium excretion. The purpose of the present 
study was to examine the effects of acute treatment with a calcium channel 
blocker (Nifedipine, shown to inhibit ANP release in vitro) on the release of 
ANP in response to saline leading in man, (a) to further investigate the role 
of calcium in ANP release (Chapter 11) and (b) with the possible therapeutic 
use of ANP (Chapters 5-10) to assess any possible interactions with calcium 
channel blockers.
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Methods:
The protocol was approved by the Western Infirmary Ethical Committee and 
all subjects gave written informed consent before participating. Eight normal 
male subjects were studied (aged 26-49 years) on two separate study days, at 
least one week apart. No formal dietary restrictions were made but subjects 
were asked to adhere to their normal diet throughout the study. On each study 
day subjects were admitted to the Unit at 8a.m. heparinised cannulae were 
inserted into opposite forearm veins for sampling and infusion. The subjects 
remained supine for the duration of the study except to pass urine. After a 
30 minute rest subjects emptied their bladders and drank 350mls tap water. 
Thereafter, urine collections were made at hourly intervals for the following 
six hours. Bolus doses of PAH and inulin (0.5 and 3.0 g respectively) were 
given at time zero and then infused at 0.5 and 1.0 g/hour respectively for the 
remaining six hours. After one hour Nifedipine (Adalat, Bayer (UK), lOmg) or 
identical placebo were given (double blind) with 150 mis tap water. A further 
hour was allowed for absorption and 1000 ml 0.9% NaCl at room temperature was 
then administered over 30 minutes by intravenous infusion. Blood samples were 
taken for measurement of PAH, inulin, electrolytes, FBC, renin, and ANP 
(Figure 1) at 1, 2, 4, and 6 hours; with additional samples for GFR, ERPF and 
ANP at 2.5, 3 and 5 hours. ERPF and GFR were calculated from plasma levels of 
PAH and Inulin assuming steady state conditions (Schnurr et al.,(1980)). Blood 
pressure, and pulse were measured at 30 minute intervals throughout.
Assays: ANP was measured by radioimmunoassay as previously reported (Richards 
et al.,(1987)). Renin, PAH and inulin were measured by established methods 
(Millar et al.,(1980), Richards et al.,(1987)).
Statistical analysis: is by repeated measures analysis of variance between
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treatments with post hoc comparison between groups using paired T-test when 
appropriate (SPSS/PC+, SPSS inc.,USA).
Results:
1. Plasma ANP (Figure 12.1).: Baseline ANP levels were well within the normal 
range (5-50 pg/ml). Overall there was no statistically significant difference 
between the plasma ANP levels and their response to saline loading in the 
presence or absence of Nifedipine. However, the peak level of ANP was slightly 
higher in the presence of Nifedipine and fell more rapidly than the placebo 
group.
2. Urine Electrolyte Excretion (Figure 12.1).: In the presence of Nifedipine 
there was an increase in the diuresis and natriuresis in response to saline 
loading. Cumulative urine volume following saline infusion was increased from 
530±96 to 698±93 mls/4hours (P=NS) and urinary sodium excretion from 54.4±3.5 
to 82.6±7.6 mmoles/ 4hours (P<0.05). Potassium excretion was not significantly 
altered. By MANOVAR only urinary Na excretion was significantly increased 
(PC0.05), the increase in UNaV being significant in the two hours following 
saline infusion (Figure 12.1).
3. Pulse and Blood Pressure. (Table 12.1). There were no significant changes 
in blood pressure or pulse rate in these normal subjects, although the 
systolic and diastolic pressures were marginally lower in the active limb 
(Nifedipine).
4. Hormone levels (Table 12.1). Renin and angiotensin II levels were 
suppressed by saline infusion in both groups but there was no difference 
between active and placebo limbs, nor was there any significant effect on 
aldosterone levels.
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FIGURE 12.1:
EFFECTS OF NIFEDIPINE ON THE ANP RESPONSE TO SALINE INFUSION.
Effects of infusion of 11 of normal saline into 8 normal 
volunteers on plasma ANP, urine volume and sodium and potassium 
excretion (UNaV, UKV, UVol). Data are given as mean±SEM. Saline 
was infused over 30 minutes starting at 2 hours (see text for 
details).
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5. Renal Function Indices (Table 12.1). Infusion of saline was associated with 
a transient rise in renal plasma flow (ERPF) and a sustained increase in 
glomerular filtration rate. There was no significant difference in the pattern 
of these effects between the active and placebo limbs. Fractional excretion 
of sodium was also transiently increased following infusion and was 
consistently higher in the active limb, being twice the level in the placebo 
limb at the 4 hour time point (i.e. two hours after the start of saline 
infusion). However, due to the baseline differences this failed to achieve 
statistical significance (P=NS).
Discussion:
The results confirm that saline infusion stimulates an increase in plasma 
ANP (Anderson et al.,(1986), Richards et al.,(1988), Ohashi et al.,(1987), 
Hodsman et al.,(1987)). However, despite the original hypothesis (Chapter 11) 
there was no evidence that Nifedipine inhibits either release or the renal 
effects of ANP.
Pretreatment with Nifedipine resulted in an upward trend in basal ANP 
levels and saline infusion resulted in slightly higher peak hormone levels. 
These observations suggest that there is no impairment of ANP release in vivo 
despite the in vitro evidence that calcium antagonists can inhibit ANP release 
(Schiebinger and Gomez-Sanchez (1990), Schiebinger (1989)). The more rapid 
fall in hormone levels in the Nifedipine group may reflect quicker excretion 
of the saline load and therefore reduction of the stimulus to ANP release. A 
rise in plasma ANP following oral Nifedipine has previously been observed 
(Rappelli et al.,(1987)), but the reason for this is not known. It may perhaps 
reflect changes in metabolism either directly or by redistribution in regional
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blood flow (as has been suggested for other vasodilators (e.g. Wilkins et 
al.,(1988)). There was no change in heart rate (an independent stimulus to ANP 
release (Schiebinger, Baker and Linden, 1987)) following Nifedipine, thus the 
effects are not secondary to reflex changes in heart rate.
In keeping with previous reports Nifedipine caused a small increase in 
basal urine volume and sodium excretion (Rappelli et al.,(1987) and for 
reviews, Loutzenhiser and Murray (1989), Chellingsworth and Kendall (1987)), 
and greatly increased the rate of clearance of the infused saline load. Since 
plasma ANP levels were similar in both active and control groups it is likely 
that this exaggerated natriuretic and diuretic effect is either due directly 
to Nifedipine or possibly through a synergistic effect between ANP and 
Nifedipine in the kidney. There was no evidence of any differences in 
glomerular filtration rate or renal plasma flow between active and control 
groups although both increased release during saline infusion. Fractional 
excretion of sodium was higher on the active treatment limb and, although this 
failed to reach statistical significance (P=0.64), the pattern of these 
effects - i.e. enhancement of fractional sodium excretion (Chapter 4) with 
Nifedipine - is consistent with potentiation of the effects of ANP in the 
kidney. Both Gaillard et al.,(1989) and Seino et al., (1988) reported a 
similar pattern. In these studies when ANP was infused in the presence or 
absence of a calcium channel blocker, there were no significant changes in 
GFR, but the ANP-induced rise in FeNa was enhanced. There was no consistent 
effect on blood flow and the implication is that calcium channel blockers 
directly enhance the effects of ANP at a tubular level.
Finally, renin levels were suppressed by saline infusion in both limbs 
of the study. The plasma renin levels were lower, although not significantly
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so, in the active limb consistent with the fact that renin release in 
negatively modulated by calcium in vitro. There were no significant changes 
in the other components of the renin-angiotensin system.
In conclusion, although the balance of evidence favours some involvement 
of calcium in the control of ANP release (Chapter 11) and although calcium 
channel blockers inhibit ANP release in vitro (Schiebinger (1989), Schiebinger 
and Gomez-Sanchez (1990)) there is no evidence from the present study that ANP 
release is inhibited. In fact, plasma levels were, if anything, higher during 
a saline load and calcium channel blockers are therefore unlikely to interfere 
with the therapeutic usefulness of ANP (or NEPi). Furthermore, sodium and 
water excretion were enhanced by Nifedipine. Whether this reflects the 
potentiation of ANP, as it appears to (Gaillard et al.,(1989), Seino et 
al.,(1988)), merits further investigation. If Nifedipine does potentiate the 
renal effects of ANP then the combination of ANP (or NEPi) and a calcium 
channel blocker may be a potent therapeutic combination (Chapter 13).
TIME (hoars) 1 2 3 4 5 6
RENIN 15.712.3 22.313.6 14.713.5 12.713.3
(p.U/ml) 13.3±1.8 21.217.5 10.0+0.7 9.511.0
ANG II 9.712.2 14.5+3.1 8.811.6 8.1+2.3
(pgM) 11.9+1.3 11.912.4 . 5.1+0.64 9.511.0
ALDO 4.1±0.8 3.110.6 3.410.5 2.910.6
(ng/'dl) 2.810.3 6.4+3.0 3.3+0.4 3.9+1.0
SYSTOLIC 11915 11615 11915 118+4 11614 11913
(mmHg) 11713 11913 12413 12014 119+4 11914
DIASTOLIC 68+4 66+5 64+4 6313 6514 6313
(mmHg) 7214 7115 7414 6714 6314 66+4
PULSE 61+3 63+3 63+3 61+4 64+3 6614
(/min) 5811 6112 59+2 5911 6112 62+2
GFR 78.014.6 99.515.9 107.616.6 111.016.5 111.016.0
(ml/min) 75.013.0 95.2+4.1 103.914.6 108.715.4 111.3+5.9
SRPF 481.2+43.7 516.1148.1 539.8150.7 483.9129.9 459.4139.9
(ml/min) 450.3118.9 502.8+34.6 499.0+32.5 496.3126.7 465.8126.2
FeNa (%) 1.26+0.20 1.10+0.11 1.76+0.28 1.22+0.25 1.0310.25
(P=0.068) 1.0510.18 1.7310.30 0.8610.20 0.98+0.10 1.0310.25
TABLE 12.1:
HORMONAL, BLOOD PRESSURE AND RENAL EFFECTS OF SALINE INFUSION - 
INFLUENCE OF NIFEDIPINE.
Changes in plasma renin, angiotensin II (Ang II) and 
aldosterone (aldo); blood pressure (systolic & diastolic) and 
pulse rate; glomerular filtration rate (GFR), renal plasma flow 
(ERPF) and fractional excretion of sodium (FeNa) in eight 
normal volunteers infused with 11 saline over 30 minutes, 
starting at 2 hours. For each variable the upper value 
(mean±SEM) is in the Nifedipine limb of the protocol (see 
text). There were no significant differences between active and 
placebo limbs.
SECTION 6 .
GENERAL DISCUSSION.
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Chapter 13:
Conclusions: Possible Clinical Applications.
With the exception of chapter 3 this thesis contains little of 
direct clinical relevance and it therefore seems appropriate to 
conclude by assessing the possible clinical importance of ANP. This 
can be broadly divided into two major limbs: the possible diagnostic 
use of plasma ANP measurements and the possible therapeutic use of 
exogenous ANP.
Diagnostic: From the data presented in chapter 3 it is clear that a 
functional ANP hormonal system is present from at least the third 
trimester of human fetal life. In both the fetus and the adult 
intravascular volume status is the most important determinant of 
plasma ANP concentration, with hormone levels being appropriately 
elevated in volume expanded states (Rhesus isoimmunisation in the 
fetus, mineralocorticoid and normal pregnancy in the adult). However, 
it is also clear that cardiac afterload has an independent stimulatory
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effect on ANP release (in pre-eclampsia, malignant phase hypertension 
and in pheochromocytoma, where elevated arterial pressure is generally 
associated with reduced intravascular volume). However, it seems 
highly unlikely that measurement of plasma ANP could contribute 
anything to the clinical assessment of patients with these conditions 
where the diagnosis is based on other factors and hormone 
measurements. Similarly, in the fetus with rhesus isoimmunisation, 
although the reciprocal relationship between plasma ANP and 
haematocrit - and hence the severity of rhesus disease - is of 
interest it is unlikely to contribute to the clinical assessment of 
these patients.
Where measurement of plasma ANP may be of clinical relevance is 
in those conditions where paradoxical changes in ANP occur. The 
clearest example of this is in pre-eclampsia (PET). In normal 
pregnancy, there is a progressive increase in ANP with gestation and 
also of renin concentration. In PET, however, this pattern is altered 
and, despite the relative reduction in intravascular volume, ANP is 
further increased and renin paradoxically reduced. Using the ratio of 
ANP/renin as a crude indicator, the ratio increased approximately 1 
(pg/ml ANP/ pU/ml Renin) during normal pregnancy to values of > 10 
were found in PET and showed a weak inverse relationship with the 
birthweight. If these neurohumoral changes predate the clinical 
development of PET they may be a useful indicator of at risk 
pregnancies worthy, at least, of further investigation.
Therapeutic: The remaining sections of this thesis deal either
directly (Section 4) or indirectly (Sections 3 & 5) with factors 
likely to influence the therapeutic usefulness of ANP.
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The pattern of actions of ANP, and the results of preliminary 
studies of ANP infusion in hypertension and heart failure (Chapter 2), 
show therapeutic potential - although we have perhaps been misled as 
to the potency of ANP from the early high dose studies. The main 
section of this thesis is devoted (Section 4) to an attempt to harness 
this potential by inhibition of ANP degradation using NEP inhibitors, 
with the studies in Sections 3 and 5 examining the interactions of 
ANP, ACE inhibitors and calcium channel blockers (possible agents for 
combination therapy with ANP or NEPi).
In 1987, (Chapter 5) the use of NEP inhibitors to inhibit the 
degradation of ANP appeared to be a means of harnessing the 
therapeutic potential of ANP. To some extent this has been realised 
with the clear demonstrations, in normal animals (Chapter 6) and 
normal man (Chapter 7) that NEP inhibition can cause increases in 
plasma ANP and a natriuresis, diuresis and suppression of the renin- 
angiotensin system consistent with an ANP-mediated effect. What was 
subsequently disappointing was the failure of prolonged NEP inhibition 
to cause a sustained increase in sodium excretion, exchangeable sodium 
or blood pressure (Chapter 8) but, more importantly, that fact that 
Ang II levels were increased in the presence of a NEPi. While, in 
retrospect, this simply reflects that Ang II is a substrate for NEP it 
is likely to limit the usefulness of NEPi especially in renin- 
dependent forms of hypertension. In mitigation, the use of NEPi in 
models of hypertension does lower blood pressure (Chapter 9, 10)
albeit by a relatively small amount and in renin-independent models of 
hypertension. Thus, NEP inhibitors have failed to achieve their 
theoretical promise but they have fulfilled some of their potential by 
producing a sustained rise in plasma ANP - a useful first step towards
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harnessing the effects of ANP.
The modest effects of NEPi have already prompted the 
investigation of therapeutic combinations (eg Koepke and diBona 
(1989)). From the data presented here the combination of ACE 
inhibitors and ANP (and, by inference NEPi) is likely to produce a 
potent natriuresis and diuresis with significant antihypertensive 
effect. This has recently been confirmed by Seymour et al.,(1991b) 
using both ACEi and NEPi and a novel compound which inhibits both 
enzymes. The use of calcium antagonists (Chapters 11 & 12) in
combination with ANP may also be a useful therapeutic combination with 
no evidence, at least in acute studies, of the postulated inhibition 
of ANP release by these agents. However, there are - at least - two 
caveats. Firstly, the use of ACEi is limited in perhaps 5% of patients 
by a kinin-induced cough. Exogenous, recombinant NEP (Kiguchi et 
al.,(1989)) can inhibit this type of cough and, presumably, the 
combined inhibition of ACE and NEP might be limited by this side 
effect. Secondly, and most importantly, the major reason for pursuing 
the therapeutic potential of ANP was the unique spectrum of actions of 
ANP (Chapters 2, 4 & 5) which cannot be achieved by any single 
available therapeutic agent. If we now have to look at therapeutic 
combinations with NEPi then we have to question whether or not these 
confer any benefit over the currently available, proven therapeutic 
combinations (e.g. thiazide diuretic + ACEi) in hypertension. Whether 
or not this is the case remains to be seen and would, at least, merit 
further investigation of these compounds.
This rather negative view on the likely therapeutic potential of 
NEPi does not necessarily detract from the attractiveness of ANP as .a 
therapeutic agent. What is required is more potent and specific
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stimulators of ANPs actions. Cyclic GMP phosphodiesterase inhibitors 
(Wilkens et al.,(1990) appear to offer a much more potent enhancement 
of ANP effects at the post-receptor level. However, these agents will 
potentiate the effects of, for example, EDRF (Endothelium Derived 
Relaxing Factor) which are mediated by soluble guanylate cyclase and 
therefore may be too potent for human use. Nevertheless, these agents 
also merit further investigation. The ideal compound has yet to be 
discovered, but perhaps the development of a specific ligand for the 
B-ANP receptor is the most likely to be attained.
Overall, the progress in research to harness the therapeutic 
potential of ANP has followed the pattern seen in ANP in general. ANP 
was initially seen as a very potent natriuretic, vasodilator hormone. 
However, with time it now appears to have a much more subtle role, 
perhaps counterbalancing the effects of the renin-angiotensin system 
(Chapter 2) under normal circumstances, but easily over-ridden by the 
activated renin-angiotensin (or other antinatriuretic) systems. 
Similarly, our hopes for the therapeutic potential of ANP may have 
waned with these initial studies of NEP inhibitors. However, the 
search for more specific and potent stimulators of ANP receptors or 
post-receptor mechanisms may yet produce a novel antihypertensive 
agent.
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Appendix 1.
Measurement of plasma ANP.
Sample Collection: Blood samples for ANP were collected through
indwelling cannulae (Venflon, Viggo, Sweden) after at least 15 minutes 
supine rest. The blood (10ml) was collected into EDTA tubes containing 
100 k.i.u. aprotinin (Trasylol, Bayer UK) on ice. The sample was 
separated at 4°C (1500 g x 15 minutes) and the plasma stored until
assay at 20°C. In fact, although rapidly separated, the blood samples
were stable for up to one hour at room temperature in the presence of 
Trasylol (data not shown).
Samples from experimental animals were collected as above, but 
generally smaller volumes (3 ml dog, chapter 4; 0.5-5 ml rat, chapter 
6). Urine samples (20ml) were similarly collected in Trasylol, then 
frozen until assay.
ANP was determined by radio-immunoassay of pre-extracted samples 
(Richards et al.,(1987)).
Extraction: Plasma (3 ml, human; 200 pi- 2 ml, rat) and urine (10 ml)
were extracted on C18 reverse phase columns (SEP-PAK, Waters
Associates, UK). The SEP PAKS were pre-activated with Methanol (5 ml) 
then washed through with 5ml distilled water. Plasma or urine samples 
were acidified before application to the columns by the addition of 
0.25 ml 2M HCl per ml of plasma/urine. The acidified sample was then 
spun to precipitate large proteins and the supernatant added to the 
columns and "washed in" with 15 ml (3 x 5 ml) 0.1% trifluroacetic acid 
(TFA). The sairples were then eluted using 2 ml 60% Acetonitrile/ 40% 
0.1% TFA. All steps were performed at room temperature, and samples 
drawn through the SEP-PAK under vacuum if required.
The eluted samples were then dried overnight under compressed air 
at 37°C and the dried samples stored at -20°C if required. For assay 
these samples were reconstituted in 0.5 ml assay buffer (below) and 
dissolved by 3 x 10 minute spells in in an ultrasonic bath (Sonitank), 
interspersed by 3 x 60 second spells in a vortex mixer.
The recovery of human plasma ANP through the extraction proceduce 
was invariably greater than 80%, and generally greater than 90%. For 
urine, the calculated recovery was 84% (n=16).
Assay: The assay buffer contained lOOrnmol/1 sodium phosphate (pH 7.4) 
containing 50 mmol/1 NaCl, 0.1% w/v bovine serum albumen, 0.1% Triton 
X-100, and 50 kiu/ml Aprotonin; all biochemicals from Sigma or BDS, UK 
except aprotonin [Trasylol, Bayer UK]).
The assay was performed - in duplicate - in 1.5ml tubes 
containing 250^ .1: 100^1 sample, 100^1 antibody at a dilution of
1:10,000, and 50p.l label (2pg X2SI-ANP in 50^ .1 buffer). The standard 
curve was prepared by serial dilution (two-fold dilutions; n=8) from 
lOOpg/tube (400 pg/ml final concentration) to 0.4 pg/tube (1..6 pg/ml 
final concentration). The assay mixtures were vortexed for 30 seconds 
then incubated for 24 hours at 4°C. Bound and free radioactivity were
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separated using dextran-coated charcoal (1ml of Norixt GSX charcoal 
6g, Dextran T70 620 mg in 11 Tris buffer) then centrifuged for 15 
minutes at 1500g. The supernatant was then aspirated and free 
radioactivity measured in a gamma counter. The concentrations of ANP 
were then determined by comparison with the standard curve.
The limit of detection of the assay is approximately 1 pg per 
tube. The intra and inter-assay coefficients of variation are 
consistently less than 10%.
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Appendix 2.
Analysis of Variance Table - for Chapter 4.
Full analysis table for chapter 4 "Renal actions of ANP: 
interactions with Ang II and ACE inhibition". P value represents the 
significance of each variable analysed by MANOVAR (with repeated 
measures, SPSS/PC+) against (A) Placebo, (B) ANP alone. Asterixes 
indicate P values close to significance (*) and NS - non-significant. 
Full analysis of each limb against both placebo and ANP (A,B) is 
included for interest, although the study was designed and analysed by 
comparing the effects of ANP alone against placebo, then the other 
limbs (3-6) against ANP alone. The Enaliprilat alone limb was added 
later and not included in the formal analysis.
For abbreviations - see list in Introduction to Thesis.
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Appendix 3:
Pharmacokinetic data - Chapter 7.
Summary of the pharmacokinetic data from chapter 7 - "The effects 
of acute administration of the NEP inhibitor UK 69,578 in normal man". 
Dose of UK 69,578 in mg/kg, with the number of completed subjects in 
brackets, variables as labelled (meaniSD). Results courtesy of Dr. NJ 
Cussans, Pfizer Central Research, UK.
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